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Abstract
Erucic acid is the trivial name of the fatty acid cis-13-docosenoic acid and occurs at high
concentrations mainly in the seeds of species of the Brassicaceae (e.g. rape seed or mustard seed).
The European Commission requested EFSA to deliver a scientiﬁc opinion on the risks for animal and
human health related to the presence of erucic acid in feed and food. For most humans, the main
contributor to dietary exposure to erucic acid was the food group ‘Fine bakery wares’. In ‘Infants’,
‘Food for infants and small children’ was the main contributor to exposure. The heart is the principal
target organ for toxic effects after exposure. Myocardial lipidosis was identiﬁed as the critical effect for
chronic exposure to erucic acid. This effect is reversible and transient during prolonged exposure. A
tolerable daily intake (TDI) of 7 mg/kg body weight (bw) per day for erucic acid was established,
based on a no observed adverse effect level of 0.7 g/kg bw per day for lipidosis in young rats and
newborn piglets. Mean chronic exposure of the different groups of the population did not exceed the
TDI. The 95th percentile dietary exposure level was highest in infants and other children, ranging from
1.3 to 7.4 mg/kg bw per day; the higher level being at the level of the TDI. This may indicate a risk
for young individuals with high erucic acid exposure. In pigs, levels of erucic acid are unlikely to
represent a health concern. However, for poultry, the small margin between the lowest observed
adverse effect level (LOAEL) and the estimated exposure may indicate a health risk where maximum
inclusion rates are applied. Due to the absence of adequate data, the risk for ruminants, horses, ﬁsh
and rabbits could not be assessed.
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Summary
Following a request from the European Commission, the EFSA Panel on Contaminants in the Food
Chain (CONTAM Panel) was asked to deliver a scientiﬁc opinion on the risks for animal and human
health related to the presence of erucic acid in feed and food. The Scientiﬁc Opinion should, inter alia,
comprise the (a) evaluation of the toxicity of erucic acid for animals and humans, considering all
relevant adverse health effects; (b) estimation of the dietary exposure of the European Union (EU)
population to erucic acid including the consumption patterns of speciﬁc (vulnerable) groups of the
population (e.g. high consumers, children, people following a speciﬁc diet, etc.); (c) estimation of the
exposure of the different animal species to erucic acid in feed and the level of transfer/carryover of
erucic acid from the feed to the products of animal origin for human consumption resulting in
unacceptable levels of erucic acid; (d) assessment of the human health risks for the EU population
including for speciﬁc (vulnerable) groups of the population as the consequence of the estimated
dietary exposure; (e) assessment of the animal health risks for the different animal species as the
consequence of the estimated exposure from animal feed.
Erucic acid is the trivial name of the fatty acid Z-13-docosenoic or cis-13-docosenoic acid. According
to the most common nomenclature for fatty acids, erucic acid is abbreviated as 22:1 n-9 or 22:1 x-9.
Erucic acid is present at high concentrations mainly in the seeds of species of the Brassicaceae (e.g.
rape seed or mustard seed and also seeds from vegetable crops such as kales, cabbages and turnips).
Although natural forms of rapeseed and mustard species contain high levels of erucic acid, usually
more than 40% of the total fatty acids, commercially bred cultivars of rapeseed developed since the
1970s have low levels of erucic acid, typically less than 0.5%. High erucic acid rapeseed (HEAR)
cultivars are still grown to meet the demand of the oleochemical industry but are exclusively intended
for non-food uses. Mustard seed production is based on cultivars with high erucic acid content. Erucic
acid is also present at low concentrations in other food sources such as ﬁsh.
Following an ad-hoc data collection, a ﬁnal dataset of 12,444 food samples representing most of
the food commodities with potential presence of erucic acid was available to estimate dietary
exposure. Samples were collected between 2000 and 2015 (half of them in 2014) in 15 different
European countries, however, most of them being from one Member State. The percentage of
left-censored data reported (results below limit of detection and/or limit of quantiﬁcation) was high
(72%). The highest number of reported samples corresponded to the food group ‘Animal and
vegetable fats and oils’ (~ 60%) and in particular to ‘Rapeseed oil’ (n = 5,832). Other food groups that
were well represented were ‘Starchy roots and tubers’ (n = 1,223), ‘Grains and grain-based products’
(n = 982) and ‘Food for infants and small children’ (n = 810).
Mean values reported in rapeseed oil were 630/1,900 mg/kg (lower bound (LB)/upper bound (UB))
with about 90% being left-censored data. The presence of erucic acid in ‘Fine bakery wares’ indicates
the use of high erucic acid oil in their preparation. For ‘Pastries and cakes’, erucic acid was quantiﬁed
in half of the samples (mean 240/290 mg/kg (LB/UB)) and for ‘Biscuits’ in about 25% of the samples
(mean 270/390 mg/kg (LB/UB)). Overall, relatively low levels of erucic acid were reported for the food
group ‘Food for infants and small children’. The highest mean values were reported for ‘Infant
formulae, powder’ (220/290 mg/kg (LB/UB)) and the lowest for ‘Ready-to-eat meal for infants and
young children’ (77/86 mg/kg (LB/UB)). The latest version of the EFSA Comprehensive European Food
Consumption database was used and consumption data were classiﬁed according to the FoodEx
classiﬁcation system. Based on the critical effect identiﬁed in toxicity studies, the CONTAM
Panel considered that only chronic dietary exposure to erucic acid had to be assessed. The highest
chronic dietary exposure was estimated in the youngest population. For the mean dietary exposure,
the highest estimate at the LB corresponded to the age classes ‘Infants’ and ‘Toddlers’ with a
maximum value of 2.8 mg/kg body weight (bw) per day, while at the UB the maximum estimate was
observed in the age class ‘Toddlers’ (4.4 mg/kg bw per day). In the highly exposed population (95th
percentile), the highest estimates were in ‘Infants’ (5.8/7.4 mg/kg bw per day (LB/UB)).
Overall, the food group ‘Fine bakery wares’, more precisely ‘Pastries and cakes’ and ‘Biscuits
(cookies)’ was the main contributor of dietary exposure to erucic acid. At the middle bound (MB), the
contribution of ‘Fine bakery wares’ in ‘Toddlers’ represented up to 39% of the total exposure
(median = 21%) and in ‘Other children’ contributed up to 48% to the total exposure (median = 28%).
Since the levels of erucic acid in ‘Fine bakery wares’ (‘Pastries and cakes’ and ‘Biscuits (cookies)’) were
not that high (240/390 mg/kg (LB/UB)), its relevant contribution is mainly driven by the high
consumption of this heterogeneous food category (e.g. croissants, doughnuts, cakes, mufﬁns, wafﬂes,
biscuits, cookies, etc.). In the age class ‘Infants’, ‘Food for infants and small children’ (FoodEx level 1)
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was the main contributor to the exposure. The contribution of the food group ‘Ready-to-eat meal for
infants and young children’ reached 54% at the MB scenario (range 20–54%) among the dietary
surveys for ‘Infants’.
Speciﬁc exposure scenarios (consumers only) were used to estimate the potential exposure via the
consumption of ‘Composite foods’ and ‘Custard’. Both maximum mean exposure (UB) and maximum
95th percentile dietary exposure (UB) via the consumption of prepared pasta alone were around 6-fold
higher than the maximum exposure estimates in ‘Toddlers’ and ‘Adults’ considering the whole diet.
Only 275 feed samples were available to estimate animal dietary exposure to erucic acid, most of
the samples collected in the EU between 2003 and 2015. Most of the feed samples referred to
‘Rapeseed oil’ (n = 193). The erucic acid content of only 28 samples of rapeseed expeller was
provided, and no data for rapeseed meal, which is the more commonly used feed. The highest
average levels of erucic acid were reported for ‘Rapeseed oil’ (1,300/4,200 mg/kg (LB/UB)).
Rapeseed cakes, meals and oils are important feed materials in diets for livestock in the EU.
Exposures to erucic acid by farmed livestock were estimated using typical feed intakes and body
weights, and feed industry guidelines for the maximum inclusion rates of rapeseed meal and oil in
livestock diets. The estimated mean exposures therefore represent worst-case scenarios. Insufﬁcient
data on levels of erucic acid in rapeseed meal or cake were available to allow P95 estimates of
exposure to be made. Since rapeseed oil or meals are not commonly included in diets for cats and
dogs, no estimates of exposure have been made for these animals. In the category ‘Ruminants and
horses’, the highest exposure was for lactating goats (5.0/7.5 mg/kg bw per day (LB/UB)). For pigs
and poultry, the highest exposures were for fattening chickens (9.4/12 mg/kg bw per day (LB/UB)).
Erucic acid is present in food and feed, predominantly as component of triacylglycerols. It is well
absorbed from the gastrointestinal tract to an extent varying between 60% and 100%, depending on
the species. Humans exhibit virtually complete absorption. Erucic acid is distributed to all organs;
however, there is little distribution into the brain. Mitochondrial b-oxidation of erucic acid is poor in rats
and pigs. Human heart mitochondria appear to also have low activity for erucic acid. Little is known
regarding the excretion of erucic acid.
There is evidence that erucic acid in the feed is transferred to products of animal origin and a
dose-related increase in erucic acid in food of animal origin has been shown. In ruminants, erucic acid
is also partially hydrogenated or isomerised in the rumen.
The heart is the principal target organ for toxic effects following short-term or long-term exposure
of rats, pigs, monkeys, rabbits and gerbils to diets with oils containing erucic acid. The most common
and sensitive effect observed in all species is myocardial lipidosis, i.e. an accumulation of
triacylglycerols in myocardium that appear as neutral lipid droplets. Lipidosis is reversible and transient
during prolonged exposure. Studies in rats and pigs showed an association between the level of erucic
acid in the diet and the severity of myocardial lipidosis. In rats, increased myocardial lipidosis is
observed at doses of 1 g erucic acid/kg bw per day or higher. In newborn pigs, increased myocardial
lipidosis is observed at a dose of 1.1 g erucic acid/kg bw per day. The overall no observed adverse
effect level (NOAEL) for lipidosis was 0.7 g/kg bw per day in a 7-day feeding study in young rats and
in a 2-week feeding study in newborn piglets. Adult pigs are able to tolerate higher levels of erucic
acid than young animals. These results suggest that the immature myocardium and/or liver may be
less able to metabolise erucic acid, making neonates especially prone to myocardial lipidosis, albeit
transiently. Myocardial lipidosis is reported to reduce the contractile force of the heart muscle.
Mitochondrial damage (megamitochondria, mitochondrial proliferation, increase in the average volume,
distortion of shape, degeneration) and disorganisation of myoﬁbrils has been reported after exposure
of rats, pigs, monkeys or rabbits to high doses of erucic acid.
Feeding rats with high erucic acid doses for 4 or more weeks is associated with the occurrence of
myocardial necrosis and ﬁbrosis. Factors other than, or in addition to, erucic acid are likely to be
responsible for the increased incidence of these lesions, e.g. fatty acid imbalance. Therefore, the
CONTAM Panel considered necrosis not a suitable endpoint for the risk assessment. A causal link
between myocardial lipidosis and myocardial lesions has not been established.
Non-cardiac effects, such as changes in the liver, kidneys, skeletal muscle, adrenals and testis
weight, have also been reported in rats and haematological and liver alterations in newborn piglets. In
all cases, these effects are observed at somewhat higher doses than those leading to cardiac lipidosis
in the same species.
Because of the lack of adequate studies, no conclusions can be drawn on the genotoxicity and
carcinogenicity of erucic acid. No major adverse reproductive and developmental effects were
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associated with feeding female rats, mice and hamsters with erucic acid-containing diets prior to
mating and during pregnancy.
In humans, a higher level of 22:1 in plasma phospholipids has been associated with higher
incidence of congestive heart failure in two independent cohorts whereas higher circulating levels of
erucic acid in erythrocytes have been associated with lower incidence of coronary heart disease. Two
studies on the possible association between cancer and erucic acid exposure were identiﬁed but no
conclusion can be drawn due to the intrinsic limitations or lack of speciﬁcity of the outcome. The
therapeutic use of erucic acid, as component of Lorenzo’s oil for treating adrenoleukodystrophy (ALD)
patients, results in haematological effects, most notably thrombocytopenia and morphological
alterations of thrombocytes, at doses of about 0.1 g/kg bw per day. Erucic acid induced lipidosis has
not been described in humans.
A high intake of erucic acid leads to lipidosis in pigs and rats, particularly in the heart, due to the
poor b-oxidation of erucic acid in mitochondria. Cardiac lipidosis is transient (reversible), even after
prolonged intake of erucic acid because of the induction of peroxisomal degradation of erucic acid.
A reduction in feed intake and milk yield by dairy cows was reported at an intake of 0.4 g erucic
acid/kg bw per day from rapeseed meal. However, the possible role of glucosinolates or other
antinutritional factors in the meal could not be ruled out. Feeding poultry with diets containing HEAR
oil resulted in growth retardation and cardiac lipidosis. High doses of erucic acid also increased the
incidence and severity of cardiac lesions (similar to those observed in the rat). In addition,
hydropericardium, effects on the liver and skeletal muscles were induced in several species fed diets
containing high doses of erucic acid. The CONTAM Panel identiﬁed a lowest observed adverse effect
level (LOAEL) of 0.02 g/kg bw per day for liver toxicity in poultry. Studies, in which poultry were fed
diets supplemented with oils and meals derived from HEAR cultivars, clearly demonstrated adverse
effects on production-related factors. However, as for other livestock, the possible effects of other
dietary constituents or characteristics on feed intake, growth rate and egg production cannot be
excluded. No conclusion regarding the adverse effects in ﬁsh, rabbits and horses could be drawn due
to the limited studies available. No studies on adverse effects in companion animals were identiﬁed.
An acute reference dose was not established because of the lack of endpoints indicative of acute
toxicity on target organs. Myocardial lipidosis, as reported in rats and pigs following feeding with HEAR
oils, was selected as critical effect for establishing a tolerable daily intake (TDI) for erucic acid. Since
there are no adequate data from human studies for dose–response assessment, the CONTAM
Panel considered the data from studies on experimental animals to identify reference points. The
CONTAM Panel selected the overall NOAEL for lipidosis of 0.7 g/kg bw per day, observed in a 7-day
feeding study in young rats and in a 2-week feeding study in newborn piglets, as reference point for
the risk assessment. Based on this NOAEL, the CONTAM Panel established a TDI of 7 mg/kg bw for
erucic acid using the default uncertainty factor of 100 to account for intra- and interspecies
differences. The CONTAM Panel noted that this TDI is well below the erucic acid dose of 100 mg/kg
bw per day causing haematological effects in ALD patients treated with Lorenzo’s oil.
Data on human dietary exposure levels to erucic acid across dietary surveys and age groups
showed mean exposure values that range from 0.3 (minimum LB) to 4.4 mg/kg bw per day (maximum
UB) across dietary surveys and age groups. The mean dietary exposure for adults ranged from 0.3 to
1.9 mg/kg bw per day across the European surveys and was the highest for toddlers and infants,
ranging from 0.5 to 4.4 mg/kg bw per day, which is below the TDI of 7 mg/kg bw per day. The 95th
percentile dietary exposure levels range from 0.7 (minimum LB) to 7.4 mg/kg bw per day (maximum
UB) across dietary surveys and age groups, with a range for adults from 0.9 to 4.3 mg/kg bw per day.
The 95th percentile dietary exposure was the highest in infants and other children, ranging from 1.3 to
7.4 mg/kg bw per day; the upper range being at the level of the TDI. This may indicate a risk for
young individuals with high erucic acid exposure.
For ruminants, no NOAEL could be identiﬁed. The dietary exposure of dairy cattle is well below the
dose at which no effect is observed on milk yield. However, the risk of other adverse effects or for
other ruminants could not be assessed. For pigs, the CONTAM Panel identiﬁed a NOAEL of 700 mg/kg
bw per day for myocardial lipidosis. The dietary exposure of pigs is well below the NOAEL for lipidosis
in pigs. For poultry, a LOAEL of 20 mg/kg bw per day was identiﬁed for liver toxicity, which is about
double the upper exposure range (12 mg/kg bw per day). The small margin between the LOAEL and
the estimated exposure may indicate a health risk for poultry where maximum inclusion rates are
applied. It should be mentioned that insufﬁcient data on levels of erucic acid in rapeseed meal or cake
were available to allow P95 estimates of exposure to be made. No NOAEL/LOAEL could be identiﬁed
for horses, ﬁsh and rabbits, and therefore, the risk of erucic acid exposure could not be assessed for
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these species. However, the CONTAM Panel noted that the exposure of horses (0.95/1.5 mg/kg bw per
day (LB/UB)) and rabbits (6.4/13 mg/kg bw per day (LB/UB)) is well below the NOAEL of 700 mg/kg
bw per day for pigs. The dietary exposure of cats and dogs to erucic acid is considered to be negligible
and no risk characterisation has been undertaken.
Several uncertainties concerning the exposure assessment and hazard identiﬁcation and
characterisation have been identiﬁed. The CONTAM Panel considered that the impact of the
uncertainties on the risk assessment of human and animal exposure to erucic acid through
consumption of food and feed is considerable. Based on the lipidosis selected as the critical effect to
derive the TDI, the CONTAM Panel concluded that the risk assessment of human exposure to erucic
acid presented in the opinion is more likely to overestimate than to underestimate the risk. For the
same reason, the CONTAM Panel concluded that the risk assessment for pigs is more likely to
overestimate than to underestimate the risk. The use of maximum inclusion rates resulted in an
overestimation of the exposure for poultry. However, considering the uncertainties related to the use of
a LOAEL as toxicological reference point for poultry, it is not possible to conclude whether the risk for
this species is overestimated.
The EFSA CONTAM Panel recommends the generation of more analytical data on the occurrence of
erucic acid in relevant food and feed commodities using sensitive and speciﬁc methods. Special
attention should be paid to processed foods such as ‘Fine bakery wares’, ‘Food for infants and small
children’ and ‘Composite foods’. There should be more information on the levels in animal-derived
products (meat, milk and eggs) resulting from the transfer of erucic acid from animal feed. There is a
need for a repeated-dose toxicity study in newborn rats or pigs with pure erucic acid in order to clarify
the potential confounding effects of other fatty acids present in the oil and to provide information
regarding the dose–response relationship. Moreover, studies should be conducted on species
differences in the cardiac and hepatic metabolism of erucic acid. Further studies are also required to
determine reference points for target livestock animals and ﬁsh.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Background
A maximum level for erucic acid in oils and fats intended as such for human consumption and in
foodstuffs containing added oils and fats has been established by Council Directive 76/621/EEC1. A
stricter maximum level for erucic acid has been established in infant formulae and follow-on formulae
by Commission Directive 2006/141/EC.2
Erucic acid is a natural plant toxin which is a contaminant according to the deﬁnition of the
contaminant provided in Council Regulation (EEC) No 315/93 of 8 February 1993 laying down
Community procedures for contaminants in food3 as the presence of erucic acid in food is the result of
the agricultural production, more in particular the choice of the variety.
To simplify the legislation, the maximum levels for erucic acid have been established in Regulation
(EC) 1881/20064, as amended by Commission Regulation (EU) No 696/20145. Council Directive
76/621/EEC shall be repealed subsequently.
The appropriateness of setting a maximum level for erucic acid has been highlighted by the
Scientiﬁc Committee on Food (SCF) in its opinion expressed on 17 September 1993 on essential
requirements for infant formulae and follow-on formulae.6
When the maximum levels of erucic acid were established by Regulation (EC) 1881/2006, it was
found necessary to review the maximum levels in the future based upon an updated risk assessment
and also to consider the appropriateness of establishing maximum levels for erucic acid in feed.
Terms of Reference
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks the
European Food Safety Authority (EFSA) for a scientiﬁc opinion on the risks for animal and human
health related to the presence of erucic acid in feed and food.
The scientiﬁc opinion should, inter alia, comprise the:
a) evaluation of the toxicity of erucic acid for animals and humans, considering all relevant
adverse health effects;
b) estimation of the dietary exposure of the European Union (EU) population to erucic acid
including the consumption patterns of speciﬁc (vulnerable) groups of the population (e.g. high
consumers, children, people following a speciﬁc diet, etc.);
c) estimation of the exposure of the different animal species to erucic acid in feed and the level of
transfer/carryover of erucic acid from the feed to the products of animal origin for human
consumption resulting in unacceptable levels of erucic acid;
d) assessment of the human health risks for the EU population including for speciﬁc (vulnerable)
groups of the population as the consequence of the estimated dietary exposure;
e) assessment of the animal health risks for the different animal species as the consequence of
the estimated exposure from animal feed.
1.2. Interpretation of the Terms of Reference
The EFSA Panel on Contaminants in the Food Chain (CONTAM) concluded that the terms of
reference provided by the Commission were clear.
1 Council Directive 76/621/EEC of 20 July 1976 relating to the ﬁxing of the maximum level of erucic acid in oils and fats intended
as such for human consumption and in foodstuffs containing added oils and fats. OJ L 202, 28.2.1976, p. 35–37.
2 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC. OJ L 401, 30.12.2006, p. 1–33.
3 Council Regulation (EEC) No 315/93 of 8 February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–3.
4 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in
foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
5 Commission Regulation (EU) No 696/2014 of 24 June 2014 amending Regulation (EC) No 1881/2006 as regards maximum
levels of erucic acid in vegetable oils and fats and foods containing vegetable oils and fats. OJ L 184, 25.6.2014, p. 1–2.
6 http://ec.europa.eu/food/fs/sc/scf/reports/scf_reports_34.pdf
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1.3. Additional information
1.3.1. Oil and oil seeds containing erucic acid
Erucic acid is present at high concentrations mainly in the seeds of some species of the plant family
Brassicaceae. Around 80–90% of the species of this family naturally contain varying amounts of erucic
acid that account for up to 60% of the total fatty acids (Kumar and Tsunoda, 1980; Goffman et al.,
1999; Velasco et al., 1999). This family contains several species that are cultivated for their seeds,
mainly for seed oil production but also for manufacturing condiments such as mustard. Most of them
belong to the genus Brassica, including rapeseed (Brassica napus L.), turnip rape (Brassica rapa L.),
Indian or oriental mustard (Brassica juncea [L.] Czern.), Ethiopian or Abyssinian mustard
(Brassica carinata A. Braun.) and black mustard (Brassica nigra [L.] Koch) (Velasco and Fernandez-
Martınez, 2009). Brassica rapa is commonly found in the literature as Brassica campestris, although the
former name is preferred according to the International Code of Botanical Nomenclature (Dixon,
2006). Therefore, B. rapa is used in this opinion with precedence over B. campestris. The CONTAM
Panel noted that B. rapa is also mistakenly referred to as rapeseed by some authors. Other species
cultivated for their seeds are white mustard (Sinapis alba L.), crambe (Crambe hispanica subsp.
abyssinica [Hochst. ex R. E. Fr.] Prina), camelina (Camelina sativa [L.] Crantz) and eruca (Eruca
vesicaria subsp. sativa [Mill.] Thell.) (Warwick, 2011). Most of these species are also cultivated as
vegetable and/or fodder crops (Velasco and Fernandez-Martınez, 2009; Warwick, 2011). Another
species, radish (Raphanus spp.), contains forms cultivated for their edible young seed pods and as
animal fodder (Warwick, 2011). Additionally, seeds from some Brassicaceae species, including some of
the abovementioned species plus others such as Brassica oleracea L., have become popular to produce
sprouts for salads (West et al., 2002), whereas a diversity of plant parts are used to make pickles
(Ayaz et al., 2006).
When in this Scientiﬁc Opinion the erucic acid content is reported as a percentage, this value refers
to the percentage erucic acid in the total fatty acids on a weight basis.
The most commercially important crop of the Brassicaceae is rapeseed, which is produced at a
higher scale compared to turnip rape (Booth and Gunstone, 2004). Both crops are nowadays cultivated
worldwide over a global acreage close to 34 million hectares, yielding a production of 23 million tonnes
seed oil. Around 20% of world acreage of rapeseed and turnip rape, which yields 38% of the world
rapeseed oil production, is located in the EU.7 Turnip rape has a more restricted distribution area than
rapeseed including parts of Sweden and Finland, western Canada, north-western China, and the Indian
subcontinent (Velasco and Fernandez-Martınez, 2009).
Although natural forms of rapeseed, turnip rape and mustard species contain high levels of erucic
acid, usually more than 40%, commercially bred cultivars of rapeseed and other species developed
since the 1970s have been essentially free from erucic acid, i.e. < 1% (Friedt and Snowdon, 2009). In
Canada, the term ‘canola’ was created to refer to cultivars with low erucic acid content and low
glucosinolate content. The ofﬁcial deﬁnition of canola is as follows:8
‘Seeds of the genus Brassica (Brassica napus, Brassica rapa or Brassica juncea) from which the oil
shall contain less than 2% erucic acid in its fatty acid proﬁle and the solid component shall contain
less than 30 micromoles of any one or any mixture of 3-butenyl glucosinolate, 4-pentenyl
glucosinolate, 2-hydroxy-3-butenyl glucosinolate and 2-hydroxy-4-pentenyl glucosinolate per gram
of air-dry, oil-free solid’.
Today the term canola is used worldwide, including in scientiﬁc literature, to refer to low erucic acid
and low glucosinolate content cultivars of Brassica species. Current rapeseed varieties are
characterised by extremely low erucic acid content, usually below 0.5% (Temple-Heald, 2004).
Evaluation of erucic acid content in the rapeseed cultivars marketed in France from 2005 to 2015
resulted in all cases in average erucic acid values below 0.5% (Appendix A, Table A.1). The Canadian
Grain Commission reported an average erucic acid content of 0.01% in rapeseed and rapeseed oil
samples collected from producers, crushing plants and grain handling ofﬁces across Western Canada
from 2009 to 2014 (Barthet, 2014). Comparative fatty acid composition of high erucic acid rapeseed
(HEAR) and low erucic acid rapeseed (LEAR) cultivars is shown in Table 1.
7 http://faostat3.fao.org/home/index.html
8 http://www.canolacouncil.org/oil-and-meal/what-is-canola/
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HEAR cultivars are still grown to meet the demand of the oleochemical industry. Currently, world
demand for high erucic acid oil is estimated to be around 0.1 million tonnes (Zanetti et al., 2012). In
the EU, high erucic acid oil production is mainly located in the United Kingdom (UK), where high erucic
acid cultivars are grown under contract at a minimum distance of 50 m from low erucic rapeseed crops
to avoid cross-pollination between both types of cultivars (Temple-Heald, 2004). Acreage of HEAR in
the UK is estimated in more than 25,000 ha.9 There is also a small-scale production of high erucic
varieties in Germany and France, estimated to be 20,000 and 14,000 ha, respectively (Merrien, 2011).
It is also produced in several countries outside the EU such as China and India.
Crambe oil is one of the oils with the highest erucic acid content, typically over 60% (Lalas et al.,
2012). It is exclusively intended for non-food uses (Warwick, 2011). Camelina oil has a relatively low
erucic acid content that typically ranges from 1% to 4%. Currently, camelina is a very minor crop that
is perceived by breeders as a potential crop for both food and non-food uses, the latter particularly in
the ﬁeld of biofuels (Vollmann and Eynck, 2015).
Oils from white mustard, black mustard and eruca are mainly produced in India at a small scale
(Grubben and Denton, 2004; Warwick, 2011; Shekhawat et al., 2012). Seed oils from these three
species contain high erucic acid levels over 30% (Goffman et al., 1999). Forms with low erucic acid
content have been developed for white mustard (Raney et al., 1995), but there is no indication that
seed oil production in India is based on low erucic acid cultivars.
Erucic acid is also present in the seeds and seed oils of other plant families, usually at lower
concentrations than in the Brassicaceae family. For example, meadow foam (Limnanthes alba Hartw.
ex Benth.; Limnanthaceae) is a North American minor annual crop producing a seed oil of great value
for the cosmetic industry. It naturally contains between 8% and 24% of erucic acid, although
improved forms with lower erucic acid levels (< 3%) have been developed (Gandhi et al., 2009).
Borage (Borago ofﬁcinalis L.; Boraginaceae) seeds produce an oil marketed as a dietary supplement on
the basis of alleged nutritional beneﬁts associated with the presence of c-linolenic acid (Ziboh, 2008).
Borage oil typically contains between 1% and 3% erucic acid, although forms with higher erucic acid
content have been identiﬁed in the wild (de Haro et al., 2002). Erucic acid levels below 3% are also
found in the seeds of some lupine species such as white lupine (Lupinus albus L.), consumed as a
popular snack in southern Europe and also used for animal feeding (Bhardwaj et al., 2004), although
higher values, up to 5%, have been reported in some environments (Boschin et al., 2008). Erucic acid
can also be found at low levels in the seed lipids of other species such as cowpea (Vigna unguiculata
[L.] Walp.) (Antova et al., 2014) and quinoa (Chenopodium quinoa Willd.) (Wood et al., 1993).
Seeds from several species of the Brassicaceae family are used to produce mustard. Annual world
production of mustard seed not intended for oil extraction is around 0.7 million tonnes, with Canada
and Nepal being the two major producers.7 In Canada, three types of mustard are grown: yellow
mustard (S. alba), and oriental and brown mustard, which are two groups of varieties of B. juncea,
differing mainly in seed colour.10 These three types contain high levels of erucic acid: around 25% in
brown and oriental mustard and around 35% in yellow mustard (Siemens, 2014). In the EU, Germany
is the main producing country of mustard seed, with a production of around 10,000 tonnes/year.
Several species of the Brassicaceae family comprise highly consumed vegetables. The most
important group is B. oleracea, which encompasses a great diversity of vegetable forms such as
Table 1: Comparison of the average percentage of major fatty acids in the seed oil of high erucic
acid rapeseed (HEAR) and low erucic acid rapeseed (LEAR) cultivars (Gunstone and
Harwood, 2007)
Fatty acid LEAR HEAR
Palmitic acid 16:0 3.6 4.0
Stearic acid 18:0 1.5 1.0
Oleic acid 18:1 n-9 61.6 14.8
Linoleic acid 18:2 n-6 21.7 14.1
Linolenic acid 18:3 n-3 9.6 9.1
Gondoic acid 20:1 n-9 1.4 10.0
Erucic acid 22:1 n-9 0.2 45.1
9 http://www.premiumcrops.com/ﬁles/Agronomist_Brieﬁng_HEAR.pdf
10 http://saskmustard.com/grower/manual/plant-description/types-of-mustards-and-their-uses/index.html
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cabbage, broccoli, cauliﬂower, kale, Brussels sprouts, collard greens and kohlrabi. Brassica vegetables
may contain only traces of erucic acid, while the seeds contain high levels. For example, mature kale
leaves have been reported to have an erucic acid content of 2 mg/kg (dry weight basis) (Ayaz et al.,
2006), and a very small amount of erucic acid has been detected in broccoli ﬂorets, around 8 mg/kg
(fresh weight basis), compared to 120,500 mg/kg in broccoli seeds (West et al., 2002). High levels of
erucic acid of up to 87,280 mg/kg have also been reported in sprouts from Brassica seeds (Bhardwaj
and Hamama, 2009).
The Brassicaceae family also encompasses important fodder crops such as forage rape (B. napus),
turnips (B. rapa), kales and cabbages (B. rapa and B. oleracea), swedes (B. napus) and fodder
radishes (Raphanus sativus). Erucic acid is only present in the seeds of these Brassicaceae crops
(Peiretti et al., 2012) and since these crops are grazed in vegetative stages of development, they are
not a source of erucic acid.
Besides the occurrence in oil seeds, erucic acid also occurs in ﬁsh and marine animals and human
milk (see Section 3.1.1.1).
1.3.2. Previous assessments
In 2003, the Food Standards Australia and New Zeeland (FSANZ) published a review of the health
effects of erucic acid (FSANZ, 2003). In the absence of adequate human data, a no observed effect
level (NOEL) of 750 mg/kg body weight (bw) per day, based on the occurrence of increased
myocardial lipidosis at 900 mg/kg bw per day in newborn pigs (Kramer et al., 1990), was considered
appropriate for extrapolation to humans. By applying an uncertainty factor of 100 (10 for extrapolation
from experimental animals to humans, 10 for variation within humans), a tolerable level for human
exposure of 7.5 mg erucic acid/kg bw per day (about 500 mg erucic acid/day for the average adult)
was calculated and proposed as the provisional tolerable daily intake (pTDI) for erucic acid. Moreover,
it was concluded that, with the current mean dietary intakes of erucic acid in canola oil by Australian
and New Zealand consumers, there is no cause for concern in terms of public health and safety, but
high consumers of canola oil have the potential to approach the pTDI.
In 1995, the SCF (1995) recommended that the content of erucic acid in infant formulae should not
exceed 1% of total fatty acids. This precautionary decision was based on toxicological studies showing
higher severity of myocardial lipidosis induced by erucic acid in newborn piglets when compared to
weaned pigs (Kramer et al., 1990) and on the observation that erucic acid may inhibit fatty acid
elongation in human cells (Koike et al., 1991).
In 2003, the SCF recommended to maintain a maximum level of erucic acid of 1% total fatty acids
in infant formulae and follow-on formulae as indicated in the Infant Formulae Directive11 (SCF, 2003).
1.3.3. Chemistry
Erucic acid is the trivial name used for the fatty acid with systematic name Z-13-docosenoic or
cis-13-docosenoic acid according to International Union of Pure and Applied Chemistry (IUPAC)
nomenclature. This can be abbreviated as 22:1D13c or 22:1 13c (Scrimgeour and Harwood, 2007;
Lobb and Chow, 2008). This nomenclature denotes a molecule with 22 carbon atoms and one double
bond in cis conﬁguration located between the carbon atoms at positions 13 and 14 counting from the
carboxylic group (Figure 1).
Notwithstanding this, the most common nomenclature for fatty acids in scientiﬁc literature counts
the position of the ﬁrst carbon of double bonds starting from the methyl group of the fatty acid and
denotes the position of the ﬁrst double bond with the preﬁxes n- or x-. Double bonds are assumed to
be in cis geometric conﬁguration unless otherwise indicated. With this nomenclature, erucic acid is
abbreviated as 22:1 n-9 or 22:1 x-9 (Lobb and Chow, 2008). The presence of trans conﬁguration is
indicated in this Scientiﬁc Opinion as trans 22:1 n-9, which is brassidic acid.
O
OH
(Z)
erucic acid
Figure 1: Molecule of Z-13-docosenoic acid (erucic acid)
11 Commission Directive 91/321/EEC of 14 May 1991 on infant formulae and follow-on formulae. OJ L 175, 4.7.1991, p. 35–49.
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The main identiﬁers12 as well as physical and chemical properties of erucic acid are summarised in
Table 2.
Erucic acid is present in seeds and oils mainly as a component of triacylglycerol molecules. These
consist of a glycerol moiety in which each of the three hydroxyl groups is esteriﬁed with the carboxyl
group of a fatty acid. The three hydroxyl groups of glycerol are designated as sn-1, sn-2 and sn-3,
with sn-2 being the central one (Belitz et al., 2009). In the seed oils of some plant species containing
erucic acid, this fatty acid is virtually excluded from the sn-2 position of the triacylglycerols, whereas in
other species there is a balanced distribution of erucic acid in the three positions of the triacylglycerol
molecule. For example, rapeseed oil contains a very low proportion of erucic acid at the sn-2 position,
while B. oleracea and Tropaeolum majus seed oils contain similar levels of erucic acid at the three
positions (Taylor et al., 1994). Such differences might have implications from a nutritional perspective,
since it is well known that stereospeciﬁcity and chain length of fatty acids at the sn-1, sn-2 and sn-3
positions of triacylglycerols is a major determinant of the metabolic route that will follow fatty acids
during digestion and absorption (Karupaiah and Sundram, 2007). However, such implications have not
been studied in the particular case of erucic acid.
Erucic acid is also present in lipid classes other than triacylglycerol, e.g. diacylglycerols, free fatty
acids, sterol esters, glycolipids and phospholipids. However, the proportion of erucic acid in these lipids
in relation to other fatty acids is lower than in triacylglycerols, particularly in the case of phospholipids
(Zadernowski and Sosulski, 1978). Studies in crambe have shown that the limited presence of erucic
acid in the membrane lipids may be caused by a low phosphatidylcholine-diacylglycerol interconversion
(Guan et al., 2014).
1.3.4. Analytical methods
Since erucic acid is a fatty acid, it is analysed using methods for fatty acids analysis. The
Commission Directive 80/891/EEC13 of 25 July 1980 laid down a Community method of analysis for
determining the erucic acid content in oils and fats and in foodstuffs containing oils and fats. This
Directive was repealed by Commission Regulation (EU) 2015/70514 of 30 April 2015 as the method of
analysis of erucic acid had become obsolete. Several associations and institutions have developed
protocols that can be used for the analysis of the fatty acid composition in biological samples and food
products. A list of relevant methods is given in Appendix B and the general principles are brieﬂy
described below.
Table 2: Main identiﬁers and physical and chemical properties of erucic acid
Identiﬁer/property Value
CAS Registry Number 112-86-7
EC Number 204-011-3
Molecular Formula C22H42O2
Molecular weight 338.56768 g/mol
Boiling point 265°C at 15 mmHg
Melting point 33.8°C
Solubility in water Insoluble: 2.66 9 104 mg dissolve in 1 L
Solubility in ethanol Soluble: 175 g dissolve in 100 mL
Density 0.860 g/cm3
Index of refraction 1.4534 at 45°C
CAS: Chemical Abstracts Service; EC: European Commission.
12 https://pubchem.ncbi.nlm.nih.gov/compound/erucic_acid#section=Top
13 Commission Directive 80/891/EEC of 25 July 1980 relating to the Community method of analysis for determining the erucic
acid content in oils and fats intended to be used as such for human consumption and foodstuffs containing added oils or fats.
OJ L 254, 25.7.1980, p. 35–41.
14 Commission Regulation (EU) 2015/705 of 30 April 2015 laying down methods of sampling and performance criteria for the
methods of analysis for the ofﬁcial control of the levels of erucic acid in foodstuffs and repealing Commission Directive
80/891/EEC. OJ L 113, 1.5.2015, p. 29–37.
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1.3.4.1. Extraction of lipids
Lipids in plant and animal tissues occur in different forms. Most oilseeds accumulate the large
majority of the lipids in the form of ﬂuid triacylglycerol droplets termed oil bodies, which are extracted
easily with solvents such as hexane or diethyl ether. But on the other hand, membrane lipids occur in
close association with other molecules such as polysaccharides and proteins. In these cases, lipid
extraction requires not only dissolving the lipids, but mainly breaking the complex interactions with
other membrane compounds. The most commonly used solvent combination for lipid extraction is
chloroform–methanol (2:1 by volume) (Dijkstra et al., 2007). Extraction with supercritical ﬂuids is a
promising alternative to conventional methods based on organic solvents (Martinez and de Aguiar,
2014).
1.3.4.2. Gas chromatography-derived methods
The most common procedure for analysis of the fatty acid proﬁle is derivatisation of fatty acids
followed by separation and identiﬁcation by gas chromatography (GC). Derivatisation consists in the
transesteriﬁcation of the carboxylic groups of the fatty acids, which reduces their polarity and makes
them more amenable to analysis by GC. In the reaction of transesteriﬁcation, a triacylglycerol reacts
with an alcohol in the presence of a catalyst, usually a strong acid or base, producing a mixture of
fatty acid alkyl esters and glycerol, and mono- and diacylglycerols are formed as intermediates (Knothe
et al., 2007). There is a number of derivatisation procedures that differ in the alcohol used, type of
catalyst used, and in parameters such as time of reaction, temperature, etc. (Christie, 1993). The most
common procedures in most internationally approved methods are based on the use of an acidic
catalyst and methanol as alcohol, which results in the formation of fatty acid methyl esters (FAMEs).
For non-polar lipids, such as triacylglycerols, an additional solvent, such as toluene, should be added to
facilitate their solubility (Dijkstra et al., 2007).
FAMEs are separated almost exclusively in capillary columns with polar polyester coatings. FAMEs
are separated in the column according to their chain length, number of double bonds, position of the
double bonds, and even the cis/trans conﬁguration of double bonds. A polyester phase with low to
medium polarity is generally adequate for the analysis of common fatty acids from plant and animal
origin. In most cases, identiﬁcation of erucic acid is simply conducted by comparing the retention time
with that of an analytical standard. Flame ionisation detectors (FID) are commonly used for fatty acid
analysis (Dijkstra et al., 2007). Exceptionally, it may be necessary to perform a conﬁrmatory
identiﬁcation using mass spectrometry (MS) detection. There are two derivatisation procedures
particularly well suited for MS detection of fatty acids, based on 3-hydroxymethylpyridinyl (picolinyl)
esters and 4,4-dimethyloxazoline derivatives, respectively (Christie, 1998). MS also allows identifying
positions of branching and in some cases the positions of unsaturation in the molecule (Dodds et al.,
2005).
1.3.4.3. High-performance liquid chromatography-derived methods
Nearly all internationally recognised protocols for analysis of fatty acids are based on GC. However,
methods for fatty acid analysis by reversed-phase high-performance liquid chromatography (HPLC) are
also available. They are particularly useful to recover speciﬁc fractions for further characterisation.
HPLC analysis also reduces the risk of isomerisation of unsaturated fatty acids. The analysis may be
conducted with or without previous derivatisation of fatty acids, using a ultraviolet–visible photodiode
array detector (Guarrasi et al., 2010).
1.3.4.4. Nuclear magnetic resonance spectroscopy
Both 1H- and 13C-nuclear magnetic resonance (NMR) spectroscopy are powerful techniques to
elucidate structural properties of fatty acids (Dijkstra et al., 2007). Procedures for determining the fatty
acid composition of oil samples by 1H-NMR analysis have also been reported (Knothe and Kenar, 2004;
Barison et al., 2010).
1.3.4.5. Near-infrared, Fourier transform near-infrared and attenuated total reﬂection-
Fourier transform infrared spectroscopy
Both near-infrared (NIR) spectroscopy and Fourier transform (FT) NIR spectroscopy are secondary
techniques for measuring the fatty acid proﬁle that requires calibration using laboratory data provided
by a primary technique, usually GC analysis of FAMEs (Velasco and Becker, 1998; Kolackova et al.,
2014). Both techniques are less accurate than GC analysis, as they accumulate the prediction error to
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their own analytical error, but have the main advantage of allowing very fast analyses without any kind
of sample preparation. NIR and FT-NIR are not adequate when an accurate analysis of the fatty acid
proﬁle is required, but they are extremely useful for screening, real-time monitoring of processes or
in-situ measurements (Perez-Marın et al., 2009). Attenuated total reﬂection-Fourier transform infrared
(ATR-FTIR) spectroscopy is also a technique used for analysis of erucic acid content in vegetable oils
(Sherazi et al., 2013) that, additionally, has the great advantage of being suitable for non-invasive
measurement of fatty acid composition in biological tissues (Yoshida, 2008).
1.3.4.6. Analytical quality assurance: performance criteria, reference materials and
proﬁciency testing
Performance criteria for the analytical methods used for the ofﬁcial control of levels of erucic acid in
foodstuffs are laid down in Commission Regulation (EC) No 2015/705. Whereas no speciﬁc methods
for the determination of erucic acid content in foodstuffs are prescribed at the EU level, laboratories
may select any validated method of analysis for the respective matrix, provided that the selected
method meets the speciﬁc performance criteria set out in the Regulation. It is recommended that fully
validated methods, i.e. validated by collaborative trial, are used where appropriate and available.
Proﬁciency testing schemes including erucic acid are conducted regularly by organisations such as The
International Bureau for Analytical Studies (BIPEA),15 Fapas,16 or The American Oil Chemists’ Society
(AOCS)17 among others. Reference materials are available from these organisations and others such as
the National Institute of Standards and Technology (NIST).18 Other suitable validated methods, e.g.
in-house validated methods may also be used provided that they fulﬁl the performance criteria set out
in the Regulation. The Regulation follows a criteria-centred approach based on a given number of
method characteristics taken individually. The limit of detection (LOD) is required to be less than 1 g/kg
fat and the limit of quantiﬁcation (LOQ) to be less than 5 g/kg fat (Commission Regulation (EC)
No 2015/705). Typical LOD and LOQ values reported in the literature using GC and FID detection, which
is the most common detection method in routine analyses, are around 0.03 and 0.1 g/kg fat,
respectively (Dixit and Das, 2012). Much lower values are reported for GC methods based on more
sensitive MS detectors (Devle et al., 2009). According to the Commission Regulation, the recovery
should be between 95% and 105%.
1.3.5. Legislation
In order to protect public health, Article 2 of Council Regulation (EEC) No 315/93 stipulates that,
where necessary, maximum tolerances for speciﬁc contaminants shall be established.19 Currently,
maximum levels (MLs) for erucic acid are laid down in the Annex, Section 8, of Commission Regulation
(EC) No 1881/2006. An ML of 50 g erucic acid/kg fat20 applies to vegetable oils and fats, and foods
containing added vegetable oils and fats with the exception of infant formulae and follow-on formulae.
For infant formulae and follow-on formulae an ML of 10 g erucic acid/kg fat applies.20
2. Data and methodologies
2.1. Data
2.1.1. Occurrence data
2.1.1.1. Data collection and validation
At the moment of receiving the request for the scientiﬁc opinion from the European Commission
(EC), no data on erucic acid (22:1 n-9) were available in the EFSA Chemical Occurrence database. The
EFSA Evidence Management Unit (DATA Unit) initiated an ad-hoc collection of data to compile
occurrence data on erucic acid levels in food and feed.21 The European national food authorities and
similar bodies, research institutions, academia, and food business operators were invited to submit
15 http://www.bipea.org/
16 http://fera.co.uk/fapas-proﬁciency-testing/
17 http://www.aocs.org/LabServices/content.cfm?ItemNumber=841&navItemNumber=640
18 http://www.nist.gov/
19 In this scientiﬁc opinion, where reference is made to European legislation (regulations, directives, decisions), the reference
should be understood as relating to the most current amendment, unless otherwise stated.
20 The maximum level refers to the level of erucic acid, calculated on the total level of fatty acids in the fat component in food.
21 http://www.efsa.europa.eu/en/dataclosed/call/150408
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data. The data for the present assessment were provided by national authorities from Austria, Cyprus,
the Czech Republic, Denmark, France, Germany, Hungary, Poland, Slovenia, Slovakia and the UK, and
by the European Vegetable Oil and Proteinmeal Industry (FEDIOL), by the Specialised Nutrition Europe
(SNE) and by the European Feed Manufacturers’ Federation (FEFAC).
The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample
Description for Food and Feed (EFSA, 2010a); occurrence data were managed following the EFSA
standard operational procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of
food consumption and occurrence data’.
By the end of December 2015, a total of 16,671 samples of food, drinking water and feed with
analytical data on erucic acid were available in the EFSA database. Approximately 2% of the samples
were reported as feed and the rest as food and drinking water samples. Data received after that date
were not included in the initial dataset used to estimate dietary exposure.
2.1.1.2. Data analysis
Following the EFSA SOP on ‘Data analysis of food consumption and occurrence data’ to guarantee
an appropriate quality of the data used in the exposure assessment the initial dataset was carefully
evaluated applying several data cleaning and validation steps. Special attention was paid to different
parameters such as ‘Sampling strategy’, ‘Sampling year’, ‘Sampling country’, ‘Analytical methods’,
‘Reporting unit’ and the codiﬁcation of the different samples under FoodEx classiﬁcation (for food) and
Commission Regulation No 68/201322 (for feed), among others. The outcome of the data analysis is
shown in Section 3.1.2.
Analytical results were reported either in whole weight basis or fat basis. Before estimating dietary
exposure, all results were converted into mg/kg whole weight. For those samples expressed on fat
weight basis, the fat content was used to convert the analytical result into whole weight; when fat
content was missing, whenever possible imputation of the fat content from reported values was done
(see Section 3.1.2).
The left-censored data (analytical data below the LOD/LOQ) were treated by the substitution
method as recommended in the ‘Principles and Methods for the Risk Assessment of Chemicals in Food’
(WHO/IPCS, 2009). The same method is indicated in the EFSA scientiﬁc report ‘Management of
left-censored data in dietary exposure assessment of chemical substances’ (EFSA, 2010b) as an option
in the treatment of left-censored data. The guidance suggests that the lower bound (LB) and upper
bound (UB) approach should be used for chemicals likely to be present in the food (e.g. naturally
occurring contaminants, nutrients and mycotoxins). At the LB, results below the LOQ or LOD were
replaced by zero; at the UB, the results below the LOD were replaced by the LOD and those below the
LOQ were replaced by the value reported as LOQ. Additionally, a middle bound (MB) approach was
also used by assigning a value of LOD/2 or LOQ/2 to the left-censored data. The use of different
cut-off values on the reported LOQs was also evaluated in order to reduce the uncertainty associated
to the exposure estimations.
2.1.2. Consumption data
2.1.2.1. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (EFSA, 2011a). The latest
version of the Comprehensive Database23 was used and contains results from a total of 51 different
dietary surveys carried out in 23 different Member States covering 94,532 individuals.
Within the dietary studies, subjects are classiﬁed in different age classes as follows:
Infants: < 12 months old
Toddlers: ≥ 12 months to < 36 months old
Other children: ≥ 36 months to < 10 years old
Adolescents: ≥ 10 years to < 18 years old
Adults: ≥ 18 years to < 65 years old
22 Commission Regulation (EU) No 68/2013 of 16 January 2013 on the Catalogue of feed materials. OJ L 29, 30.1.2013, p. 1–64.
23 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb
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Elderly: ≥ 65 years to < 75 years old
Very elderly: ≥ 75 years old
Two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’
(≥ 15 years to ≤ 45 years old; Latvia) and ‘Lactating women’ (≥ 28 years to ≤ 39 years old; Greece).
For chronic exposure assessment, food consumption data were available from 44 different dietary
surveys carried out in 19 different European countries. When for one particular country and age class
two different dietary surveys were available, only the most recent one was used. This result in a total
of 35 dietary surveys selected to estimate chronic dietary exposure. In Appendix C, Table C.1, these
dietary surveys and the number of subjects available for the chronic exposure assessment are
described.
Overall, the food consumption data gathered by EFSA in the Comprehensive Database are the most
complete and detailed data currently available in the EU. Consumption data were collected using single
or repeated 24- or 48-h dietary recalls or dietary records covering from 3 to 7 days per subject. Owing
to the differences in the methods used for data collection, direct country-to-country comparisons can
be misleading.
2.1.2.2. Feed consumption data
There is considerable variation in both the feeds used and the feeding systems adopted for farmed
livestock and companion animals throughout the EU. This variation is largely due to the availability of
feeds and market demands for speciﬁc animal products, the quality of the feeds available and
nutritional needs of the animals concerned.
Estimating the exposure to erucic acid requires estimates of feed consumed and levels of erucic
acid in feed. In the absence of an EU database on feed consumption by livestock and companion
animals, estimates of feed intake have been derived from published guidelines on nutrition and feeding
(AFRC, 1993; Carabano and Piquer, 1998; NRC, 2007a,b; Leeson and Summers, 2008; McDonald
et al., 2011; EFSA FEEDAP Panel, 2012; OECD, 2013), data on EU manufacture of compound feeds24
and expert knowledge of production systems in Europe. In addition, maximum recommended levels of
rapeseed meal and rapeseed oil have been taken from feed industry publications (Ewing, 1997; Canola
Council of Canada, 2015). Details are given in Appendix D. It should be stressed that these do not
represent ‘average’ feed intakes or diets, nor are the feeding systems ‘typical’ for all of Europe. Rather,
the approach adopted here provides likely upper limits of exposure to erucic acid.
2.1.2.3. Food classiﬁcation
Consumption data were classiﬁed according to the FoodEx classiﬁcation system (EFSA, 2011b).
FoodEx is a food classiﬁcation system developed by EFSA in 2009 with the objective of simplifying the
linkage between occurrence and food consumption data when assessing the exposure to hazardous
substances. It contains 20 main food groups (ﬁrst level), which are further divided into subgroups
having 140 items at the second level, 1,261 items at the third level and reaching about 1,800
endpoints (food names or generic food names) at the fourth level.
In 2011, a new version of FoodEx, named FoodEx2 has been developed and is described in the
scientiﬁc document ‘Report on the development of a Food Classiﬁcation and Description System for
exposure assessment and guidance on its implementation and use’ (EFSA, 2011c). The last release of
FoodEx2 complements the previous hierarchical classiﬁcation system of basic codes with more detailed
food levels and gives the possibility of reporting additional information through the use of facets and
facet descriptors (EFSA, 2015).
2.1.3. Toxicokinetic and toxicological data
With the exception of one document provided to EFSA, all data were obtained from the scientiﬁc
literature as described in Section 2.2.2.
24 www.fefac.eu
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2.2. Methodologies
2.2.1. Dietary exposure assessment
2.2.1.1. Dietary exposure assessment in humans
The CONTAM Panel considered that only chronic dietary exposure to erucic acid had to be assessed
(see Section 3.3.6). As suggested by the EFSA Working Group on Food Consumption and Exposure
(EFSA, 2011a), dietary surveys with only 1 day/subject were not considered as they are not adequate
to assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary studies,
when the protocol prescribed more reporting days per individual, were also excluded for the chronic
exposure assessment. Thus, for chronic exposure assessment, food consumption data were used from
35 different and most recent dietary surveys carried out in 19 different European countries present in
the latest version of the Comprehensive Database (Appendix C, Table C.1).
For calculating chronic dietary exposure to erucic acid, food consumption and body weight data at
the individual level were accessed in the Comprehensive Database. Occurrence data and consumption
data were linked at the lowest (most detailed) FoodEx level possible. In addition, the different food
commodities were grouped within each food category to better explain their contribution to the total
dietary exposure to erucic acid. Exposure estimates were calculated for each dietary survey and age
class. Not all countries provided consumption information for all age groups, and in some cases, the
same country provided more than one consumption survey. The mean and the high (95th percentile)
chronic dietary exposures were calculated by combining erucic acid mean occurrence values for food
samples collected in different countries (pooled European occurrence data) with the average daily
consumption for each food at individual level in each dietary survey.
All analyses were run using the SAS Statistical Software (SAS enterprise guide 5.1).
2.2.1.2. Dietary exposure assessment in animals
Animal exposure to erucic acid by animals was determined by its concentration in the feed and the
quantity of feeds consumed. In the absence of data on concentrations of erucic acid in compound
feeds, the CONTAM Panel has used industry data on levels of inclusion of rapeseed meal and rapeseed
oil for livestock, ﬁsh and companion animals. Details of feed intakes and levels of erucic acid used in
estimating animal exposure to erucic acid are given in Appendix D.
2.2.2. Literature search and appraisal of studies
2.2.2.1. Strategy for literature search
A comprehensive search for literature was conducted for peer-reviewed original research pertaining
to adverse health effects on animals (experimental, livestock, horses and pets) and humans. The
search strategy was designed to identify scientiﬁc literature dealing with toxicity, mode of action,
toxicokinetics and human data on erucic acid. An overview of the search terms is given in Appendix E,
Section E.1.
It should be noted that a narrative approach was used for those sections dealing with methods of
analysis, chemistry, occurrence and exposure since the identiﬁed papers are only used to give
background information to the reader.
The literature search was not restricted to publications in English. A ﬁrst literature search was
performed in April 2015 (March 2016 for papers on the occurrence in human milk) and has been
updated in May 2016 to identify papers dealing with toxicity, mode of action, toxicokinetics and human
data. Web of Science25 and PubMed26 were identiﬁed as databases appropriate for retrieving literature
for the present evaluation. The references obtained from the literature search were imported and
saved using a software package (EndNote27). Additionally, reviews, relevant scientiﬁc evaluations by
national or international bodies were considered for the current risk assessment, i.e. previous
25 Web of Science (WoS), formally ISI Web of Knowledge, Thomson Reuters. Available at: http://thomsonreuters.com/thomson-
reuters-web-of-science/
26 PubMed, Entrez Global Query Cross-Database Search System, National Center for Biotechnology Information (NCBI), National
Library of Medicine (NLM), Department of the National Institutes of Health (NIH), United States Department of Health and
Human Services. Available at: http://www.ncbi.nlm.nih.gov/pubmed/
27 EndNote X5, Thomson Reuters. Available at: http://endnote.com/
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evaluations of FSANZ (2003) and SCF (1995, 2003). In addition, when relevant papers were identiﬁed
during the risk assessment process (e.g. from other studies or reviews) they were also considered.
The references obtained were screened using title and abstract to identify the relevant literature
and exclusion criteria are shown in Appendix E, Section E.2.
2.2.2.2. Appraisal of studies
Information retrieved has been reviewed by the CONTAM working group (WG) on erucic acid in
food and feed, and has been used for the present assessment based on expert judgement. Any
limitations in the information used are documented in this scientiﬁc opinion.
Selection of the scientiﬁc papers for inclusion or exclusion was based on consideration of the extent
to which the study was relevant to the assessment and general study quality considerations (e.g.
sufﬁcient details on the methodology, performance and outcome of the study, on dosing and route of
administration and on statistical description of the results (EFSA, 2009), irrespective of whether they
yielded positive, negative or null results).
Toxicological studies in experimental animals which did not provide information on the erucic acid
concentration in the administered material were excluded.
All information retrieved as described in the previous paragraph has been reviewed and used for
the present assessment using expert judgement.
It should be noted that no comprehensive literature search, appraisal of the studies and reporting
was carried out for scientiﬁc literature dealing with methods of analysis, chemistry, occurrence and
exposure since the identiﬁed papers are only used to give background information for the reader.
2.2.3. Methodology applied for risk assessment
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO/IPCS (2009), which include hazard identiﬁcation and characterisation,
exposure assessment and risk characterisation. Additionally to the principles described by WHO/IPCS
(2009), EFSA guidance pertaining to risk assessment has been applied for the present assessment (see
Appendix E, Section E.3).
The evaluation of the inherent uncertainties in the assessment of exposure to erucic acid has been
performed following the guidance of the Opinion of the Scientiﬁc Committee related to Uncertainties in
Dietary Exposure Assessment (EFSA, 2006). In addition, the report on ‘Characterizing and
Communicating Uncertainty in Exposure Assessment’ has been considered (WHO/IPCS, 2008).
According to the guidance provided by the EFSA opinion (2006), the following sources of uncertainties
have been considered: assessment objectives, exposure scenario, exposure model, model input
(parameters) and other uncertainties.
3. Assessment
3.1. Occurrence data
3.1.1. Previously reported occurrence data
3.1.1.1. Food
Since erucic acid is a fatty acid of which the occurrence is reported in food nutrients databases, the
CONTAM Panel consulted four comprehensive food nutrients databases (Max Rubner Institut, 2010;
NFI, 2015; Public Health England, 2015; US Department of Agriculture, 2015) to collect previously
reported occurrence data. In total, 12,934, 417, 533 and 5,487 entries, respectively, have been
checked for occurrence of erucic acid. Information from scientiﬁc literature has been retrieved only in
particular cases to ﬁll in gaps found in the databases or in relation to food types of particular interest
for this opinion. Appendix F provides for the different food groups examples of the occurrence of
erucic acid in foods. When the amount of erucic acid per unit of weight of the sample was available or
could be computed, it has been converted to mg/kg. Sources providing erucic acid as percentage of
total fatty acids but not the lipid content of the sample have not been considered. Foods were grouped
following the FoodEx classiﬁcation (EFSA, 2011b). Food groups in which no erucic acid is reported are
included as footnotes in the tables in Appendix F.
Erucic acid mainly occurs in oil seeds from the Brassicaceae family (see Section 1.3.1). Since these
oil seeds and the derived oils are used in a wide variety of foods, erucic acid occurs in many different
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food groups. Besides the occurrence in oil seeds, erucic acid also occurs naturally in ﬁsh and seafood.
These food groups mainly contain cetoleic acid (22:1 n-11), which is usually accompanied by minor
proportions of erucic acid (Ackman, 2008). It is important to note that both fatty acids are not easily
separated and identiﬁed under non-optimal analytical conditions (Ackman, 2008), which leads to
relatively common misidentiﬁcations in food nutrients databases and scientiﬁc literature, as detailed
below.
It is also of importance that the database of the Max Rubner Institut provides a single value for
22:1 fatty acids, with no distinction between erucic acid (22:1 n-9) and cetoleic acid (22:1 n-11) or
between cis and trans isomers. Similarly, the US Department of Agriculture database does not
differentiate between erucic acid and cetoleic acid, and it reports cis 22:1 as the sum of both 22:1 n-9
and 22:1 n-11. Therefore, information from these databases has not been included in Appendix F,
Table F.7 (Fish and other seafood). For the other tables this is not a major problem since erucic acid is
the only 22:1 isomer present in vegetable food and 22:1 n-11 isomers are in general not present in
non-marine animal food (Chow, 2008). The exceptions are food samples containing partially
hydrogenated oils that can contain positional isomers of 22:1. In these cases, a slight overestimation
of erucic acid can be expected in data from the database of the Max Rubner Institut and the US
Department of Agriculture. The database of Public Health England reports separately cis + trans 22:1
n-9 and cis + trans 22:1 n-11. The tables in Appendix F only include data of cis + trans 22:1 n-9.
Slight overestimation of the erucic acid concentration can be also expected in samples containing
brassidic acid (trans 22:1 n-9). The database of the National Food Institute of Denmark contains data
on 22:1 n-9. Nonetheless, the CONTAM Panel noted some putative fatty acid misidentiﬁcations in ﬁsh
samples of the databases, which contained high levels of erucic acid (22:1 n-9) but no cetoleic acid
(22:1 n-11). Those samples have not been taken into account in this Opinion because they did not
follow the expected ratios of both isomers (Ackman, 2008), which might indicate wrongly identiﬁed
fatty acids. For example, four samples of herring in the database of the National Food Institute of
Denmark averaged 1,392 mg/kg for erucic acid and 27,035 mg/kg of cetoleic acid, while one sample
had erucic acid content of 19,600 mg/kg and no cetoleic acid. Similarly, one sample of mackerel in the
database of Public Health England contained both erucic acid (2,100 mg/kg) and cetoleic acid
(34,300 mg/kg), but another sample contained much higher erucic acid content (27,900 mg/kg) and
no cetoleic acid.
Grains and grain-based products (Appendix F, Table F.1) contain in general low concentrations of
erucic acid, with the exception of several samples of biscuits, cakes and pastries with concentrations
up to 24,660 mg/kg. Other foods with high levels of erucic acid within this food category included
bread (up to 1,500 mg/kg), crackers (up to 1,170 mg/kg), doughnuts (up to 3,190 mg/kg), mufﬁns
(up to 1,040 mg/kg) and pancakes (up to 1,960 mg/kg). Relatively high concentrations of erucic acid
(up to 1,066 mg/kg) have been also reported for quinoa seeds. Although quinoa is not a cereal, as it
belongs to the Amaranthaceae family, the seeds have similar uses as cereals and they are accordingly
considered as pseudo cereals. Quinoa is one of the few plant species out of the Brassicaceae family
that can accumulate erucic acid in the seed, with a level typically below 2% of the total fatty acids
(Wood et al., 1993).
In vegetables and vegetable products (Appendix F, Table F.2), the highest erucic acid concentration
is found in sprouts from Brassica seeds rich in erucic acid. Brassica seedlings maintain a high oil
concentration for several days after germination (i.e. around 64% of the initial value in dry seeds after
8 days) and practically unchanged proportion of erucic acid (Dawood et al., 2013). This makes sprouts
from high erucic acid seeds rich sources of erucic acid. Other vegetable samples have levels of erucic
acid less than 1,000 mg/kg.
Relatively low levels of erucic acid are generally found in starchy roots and tubers (Appendix F,
Table F.3). The highest concentration (up to 4,290 mg/kg) corresponded to French fries.
In the food category of legumes, nuts and oilseeds (Appendix F, Table F.4), the highest erucic acid
concentration corresponds to seeds of the Brassicaceae family, mainly Brassica spp. (rapeseed, turnip
rape, mustards, crambe), with erucic acid concentration up to 200,000 mg/kg. High erucic acid
concentrations, up to 42,744 mg/kg, have also been reported for borage seeds. The highest erucic
acid concentration in legume seeds is found in lupine and cowpea seeds, in which erucic acid typically
represents up to 3% of the total fatty acids (Bhardwaj et al., 2004; Antova et al., 2014). Within the
different lupine species, the highest erucic acid concentrations are usually found in white lupine
(Lupinus albus L.), whose seeds are a popular snack in the Mediterranean region (Cowling, 2001). In
nuts, the highest erucic acid concentration (2,370 mg/kg) was found in a sample of macadamia nuts.
Considering that macadamia does not accumulate naturally erucic acid in the nuts (Maguire et al.,
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2004), the erucic acid present in this sample is expected to originate from the oil used for roasting the
nuts.
In general, erucic acid is not found in fruit and fruit products (Appendix F, Table F.5). In meat
samples (Appendix F, Table F.6), erucic acid is generally not detected or present at low levels, with
some exceptions such as soy sausages showing an erucic acid content of up to 4,020 mg/kg. The
highest erucic acid concentrations in ﬁsh and other seafood (Appendix F, Table F.7) have been
reported in samples of ﬁsh pa^te and halibut (4,300 mg/kg), salmon (3,990 mg/kg), herring
(2,480 mg/kg), sprat (2,390 mg/kg) and mackerel (2,190 mg/kg).
Low levels of erucic acid are generally present in the food categories milk and dairy products
(Appendix F, Table F.8) and sugar and confectionary (Appendix F, Table F.9), with the highest
concentration in a sample of cheese (400 mg/kg) in the former and a sample of chocolate bar
(910 mg/kg) in the latter.
Among animal and vegetable fats and oils (Appendix F, Table F.10), oils from high erucic acid
cultivars of mustard and rapeseed have the highest concentrations of erucic acid (above 500,000 mg/
kg). Conversely, oils from low erucic acid rapeseed cultivars, also known as canola, had much lower
concentrations of erucic acid, up to 2,410 mg/kg. Some oil samples with a high erucic acid
concentration from seeds or fruits such as corn, cottonseed, ﬂaxseed, palm, peanut, safﬂower, sesame
and sunﬂower that do not accumulate erucic acid (Gunstone and Harwood, 2007), are most likely the
result of oil adulterations or analytical misidentiﬁcations. In the UK, the Food Standards Agency (FSA)
reported concentrations up to 270,000 mg/kg in the oil from pickle samples. These samples have been
taken from pickles imported from Bangladesh, China, India and Pakistan (FSA, 2004), which are
countries in which the use of high erucic acid oil for food is still common. High erucic acid
concentrations are also reported for samples of shortenings (up to 58,740 mg/kg), margarine (up to
45,980 mg/kg) and butter (up to 9,560 mg/kg).
In general, no erucic acid is found in fruit and vegetable juices (Appendix F, Table F.11). In
non-alcoholic beverages (Appendix F, Table F.12), two samples of cocoa drinks contained erucic acid
up to 3,450 mg/kg. The group of herbs, spices and condiments (Appendix F, Table F.13) contains food
products in which erucic acid is found at high concentrations, mainly mustards (up to 20,790 mg/kg)
and to a lesser extent mayonnaise (up to 3,100 mg/kg), sauces, salad dressings and coleslaw (up to
about 1,000 mg/kg). The reason for the high erucic acid content in mustard samples is that mustard is
mainly produced from high erucic acid-containing Brassica juncea and Sinapis alba seeds, where
between 25% and 35% of the total fatty acids is erucic acid (Siemens, 2014). Mustard is therefore one
of the food products with the highest erucic acid content that can be found in European markets.
Low erucic acid levels were identiﬁed in food for infants and small children (Appendix F, Table F.14)
and products for special nutritional use (Appendix F, Table F.15). Composite dishes (Appendix F,
Table F.16) have in general a low erucic acid content, but there are some notable exceptions, e.g.
11,000 mg/kg in a sample of grilled salmon (farmed) with 15.6% fat content, in which high levels of
cetoleic acid were also present (96,000 mg/kg), or 20,000 mg/kg in a sample of roasted chicken skin,
in which high erucic acid oil was probably used for roasting. Apart from these samples, the highest
concentrations (about 5,000 mg/kg) corresponded to meat- and vegetable-based dishes. In the food
category of snacks, desserts and other foods (Appendix F, Table F.17), the highest levels of erucic acid
(up to 3,190 mg/kg) are found in milk-based desserts. No erucic acid is found in eggs and egg
products, alcoholic beverages, and drinking water.
In addition, notiﬁcations on the occurrence of erucic acid in different food commodities are
reported in the Rapid Alert System for Food and Feed (RASFF). RASFF is a key tool to ensure the
cross-border follow of information to swiftly react when risks to public health are detected in the food
chain. Around 50 notiﬁcations have been made since 2003 notifying high levels of erucic acid in
diverse food commodities. The occurrence data largely refer to levels of erucic acid in samples of
pickles (pickles and its oil) and mustard oil coming from Asian countries such as Bangladesh, India and
Pakistan. As an example, erucic acid levels up to 49.3% have been reported in mustard oil from
Bangladesh or up to 56.2% in samples reported as mango hot pickle, also from Bangladesh.
Human milk
Milk is a complex ﬂuid containing around 3-5% lipids that mainly occur as globules emulsiﬁed in the
aqueous phase. About 98% of the human milk lipids are triacylglycerols, the remaining part being
mainly phospholipids and cholesterol (Jensen, 1999). The maternal diet is the main factor inﬂuencing
the fatty acid composition of the milk lipids, although other factors such as time post-partum,
gestational age, parity (number of pregnancies and number of pregnancies carried to a viable
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gestational age) or diseases also can inﬂuence the fatty acid proﬁle (Jensen, 1999). Table 3 provides
examples of levels of erucic acid in human milk from European women. In general, the percentage
erucic acid of the total fatty acids in human milk ranged from 0.06% to 0.22% (Table 3). However in
one study with Greek women, lower percentages (0.001–0.004%) were reported.28 The highest
percentages (≥ 0.18%) were observed at the beginning of lactation (Precht and Molkentin, 1999;
Marangoni et al., 2000; Lopez-Lopez et al., 2002; Mihalyi et al., 2015).
3.1.1.2. Feed
Erucic acid is a component of the oil seed and after oil extraction, the remaining meal is widely
used as a protein source in animal feeds. Even under industrial oil extraction conditions, a small
proportion of the oil remains in the meal. Rapeseed meal typically contains 3.5% of oil on a 12%
moisture basis, although this depends on the extraction conditions (Newkirk, 2009). Therefore, the
erucic acid content in the meal will depend on the amount of remaining oil in the meal and the
proportion of erucic acid in the oil. Rapeseed meal used for livestock feed in the EU is produced using
the double-zero varieties, in which oil contains < 5% erucic acid (Commission Regulation (EC)
No 1881/2006) and typically oils with an erucic acid content at or below 0.5% are used (see
Appendix A, Table A.1). Since the oil content of rapeseed meal is typically 3.5%,29 the erucic acid
content of the meal is likely to be < 175 mg/kg. For example, a meal containing 3.5% oil from a
modern rapeseed cultivar with low erucic acid content (e.g. 0.1%) will contain only 35 mg erucic acid/kg
meal. Some whole rape seed is also used as feed for livestock.
3.1.2. Current occurrence data
3.1.2.1. Food
An initial number of 16,401 food samples with analytical data on erucic acid were available. As
described in Section 2.1.1, the occurrence data were carefully analysed before being used to estimate
dietary exposure. A total of 3,957 food samples were excluded from the ﬁnal dataset as described in
Appendix C, Table C.2.
Table 3: Levels of erucic acid in human milk reported for different European countries
Country N
Percentage erucic acid of total
fatty acids
Concentration of
erucic acid in
human milk
(mg/L)(d)
References
United
Kingdom
44 0.10  0.00(a) –(e) Yuhas et al. (2006)
The
Netherlands
21–44 0.10  0.03–0.11  0.04(b) 35–36.3 Beijers and Schaafsma
(1996)
Poland 20–136 0.13  0.07–0.14  0.09(b) 38.9–39.0 Szlagatys-Sidorkiewicz et al.
(2013)
Germany 40 0.18  0.06(b) 52.2 Precht and Molkentin (1999)
Hungary 46–87 0.07–0.18(c) –(e) Mihalyi et al. (2015)
France 10 0.12  0.03(a) –(e) Chardigny et al. (1995)
Italy 10–95 0.06  0.03–0.22  0.08(b) –(e) Marangoni et al. (2000)
Portugal 31 0.06  0.01–0.11  0.02(b) –(e) Ribeiro et al. (2008)
Spain 120 0.06  0.03–0.18  0.11(b) –(e) Lopez-Lopez et al. (2002)
Spain 8–12 0.11  0.02–0.16  0.03(b) –(e) Rueda et al. (1998)
Greece 24–64 0.0013  0.061–0.004  0.02(b) 0.34–1.27 Antonakou et al. (2013)
N: number of samples.
(a): Mean  standard error.
(b): Mean  standard deviation.
(c): Standard error and standard deviation not reported.
(d): Concentration calculated based on fat content and percentage of erucic acid.
(e): Concentration of erucic acid in human milk was not calculated due to lack of information.
28 Data conﬁrmed by the authors.
29 www.feedipedia.org
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Brieﬂy, 1,729 samples of diverse types of oil (coconut oil, almond oil, corn oil, grape seed oil,
linseed oil, olive oil, palm oil, soybean oil, sunﬂower oil, safﬂower oil, walnut oil and wheat germ oil)
were excluded from the ﬁnal dataset as these oils should not contain naturally erucic acid (Gunstone
and Harwood, 2007). Most of the samples (87%) belonged to three types of oil, olive oil (n = 515),
sunﬂower oil (n = 478) and pumpkinseed oil (n = 328) of which 95% was left-censored. Mean LB
erucic acid levels in these samples ranged from 5 (in pumpkinseed oil) to 146 mg/kg (in sunﬂower oil)
and UB levels from 44 (in pumpkinseed oil) to 880 mg/kg (in olive oil). In the remaining types of oil
(13% of the total number of samples) the highest number of quantiﬁed samples was reported for
safﬂower oil (26 out of 68 samples). Mean erucic acid levels were between 21 mg/kg (LB) in palm oil
and 1,440 mg/kg (UB) in wheat germ oil. A special case refers to ‘Peanut oil’ for which 70% of the
samples (n = 96) reported levels of erucic acid. Although peanut oil does not contain erucic acid
naturally (Carrın and Carelli, 2010), the high amount of quantiﬁed samples seems to indicate an
extensive presence of adulterated peanut oil in the market. Moreover, the main producing countries of
rapeseed oil are also high producers of peanut oil. Based on this fact, the CONTAM Panel decided to
keep the samples of peanut oil in the ﬁnal dataset. Additionally, 415 samples of vegetable oil reported
without further information on the seed/fruit used to extract the oil were also excluded.
The results of 1,783 samples were reported on fat weight basis without information on fat content.
Almost 800 of these samples were kept in the ﬁnal dataset, as the fat content was imputed by using
the fat content of similar samples or the EFSA composition database (mainly oil samples, food for
infants and few samples of ﬁsh). For around 1,000 samples, the imputation was not possible as they
refer to foods subjected to a high variation in their fat content and, therefore, the assignment of a fat
content would largely increase the uncertainty.
The presence of a high percentage of left-censored data together with high left-censoring limits can
provoke substantial differences between LB and UB scenarios increasing the uncertainty associated to
the dietary exposure estimations. Based on the EFSA internal guidance on the application of LOD/LOQ
cut-offs, special attention was paid to food groups for which the difference between LB and UB was
higher than 40% and that were relevant for the exposure. Two main food groups were identiﬁed,
‘Grain and grain-based products, in particular ‘Pastries and cakes’ and ‘Biscuits (cookies)’ and ‘Ready-
to-eat meal for infants and young children’. By analysing both distributions, that of the reported LOQs
and that of the quantiﬁed results, several values were selected and subsequently applied as cut-offs to
the LOQs reported for these food groups. A total of 178 samples were excluded following this criterion.
Appendix C, Table C.3 shows the effect of these cut-offs on the occurrence values for the main
selected food groups.
A total of 63 samples reported as ‘Composite food’ were also excluded from the ﬁnal dataset. This
food group, that represents ready-to-eat foods collected in shops, restaurants and processing plants,
contained a very heterogeneous mix of samples with a very limited number of samples reported for
each subgroup (see Appendix C, Table C.4). For some of these samples relatively high values of erucic
acid were reported, indicating the use of rapeseed oil and/or speciﬁc herbs/spices/condiments in their
preparation. The consumption data on composite foods contained in the Comprehensive Database
does not allow knowing whether composite foods were prepared at home or bought in retails or
consumed outside. This could have an inﬂuence on how the different composite foods were prepared
(type of oil, herbs, spices, etc. used) and, therefore, in their levels of erucic acid. Then, the level of
disaggregation of the reported foods is different depending on the dietary survey. It could be that
countries which report a higher number of eating occasions for composite foods mainly refer to home-
made foods while in dietary surveys with a higher level of disaggregation, the consumption refers to
ready-to-eat foods. Therefore, considering the uncertainty regarding the consumption of composite
food and the limited number of available occurrence data, the CONTAM Panel decided to exclude these
samples from the ﬁnal dataset used in the general exposure scenario. However, a particular exposure
scenario was carried out combining some of the reported composite samples with consumption values
derived from the Comprehensive Database in order to address the potential contribution of this type of
food commodities on the exposure to erucic acid (see Section 3.2.1.2). Finally, two samples of
‘Custard’ were also excluded from the ﬁnal dataset as the standard recipe for this dessert (milk, eggs,
sugar) does not include ingredients that might contain erucic acid. The average value reported for
these samples of ‘Custard’ was 1,010 mg/kg (LB=UB); a speciﬁc exposure scenario was also elaborated
to estimate the potential exposure to erucic acid from the consumption of these custard samples (see
Section 3.2.1.2).
After the quality assessment of the analytical data on erucic acid, a total of 12,444 food samples
were available to estimate dietary exposure. Before the occurrence data were used to estimate dietary
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exposure, the data were grouped at different FoodEx levels according to their erucic acid levels and
the number of samples reported (Appendix C, Table C.5).
The highest number of available samples corresponded to the food group ‘Animal and vegetable
fats and oils’ (~ 60%) and in particular to ‘Rapeseed oil’ (5,832 samples). Other food groups that were
well represented were ‘Starchy roots and tubers’ (n = 1,223), ‘Grains and grain-based products’
(n = 982) and ‘Food for infants and small children’ (n = 810).
The highest individual value for erucic acid was reported for one sample of rapeseed oil
(550,000 mg/kg), in line with maximum values reported in different databases as shown in
Appendix F, Table F.10. Mean values were 630/1,900 mg/kg (LB/UB), probably due to the fact that
among the 5,832 samples of rapeseed oil, more than 90% were left-censored data. The average value
reported for the quantiﬁed samples (n = 615) was 6,000 mg/kg. For the left-censored data, an LOQ of
5,000 mg/kg was reported in 98% of the cases which is in line with the fact that current rapeseed
varieties are characterised by very low erucic acid content, usually below 0.5% (Temple-Heald, 2004).
It is worth mentioning that the average level of erucic acid among the quantiﬁed samples of peanut oil
(n = 68) was 2,700 mg/kg, this may indicate an adulteration with HEAR oil.30
Only few samples (n = 50) of ﬁsh and ﬁsh products were available. Overall, the highest value of
erucic acid was reported for one sample of ‘Herrings’ (7,200 mg/kg). The three main groups of ﬁsh
samples were ‘Tuna’ (n = 18), ‘Sardine and pilchard’ (n = 14) and ‘Salmon and trout’ (n = 9). ‘Sardine
and pilchard’ and ‘Salmon and trout’ samples contain similar average levels of erucic acid
(LB = UB = ~ 1,000 mg/kg) while the levels reported for ‘Tuna’ were much lower (7/70 mg/kg
(LB/UB)). The highest values of erucic acid among the samples of ‘Sardine and pilchard’ were reported
for samples of sardines canned in oil; it cannot be excluded that part of the erucic acid comes from
the oil even though the samples were reported as canned in ‘olive oil’.
As mentioned in Section 3.1.1.1 no erucic acid is, in general, quantiﬁed in meat. Available samples
for this scientiﬁc opinion mainly refer to meat imitates (soy protein), in particular to soy sausages that
may have used rapeseed oil and/or different spices in their preparation, which may explain the erucic
acid values detected (LB = UB = 900 mg/kg; Appendix C, Table C.5).
Relatively high values were reported for samples of mixed spices (mean LB = UB = 62,000 mg/kg)
and for some mustard samples (LB = UB = 20,000 mg/kg) within the food group ‘Herbs, spices and
condiments’. Erucic acid was also reported in relatively high concentration in ‘Mayonnaise’
(LB = UB = 2,700 mg/kg) indicating, presumably, the use of rapeseed oil or mustard during its
preparation.
Erucic acid could not be quantiﬁed in milk or many different types of cheese. However, some
cheese varieties prepared/preserved using oil and/or spices (Gouda, Feta, Trappist), reported some
levels of erucic acid in their composition (100–200 mg/kg, LB).
The only reported levels of erucic acid for the food group ‘Legumes, nuts and oilseeds’
corresponded to samples of ‘Rape seeds’ and ‘Peanuts’. Since peanuts do not naturally contain erucic
acid (Carrın and Carelli, 2010), the levels are assumed to originate from oil used for roasting the nuts.
It is also important to note the presence of erucic acid in ‘Fine bakery wares’ which indicates the
common use of rapeseed oil in the preparation of these products. For ‘Pastries and cakes’, erucic acid
was quantiﬁed in half of the samples (mean 240/290 mg/kg (LB/UB)) with a 95th percentile
concentration of 1,100 mg/kg (LB = UB). The average levels of erucic acid were even higher in
‘Biscuits’ (mean 270/390 mg/kg (LB/UB)) so it was the 95th percentile concentration (1,800 mg/kg
LB = UB). However, the prevalence of erucic acid in ‘Biscuits’ was lower than in ‘Fine bakery wares’
since only in about 25% of the samples erucic acid was quantiﬁed.
Erucic acid in ‘Starchy roots and tubers’ should be in general non-existent or negligible; the
quantiﬁed samples reported in Appendix C, Table C.5 correspond to processed foods (French fries,
potato croquettes), where the erucic acid originates from the oil used during cooking.
No erucic acid was quantiﬁed in the few samples of ‘Vegetables and vegetable products (including
fungi)’ except in one sample of mustard sprouts for which an erucic acid concentration of 179,000 mg/
kg was reported. This is in accordance with the high levels of erucic acid for mustard seeds mentioned
in Section 3.1.1.1.
Within the food group ‘Sugar and confectionary’ particularly high levels of erucic acid were
quantiﬁed in some samples of chocolate spread codiﬁed as ‘Chocolate, cream’ (170/250 mg/kg (LB/UB)).
In total, twelve samples out of thirty-two reported the presence of erucic acid. The most plausible reason
30 Adulteration with 5% rapeseed oil to arrive to 2,700 mg/kg it would imply rapeseed oil with erucic acid content above
50,000 mg/kg (HEAR).
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for the levels of erucic acid reported in the samples of ‘Chocolate, cream’ should be the oil used in its
preparation. Among the samples reported as ‘Products for special nutritional use’ the highest levels of
erucic acid were quantiﬁed in samples of ‘Supplements containing special fatty acids (e.g. omega-3,
essential fatty acids)’ with mean values of 4,200/4,300 mg/kg (LB/UB) (n = 26) and ‘Unspeciﬁed dietary
supplements’ with mean values of 12,100/12,400 mg/kg (LB/UB) (n = 22).
A total of 810 samples were reported for the food group ‘Food for infants and small children’. They
were mainly contained in four groups, ‘Infant formulae, powder’ (n = 218), ‘Follow-on formulae,
powder’ (n = 191), ‘Cereal-based food for infants and young children’ (n = 166) and ‘Ready-to-eat
meal for infants and young children’ (n = 156). Overall, relatively low levels of erucic acid were
reported for these samples. The highest mean values were reported for ‘Infant formulae, powder’
(220/290 mg/kg (LB/UB)) and the lowest for ‘Ready-to-eat meal for infants and young children’
(77/86 mg/kg (LB/UB)).
The CONTAM Panel noticed that erucic acid can be present in different food additives derived from
fatty acids. Among them, ammonium phosphatides (E 442), obtained from partially hardened rapeseed
oil (FAO/WHO, 2006) could be mentioned, but also mono- and diglycerides and polyglycerol esters of
fatty acids (E 470a, E 470b, E 471, E 472a, E 472b, E 472c, E 472d, E 472e, E 472f, E 475, E 477,
E 479b), which are used as emulsiﬁers in many different food commodities. However, the contribution
to the presence of erucic acid from the use of these additives is expected to be minor as compared to
that coming from the presence of rapeseed oil as ingredient.
As shown in Figure 2, the samples contained in the dataset used to estimate exposure were
collected in 13 different European countries, most of them in Germany (4,822 samples). For more than
5,000 samples, the sampling country was reported as ‘European Union’; they were mainly reported by
FEDIOL but also by SNE. These samples mainly corresponded to rapeseed oil (99%). The samples
were collected between 2000 and 2015, with half of the samples collected in 2014 (Figure 3).
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Figure 2: Distribution of food samples analysed for erucic acid across different European countries
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Analytical methods
Only limited information was reported on the analytical methods used to analyse erucic acid. For
around 30% of the cases no information was provided. In 10% of the samples only the
chromatographic technique used in the analysis was reported (GC) without further information on the
method of detection. For the remaining samples (60%) GC-FID was used.
Among the samples reported as being analysed by GC-FID a very wide range of LOQs was noted.
The lowest LOQ was reported for the analysis of unspeciﬁed savoury sauces (0.042 mg/kg) while the
highest was reported for the analysis of some samples of rapeseed oil (20,000 mg/kg). More detailed
information on the reported LOQs in the different food groups (at FoodEx level 1) is shown in Table 4.
3.1.2.2. Feed
A total of 270 feed samples were initially reported. One sample of ‘Rape seed’, which was reported
on a fat weight basis but without further information on its fat content, was excluded. In addition, six
samples wrongly reported as food were re-codiﬁed as feed, leading to a ﬁnal number of 275 feed
samples. Table 5 shows the feed samples classiﬁed according to the catalogue of feed materials
Table 4: Range of limits of quantiﬁcation in food samples (FoodEx 1 level) reported as analysed by
gas chromatography-ﬂame ionisation detection (6,958 samples) from the ﬁnal dataset
(n = 12,444) used to estimate dietary exposure assessment
Reported limits of quantiﬁcation (mg/kg; whole weight)
FoodEx level 1
N Minimum Maximum
Grains and grain-based products 26 1.4 1,000
Vegetables and vegetable products
(including fungi)
22 500 1,000
Legumes, nuts and oilseeds 3 100 5,000
Fish and other seafood 44 3,333 3,333
Milk and dairy products 338 2.8 1,000
Eggs and egg products 21 100 1,000
Sugar and confectionary 193 500 1,000
Animal and vegetable fats and oils 5,753 2 20,000
Herbs, spices and condiments 17 0.042 1,000
Food for infants and small children 517 0.24 500
Products for special nutritional use 7 4.8 1,000
Snacks, desserts, and other foods 17 1,000 1,000
N: number.
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Figure 3: Distribution of food samples analysed for erucic acid over the sampling years
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described in Commission Regulation 68/2013.31 Apart from the 193 samples of rapeseed oil, a very
limited number of feed samples was available.
Erucic acid concentrations of 193 samples of rapeseed oil were provided, with mean values of
1,300/4,200 mg/kg (LB-UB), respectively. Oil extraction from seeds involves a number of processes.
The ﬁrst is a physical process, resulting in the production of rapeseed ‘cake’, with oil contents typically
~ 10%. This may be used as livestock feeds, particularly in organic production systems. However, most
of the cake undergoes a second process involving solvent extraction, resulting in a ‘meal’ with oil
contents nearer to 3–5%.31 Since erucic acid is extracted in the oil, it follows that levels are likely to be
higher in the cakes than the meals. A number of samples (n = 28) were reported as either ‘rapeseed
expeller’ or ‘rapeseed meal’. However, as these samples contained a rather high amount of fat (~ 10%)
they were all considered as ‘rapeseed expeller’, which usually has fat contents similar to those reported.
Average levels of erucic acid in the samples of rapeseed expeller were 460/470 mg/kg (LB/UB). In
addition, data on 21 samples of sunﬂower oil were provided. Sunﬂower oil is not normally used in feed
for livestock, and since all of these were left-censored, they were not included in estimates of exposure.
Table 5: Mean and 95th percentile concentrations (mg/kg) in feed samples classiﬁed according to
the Catalogue of feed materials speciﬁed in Commission Regulation (EU) No 68/201332
Mean
(mg/kg)(b)
95th
percentile
(mg/kg)(a),(b)
N % LC LB UB LB UB
Cereal grains,
their products and
by-products
Maize Maize germ 1 100 0 20 – –
Miscellaneous Fatty acids Fatty acids 2 0 626 626 – –
Oil seeds, oil
fruits, and
products derived
thereof
Rape seed Rapeseed, expeller 28 11 456 467 – –
Toasted soy
(beans)
Soy (bean) expeller 1 100 0 1,000 – –
Soy beans, extruded 1 0 180 180 – –
Sunﬂower seed Sunﬂower seed 1 100 0 20 – –
Camelina seed Camelina, expeller 1 0 3,670 3,670 – –
Vegetable oil and
fat
Rapeseed oil 193 83 1,326 4,165 9,000 9,000
Sunﬂower oil 21 100 0 1,190 – –
Borage oil 2 0 26,384 26,384 – –
Unspeciﬁed
vegetable oil
1 0 1,195 1,195 – –
Other seeds and
fruits, and
products derived
thereof
Grape pips Grape pips meal 1 100 0 20 – –
Land animal
products and
products derived
thereof
Animal fat (Feed) Animal fat (Feed) 12 0 1,231 1,231 – –
31 Source: Animal Feed Resources Information System (www.feedipedia.org).
32 Commission Regulation (EU) No 68/2013 of 16 January 2013 on the Catalogue of feed materials Text with EEA relevance. OJ
L 29, 16.1.2013, p. 1.
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In most of the samples (n = 201), reported by FEDIOL, the country of sampling was only speciﬁed
as ‘European Union’ without further information. Among the samples for which information was
reported, the main sampling countries were Poland (n = 47) and Denmark (n = 12). With regard to
the sampling year, samples were collected between 2003 and 2015, with the highest prevalence for
the years 2014 (n = 68) and 2015 (n = 150).
GC with FID detection was the selected method for the analysis of most of the feed samples
(n = 259). The lowest LOQ was reported for the analysis of rape seeds, 39 mg/kg whole weight, while
the highest LOQ was reported for the analysis of rapeseed oil (5,000 mg/kg whole weight).
3.1.3. Food and feed processing
Erucic acid is most commonly found in seeds of the Brassicaceae family, which are widely grown as
sources of oil both for human consumption (e.g. oilseed rape) and industrial purposes (e.g. HEAR or
crambe). The seeds are initially physically pressed to remove the oil, and then in most cases, the
‘expeller cake’ is processed further by solvent extraction, leaving the ‘meal’. Most of the erucic acid is
extracted with the oil. While some remains in the rapeseed expeller (after crushing) and even less in
the rapeseed meal (after solvent extraction), levels are signiﬁcantly lower than in the original seed.
After extraction and reﬁning, some uses of the oil require its chemical transformation to acquire the
plasticity demanded by the margarine and shortening industries. Such transformation can be achieved
by hydrogenation, which consists in addition of hydrogen to the oil in the presence of a catalyst, a
process that ‘removes’ double bonds and subsequently reduces the degree of unsaturation of the oil
(Farr, 2005). The reduction of the degree of unsaturation not only confers plasticity to the oil, but also
increases its oxidative stability, as double bonds in the fatty acid chain are the main oxidation centres
in the oil. This makes partially hydrogenated oils particularly suitable for high temperature uses such
as deep frying (Rossell, 2001). During partial hydrogenation trans isomers of fatty acids can be
formed. For example, margarines are reported to contain from 3 to 26 g/100 of trans fatty acids
(Tarrago-Trani et al., 2006). Trans fatty acids can be also formed during the reﬁning of the oil,
particularly in the deodorisation step, although at lower scale than in the hydrogenation process
(Martin et al., 2007). The effect of hydrogenation on the fatty acid proﬁle of the oil depends on the
degree of hydrogenation and the conditions of the process. In ﬁsh oil with high 22:1 content (e.g.
herring oil), conventional partial hydrogenation reduces only slightly the total content of 22:1 fatty
acids but about 50% of them change from cis to trans conﬁguration. In addition to geometrical
isomers, partial hydrogenation results in the formation of positional isomers (Opstvedt et al., 1990), for
example 22:1 n-13 and 22:1 n-15, which are difﬁcult to separate from 22:1 n-11 in chromatographic
analysis of fatty acid methyl esters (Shimizu and Ando, 2012).
Mean
(mg/kg)(b)
95th
percentile
(mg/kg)(a),(b)
N % LC LB UB LB UB
Compound feed Compound feed,
unspeciﬁed
Compound feed,
unspeciﬁed
2 0 1,500 1,500 – –
Complete feed Fattening chickens
(broilers)/
complete feed
3 100 0 20 – –
Pet food, dogs/
complete feed
3 0 429 429 – –
Pet food, cats/
complete feed
1 0 1,000 1,000 – –
Piglets (weaning
diets)/complete
feed
1 0 144 144 – –
N: number of samples; LB: lower bound; LC: left-censored; UB: upper bound.
(a): The 95th percentile with less than 60 observations may not be statistically robust (EFSA, 2011b). Those estimates were not
included in this table.
(b): Values were rounded to the nearest whole number (0 decimal places).
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3.2. Dietary exposure assessment
3.2.1. Dietary exposure assessment of erucic acid in humans
3.2.1.1. Previously reported exposure assessments in humans
FSANZ estimated dietary exposure to erucic acid from canola oil (FSANZ, 2003). Using the highest
reported level of erucic acid (1.6%), the mean intake for consumers only was 124 mg/day and for
high consumers 348 mg/day, corresponding to 1.8 and 5.0 mg/kg body weight (bw) per day assuming
a body weight of 70 kg.
Based on a 24-h dietary recall, dietary intakes of erucic acid were estimated during the National
Health and Nutrition Examination Survey (NHANES) 1999–2000 survey (Ervin et al., 2004). The mean
dietary intake was 40 mg/day (median 10 mg/day) across the different age classes. The mean intake
was 20 mg/day for children under 6 years, corresponding to 1.7 mg/kg bw per day using the default
body weight of 12 kg for toddlers (EFSA Scientiﬁc Committee, 2012). For adults (20–59 years), the mean
intake was 50 mg per day, corresponding to 0.7 mg/kg bw per day assuming a body weight of 70 kg.
Udipi et al. (2006) estimated the fatty acid intakes of healthy adult males (n = 25/region) from
three regions in India using dietary records, food frequency questionnaires and chemical analysis of
the diet. The mean erucic acid intake was reported only for the region West Bengal and was
17.3  8.3% of the total fat intake. The authors reported that this high erucic acid intake was due to
the high mustard oil consumption. By using the total fat intake of 70.9  21.3 g/day reported for this
region, the CONTAM Panel calculated an erucic acid exposure of 12.3 g/day or 180 mg/kg bw per day
for a 70 kg adult.
3.2.1.2. Current dietary exposure assessment in humans
Chronic dietary exposure was estimated across Europe following the methodology described in
Section 2.2.1.1. Before linking consumption and occurrence data, some adjustments of the
consumption data were done to reduce uncertainty and reach more accurate exposure estimates.
Among these adjustments, it is worth mentioning the use of a factor of 0.125 to convert the reported
consumption data on both liquid ‘Infant formula’ and liquid ‘Follow-on formula’ into powder as only
occurrence data on the latter form were available (see Appendix C, Table C.5). Likewise, factors of 0.25
(when reconstituted with water) and 0.15 (when reconstituted with milk) were applied to the food
group ‘Cereal-based food for infants and young children’ when the eating occasions were reported as
consumed (liquid) since the occurrence data also referred to the analysis of the powder form.
When no plausible reasons exist that may justify the presence of erucic acid, samples that
belonged to one particular food group and that were all reported as left-censored data were not used
for dietary exposure estimations to avoid unwanted bias in the UB estimations. These samples mainly
belonged to food groups such as ‘Drinking water’, ‘Fruit and fruit products’, ‘Eggs and egg products’
and ‘Non-alcoholic beverages’ among others (Appendix C, Table C.5).
Table 6 shows summary statistics of the chronic dietary exposure assessment to erucic acid using
the available occurrence data. Detailed mean and 95th percentile dietary exposure estimates
calculated for each of the 35 dietary surveys are presented in Appendix C, Table C.6.
Table 6: Summary statistics of chronic dietary exposure assessments to erucic acid across European
dietary surveys (mg/kg bw per day)
Mean dietary exposure (mg/kg bw per day)
LB(c) UB(c)Age class(a)
N Min Median Max Min Median Max
Infants 6 0.5 1.8 2.8 1.0 2.5 3.6
Toddlers 10 1.1 2.0 2.8 1.7 2.8 4.4
Other children 18 1.0 1.7 2.4 1.5 2.5 3.2
Adolescents 17 0.5 1.0 1.6 0.8 1.3 2.2
Adults 17 0.3 1.0 1.5 0.6 1.3 1.9
Elderly 14 0.3 0.9 1.4 0.5 1.3 1.7
Very elderly 12 0.4 1.0 1.3 0.6 1.3 1.5
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Highest chronic dietary exposure was estimated in the youngest population. Concerning mean
dietary exposure, the highest estimate at the LB corresponded to the age classes ‘Infants’ and
‘Toddlers’ with a maximum value of 2.8 mg/kg bw per day, while at the UB the maximum estimate was
observed in the age class ‘Toddlers’ (4.4 mg/kg bw per day). In the highly exposed population,
referring to the 95th percentile of the distribution of the exposure for each dietary survey and age
class, the highest estimates were in ‘Infants’ with values of 5.8/7.4 mg/kg bw per day (LB/UB). Dietary
exposure in speciﬁc groups of the population, namely ‘Pregnant women’ and ‘Lactating women’, were
within the range of exposure estimates in the adult population.
Detailed contribution of the different food categories at FoodEx level 1 and grouped by age classes
is shown in Appendix C, Table C.7. Estimations of exposure at the middle bound (MB) were used to
explain the contribution of the different food commodities.
Overall, the main contributor to dietary exposure to erucic acid was the food group ‘Fine bakery
wares’, more precisely ‘Pastries and cakes’ and ‘Biscuits (cookies)’. This food group was particularly
important in ‘Toddlers’ and ‘Other children’, although it was also a main contributor to the dietary
exposure in the adult population. At the MB, the contribution of ‘Fine bakery wares’ in ‘Toddlers’
represented up to 39% of the total exposure (median = 21%), and in ‘Other children’ contributed up
to 48% to the total exposure (median = 28%). Since the levels of erucic acid in ‘Fine bakery wares’
(‘Pastries and cakes’ and ‘Biscuits (cookies)’) are not that high (240/390 mg/kg, LB/UB), its relevant
contribution is probably mainly driven by its relatively high consumption of this heterogeneous food
category (e.g. croissants, doughnuts, cakes, mufﬁns, wafﬂes, biscuits, cookies, etc.). The reported
values on erucic acid for ‘Pastries and cakes’ and ‘Biscuits’ (see Appendix C, Table C.5) show that, as
commented above, the use of rapeseed oil in the elaboration of these food commodities seems to be
rather common practice in industry.
Two other food groups that were also relatively important contributors to the dietary exposure to
erucic acid across all age classes (excluding ‘Infants’) were ‘Potatoes and potato products’ and
‘Margarine and similar products’, processed food commodities where rapeseed oil seems to be used in
their preparation. In both cases, the contribution at the MB was greater than 20% in several
population groups, with ‘Potatoes and potato products’ reaching up to 29% and ‘Margarine and similar
products’ up to 27% of the total exposure to erucic acid.
In the age class ‘Infants’, ‘Food for infants and small children’ (FoodEx level 1) was the main
contributor to the exposure. Among the different types of food for infants, the food group ‘Ready-to-
eat meal for infants and young children’ was the most important contributor in the dietary survey with
the highest exposure. The contribution of this food group went up to 54% at the MB scenario (range
20–54%) among the dietary surveys for ‘Infants’. Other food groups such as ‘Cereal-based food for
infants and young children’, ‘Follow-on formulae, powder’ and ‘Infant formulae, powder’ also had an
important contribution in different dietary surveys for ‘Infants’.
For the adult population, the food group ‘Condiments’ was the main contributor to the exposure in
a few dietary surveys, representing in some cases half of the total contribution (MB approach). The
high contribution of ‘Condiments’ was driven by the consumption of ‘Mustard, mild’ that although
consumed in low amounts contains very high levels of erucic acid (~ 14 g/kg). The contribution of
95th percentile dietary exposure(b) (mg/kg bw per day)
LB(c) UB(c)
Age class(a) N Min Median Max Min Median Max
Infants 5 1.3 4.1 5.8 2.4 5.7 7.4
Toddlers 7 3.0 4.1 4.4 4.2 5.5 6.0
Other children 18 2.1 3.9 5.3 3.1 4.9 6.7
Adolescents 17 1.2 2.4 4.8 1.7 2.9 5.4
Adults 17 0.9 2.1 3.8 1.3 2.6 4.3
Elderly 14 0.7 2.4 3.9 1.1 2.8 4.2
Very elderly 9 1.1 2.7 3.2 1.4 3.1 3.5
bw: body weight; LB: lower bound; Max: maximum; Min: minimum; n: number of surveys; UB: upper bound.
(a): Section 2.1.2.1 describes the age range within each age class.
(b): The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically
robust (EFSA, 2011b). Those estimates were not included in this table.
(c): Estimates were rounded to one decimal place.
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‘Fish meat’ to the total exposure to erucic acid was also important in some adult populations in
different dietary surveys, with contributions up to 41% of the total exposure (MB scenario).
Speciﬁc exposure scenarios
Considering the relatively low levels of erucic acid in ‘Human milk’ (Table 3), the CONTAM
Panel concluded that a speciﬁc scenario to evaluate the exposure to erucic acid via the consumption of
human milk was not pertinent. Likewise, considering the occurrence values described in
Section 3.1.2.1 and the main contributors to dietary exposure to erucic acid, a speciﬁc scenario for
vegetarians was considered not necessary.
Speciﬁc exposure scenario for composite foods and custard
Potential dietary exposure to erucic acid via the consumption of composite food (ready-to-eat-food)
was also evaluated for adults and toddlers (Table 7). To estimate exposure, the occurrence values
reported to EFSA for different types of composite food (see Appendix C, Table C.4) were combined
with chronic consumption of these commodities (consumers only) obtained from the Comprehensive
database. The consumption of ‘Pasta, cooked’ used in the estimations refers to the consumption value
obtained from the Comprehensive database multiplied by a factor of 2.5 to convert the raw amount
into cooked.
Similarly, the consumption data were also used to estimate the potential exposure to erucic acid
from the consumption of custard with high levels of erucic acid. As mentioned in Section 3.1.2.1,
erucic acid is not expected to be found in samples of custard; however, as two samples were reported
with relatively high levels of erucic acid (1,010 mg/kg, LB = UB) the CONTAM Panel decided to create
a scenario to consider the potential exposure to erucic acid through the consumption of this dessert.
Table 7 shows that the only consumption of prepared dishes of pasta at the reported mean levels
of erucic acid (2,700 mg/kg) might result in a high exposure to this substance as compared to the
Table 7: Dietary exposure to erucic acid from consumption of speciﬁc composite foods and custard
combining reported occurrence values for these foods (Appendix C, Table C.4 and
Section 3.1.2.1) with chronic consumption data (consumers only)
Mean dietary exposure(a) (mg/kg bw per day)
Toddlers Adults
% consumers Exposure LB Exposure UB % consumers Exposure LB Exposure UB
Pasta, cooked 25–94 2.9–23.7 2.9–23.7 2–90 0.8–11.2 0.8–11.2
Meat-based meals 2–72 0.7–1.2 0.7–1.2 0.1–91 0.1–0.8 0.1–0.8
Ready-to-eat
soups
0.5–64 0.02–0.5 0.1–1.5 1–70 0.002–0.1 0.01–0.2
Prepared salads 0.3–14 1.1–2.6 1.1–2.6 0.1–80 0.4–3.2 0.4–3.2
Custard 0.4–37 0.7–5.6 0.7–5.6 0.2–32 0.1–3.2 0.1–3.2
95th percentile dietary exposure(b) (mg/kg bw per day)
Toddlers Adults
% consumers Exposure LB Exposure UB % consumers Exposure LB Exposure UB
Pasta, cooked 25–94 7.5–41.9 7.5–41.9 2–90 2.4–24.3 2.4–24.3
Meat-based meals 2–72 1.8–2.0 1.9–2.1 0.1–91 0.3–1.2 0.3–1.3
Ready-to-eat soups 0.5–64 0.1–0.2 0.3–0.8 1–70 0.01–0.2 0.02–0.5
Prepared salads 0.3–14 – – 0.1–80 1.1–7.9 1.1–7.9
Custard 0.4–37 7.4–14.1 – 0.2–32 0.2–3.3 0.2–3.3
bw: body weight; LB: lower bound; UB: upper bound.
(a): Range of mean dietary exposure (mg/kg bw per day) across all dietary surveys.
(b): Range of 95th dietary exposure (mg/kg bw per day) across all dietary surveys. Only dietary surveys with more than 60
consumers were considered.
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levels reported in Table 6 (having in mind that estimates in Table 7 refer to consumers only). Both
maximum mean exposure (UB) and maximum 95th percentile dietary exposure (UB) via the
consumption of pasta in consumers only were around 6-fold higher than the maximum exposure
estimates in ‘Toddlers’ and ‘Adults’ considering the whole diet.
The origin of the erucic acid in the samples of pasta is uncertain, although it seems evident that it
is not from the pasta itself but more from the rapeseed oil and/or different spices that may have been
used to condiment the pasta. It is worth commenting that these results should be interpreted very
cautiously since they are based on only three samples. Similar interpretation should be done for the
exposure estimations derived from the consumption of ‘Custard’ (n = 2) and ‘Prepared salads’ (n = 3).
As commented in Section 3.1.1.1, several samples of ‘Pickles’ with very high levels of erucic acid
have been reported in RASFF in recent years. Although pickles seem to be rarely consumed in Europe
(around 1,000 consumers for ‘Pickles and chutneys’ in the Comprehensive database, 0.1–14%
consumers across dietary surveys), it is important to note that due to the high levels of erucic acid
reported, even the consumption of small amounts of this food commodity may result in very high
exposure to erucic acid. If we considered an average content of 15 g/kg of erucic acid (whole weight)
extracted from RASFF notiﬁcations, and average and 95th chronic consumption for ‘Pickles and
chutneys’ from the Comprehensive database (consumers only), the range of chronic exposure to erucic
acid via the consumption of pickles in the adult population would be 0.9–7.8 mg/kg bw per day among
the mean consumers and 2.9–7.8 mg/kg bw per day33 for the high consumers (only four dietary
surveys considered with at least 60 consumers). These exposure estimations should be carefully
interpreted since there are doubts on whether the RASFF notiﬁcations refer to the oil used to preserve
the pickle or to the pickle itself, and due to the fact that the consumption data do not distinguish
between pickles preserved in oil or in brine/vinegar solutions.
3.2.1.3. Non-dietary exposure
Additional exposure may occur from the commercial use of erucic acid in cosmetics, lubricants,
surfactants, textiles, polymers and inks (T€opfer and Martini, 1998; Murphy, 2012). However, absorption
via the skin is not known and the contribution to the total exposure via this route is not known.
3.2.2. Dietary exposure assessment of erucic acid in animals
3.2.2.1. Previously reported exposure assessments in animals
The CONTAM Panel has not identiﬁed any previous assessments of exposure to erucic acid by farm
livestock or companion animals.
3.2.2.2. Current exposure assessment in animals
The main source of exposure to erucic acid is from the seeds of oilseed rape (Brassica napus).
Seeds and meals from other Brassicaceae crops may also be used, but generally in niche animal feeds,
and no data are available on their use. In the absence of sufﬁcient data on levels of erucic acid in
other oilseeds and their meals, only data for rapeseed meal and rapeseed oil have been used to
estimate exposure to erucic acid. A number of plants of the Brassicaceae family, including swedes,
turnips, kale and forage rape, are grown as feeds for ruminants, but are fed whole and before the
plant matures and seed development commences. Since erucic acid is only found in the seeds of
Brassica plants, these crops do not represent a source of exposure to erucic acid.
While some whole seeds are fed to livestock (generally restricted to pig and some poultry diets),
most are subjected to oil extraction with the resulting cake or meal used as feed. Within the EU, some
6.8 million tonnes of rapeseed meals were used in the manufacture of compound feeds in 2012/13, of
which 5 million tonnes originated in the EU.34 In addition, rapeseed meals may be fed directly to
livestock on farms as part of their daily ration, although there are no data on the amounts used in this
way.
Rapeseed cakes and meals are important feed materials in diets for all livestock in the EU. They are
principally used as a source of protein, and are included in the diets of all farm animals. The amounts
fed will be determined by a number of factors, including the nutritional requirements of the animals
and the cost of the cakes/meals relative to other sources of protein. Vegetable oils, including rapeseed
33 The maximum mean consumption across dietary surveys was equal to the maximum 95th chronic consumption resulting in
the same exposure estimate.
34 Source: FEFAC statistics (www.fefac.eu).
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oil, are also important ingredients of livestock diets, predominantly because of their high energy
content. Levels of inclusion are variable, according to the nutritional needs of the animal, but generally
do not exceed about 5% of the total ration. Rapeseed oil is not normally the sole vegetable oil used,
but will be part of a blend of oils.
In the absence of data on the amounts of rape seeds and rapeseed products consumed on a daily
basis, the CONTAM Panel has used published recommended maximum inclusion levels for rapeseed
meal and oil for each of the different categories of livestock (Ewing, 1997; Canola Council of Canada,
2015). These recommended levels have been applied to the mean lower bound (LB) and upper bound
(UB) levels reported for rapeseed oil and rapeseed meal (Table 5) to obtain levels of erucic acid in the
diets and estimated exposures. These are given in Tables 8–10 below. Insufﬁcient data on levels of
erucic acid in rapeseed meal or cake were available to allow P95 estimates of exposure to be made.
Details of feed intakes and diet compositions used to estimate exposure are given in Appendix D.
Ruminant and horses
Rapeseed meal is widely used in the diets of ruminants, and in this Opinion, an inclusion rate of
25% in the compound feed has been assumed (20% for lactating sheep and lactating and fattening
goats) (Ewing, 1997). The use of rapeseed oil, regardless of the erucic acid level, is limited due to
potential adverse effects on rumen fermentation, although it may be present in blends of vegetable
oils used in compound feeds. Estimates of exposure have assumed a maximum inclusion rate in the
compound feed of 2%.
Pigs, poultry, salmonids and rabbits
Levels of rapeseed meal in diets of pigs, poultry, salmonids and rabbits vary from 5% to 30%,
depending on the species and/or age of the animal. Levels of rapeseed oil also vary; in practice lower
amounts are used in pig diets because of the effect on the level and composition of body fat. For
poultry, it is common to add 1.0–1.5% rapeseed oil to the diet (Canola Council of Canada, 2015). Full-
fat rape seed, after particle size reduction (rolling) is an important protein and energy ingredient in
broiler diets in a number of EU countries, but in the absence of data on erucic acid content of full-fat
rape seed this has not been included in estimates of exposure.
Table 8: Estimated mean lower bound and upper bound diet concentration and daily exposure by
ruminants and horses to erucic acid
Diet concentration
(mg/kg)
Intake
(mg/day)
Intake
(mg/kg bw per day)
Dairy: high yielding
LB 56 1,164 1.8
UB 80 1,656 2.6
Beef: fattening
LB 21 202 0.51
UB 30 288 0.72
Sheep: lactating
LB 59 165 2.8
UB 88 247 4.1
Goats: lactating
LB 88 300 5.0
UB 132 451 7.5
Goats: fattening
LB 47 71 1.8
UB 71 106 2.7
Horses
LB 48 427 0.95
UB 77 690 1.5
bw: body weight; LB: lower bound; UB: upper bound.
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Companion animals (cats and dogs)
Information provided to EFSA by the European Pet Food Industry Federation (FEDIAF) indicated
that meal, rapeseed oil and meals and oils from other Brassicaceae crops are not common constituents
of cat and dog foods (FEDIAF, Personal communication by email, May 2016). Therefore, no exposure
assessments have been undertaken for these animals.
3.3. Hazard identiﬁcation and characterisation
3.3.1. Toxicokinetics
3.3.1.1. Absorption of erucic acid
Most studies on the absorption of erucic acid have been conducted using oils with a high content of
erucic acid, such as rapeseed or mustard oil. In order to take into account both the lipase-catalysed
hydrolysis of the triacylglycerols in the intestine and the passage of the released erucic acid through
the intestinal mucosa, the apparent coefﬁcient of digestibility was calculated from the amount of fat
ingested minus the amount excreted with the faeces, and expressed as percentage of the ingested fat.
In general, the digestibility of triacylglycerols depends primarily on the type of acyl groups (fatty acids)
and their location in the triacylglycerol molecule. Fatty acids located at position 2 of the triacylglycerol
Table 9: Estimated mean lower bound and upper bound diet concentration and daily exposure by
pigs, poultry, salmonids and rabbits to erucic acid
Diet concentration
(mg/kg)
Intake
(mg/day)
Intake
(mg/kg bw per day)
Pig starter
LB 85 85.4 4.3
UB 172 172 8.6
Pig ﬁnisher
LB 131 393 3.9
UB 218 655 6.6
Lactating sow
LB 131 786 3.9
UB 218 1,310 6.6
Chickens for fattening
LB 157 18.8 9.4
UB 203 24.3 12
Laying hens
LB 111 13.3 6.7
UB 156 18.7 9.4
Turkeys for fattening
LB 131 52.4 4.4
UB 218 87.3 7.3
Ducks for fattening
LB 108 15.1 5.1
UB 195 27.3 9.1
Salmonids
LB 158 6.30 3.2
UB 302 12.1 6.
Rabbits
LB 85 12.8 6.4
UB 172 25.7 13
bw: body weight; LB: lower bound; UB: upper bound.
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are faster released than fatty acids at positions 1 and 3. Erucic acid is predominantly located at
positions 1 and 3.
The apparent digestibility coefﬁcients of rapeseed oil with a high content of erucic acid has been
determined for several species including humans and found to vary between 58% and 100%,
depending on the species and also somewhat on the amount of oil in the diet (Table 10). In these
studies, only the digestibility of total rapeseed oil but not that of erucic acid has been determined.
High values of near 100% for the digestibility of rapeseed oil have consistently been found for
humans. Digestibility appears to be also very high in swine and dogs but somewhat lower in rodents,
although strain differences exist, e.g. between Sprague–Dawley and Wistar rats (Table 10).
Rocquelin and Leclerc (1969) compared the digestibilities of rapeseed oil with a high (44.7%) and a
‘nearly zero content’ of erucic acid (1.9%), and peanut oil in Wistar rats fed diets containing 15% by
weight of one of the oils up to 9 days. There was no signiﬁcant difference in feed consumption
between the groups, but faecal excretion of dry material was more enhanced in rats fed with diets
containing high erucic acid levels. A lower digestibility (81%) was noted for rapeseed oil with a high
content of erucic acid compared to the other two fats (92–95%). Erucic acid and eicosenoic acid,
representing 55% of the total fatty acid content of high erucic acid rapeseed oil, appear to be
responsible for the lower digestibility of the oil, as they represent 85% of the faecal fatty acids.
The coefﬁcient of digestibility was studied in young male Sprague–Dawley rats for free erucic acid
in comparison to some of its esters. Free erucic acid had a digestibility of 53% while methyl erucate
had 62% and ethyl erucate 59% (Carroll, 1958). In another study, free erucic acid had a digestibility
of 48% and glycerol trierucate 63% (Carroll and Richards, 1958). The coefﬁcient of digestibility was
shown to be slightly affected by a number of other factors, e.g. the level of protein and calcium in the
diet, and the age of the animals (Carroll and Richards, 1958).
Sergiel and Gabucci (1980) studied the digestibility and faecal excretion patterns in Wistar rats of
erucic and brassidic acid esteriﬁed in different triacylglycerol structures. Rapeseed and peanut oils
were used as controls. Rats were fed diets containing 15% by weight of one of the oils for up to
11 days. Digestibility of glycerol trierucate or interesteriﬁed glycerol trierucate was similar to that of
peanut oil but higher than that of rapeseed oil, whereas digestibility of glycerol tribrassidate and
interesteriﬁed glycerol tribrassidate was lower. The high amount of glycerol-2-monoerucate, resulting
from diets containing glycerol trierucate, explained the better digestibility of erucic acid as compared
to that of rapeseed oil which had a very small erucic acid content on the 2-position. Glycerol
tribrassidate had a poor digestibility because its hydrolysis by pancreatic lipase was delayed in the
intestinal lumen.
After oral intake of rapeseed oil, the triacylglycerols in human lymphatic fat exhibited the same
percentage of erucic acid as in the rapeseed oil (Fernandes et al., 1955), while the percentage of
Table 10: Digestibility of rapeseed oil in humans and various animal species receiving diets
containing high erucic acid rapeseed oil (in human studies: 2.5–10%, in animal studies:
15–25%)
Species Age, gender, strain Digestibility (%) Reference
Humans Adults, gender not speciﬁed 99 Deuel et al. (1949)
Male and female adults 96 Vaisey et al. (1973)
Dogs Weaned, gender and strain not speciﬁed 94 Crampton et al. (1960)
Swine Weaned, gender and strain not speciﬁed 78 Crampton et al. (1960)
Adult Large White Yorkshire, gender not
speciﬁed
94–100 Paloheimo and Jahkola (1959)
Guinea pigs Weaned, gender and strain not speciﬁed 72 Crampton et al. (1960)
Adult males, strain not speciﬁed 61 Carroll (1957)
Lambs 3-day-old, gender not speciﬁed, cross-
bred
62 Walker and Stokes (1970)
Rabbits Adult males, strain not speciﬁed 58 Carroll (1957)
Rats Adult females, strain not speciﬁed 77–82 Deuel et al. (1948)
Adult males, Sprague–Dawley 58 Carroll (1957)
Adult males, Sprague–Dawley 65 Beare et al. (1960)
Adult males, Wistar 83 Beare et al. (1960)
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erucic acid in rat intestinal lymph triacylglycerols was about 70% of that of the dietary oil (Caselli
et al., 1979), consistent with the higher digestibility in humans (see above).
A radiotracer study on the absorption of free erucic acid in young adult rats has been conducted by
Carroll (1962). After oral dosing of 2-14C-erucic acid, about 20% and 5% of the administered
radioactivity was still in the intestinal tract after 6.5 and 24 h, respectively. Nearly the same values
were found for palmitic acid (16:0) and nervonic acid (24:1 n-9). However, palmitic acid produced
more respiratory carbon dioxide during the ﬁrst 6 h than erucic and nervonic acid, suggesting
differences in the rate of b-oxidation.
3.3.1.2. Distribution of erucic acid
Like other long-chain fatty acids, free erucic acid is assumed to be transported in the blood mainly
bound to serum albumin. A recent study has elucidated the interaction of erucic acid with bovine
serum albumin (Shu et al., 2015). Using multiple spectroscopic methods and molecular docking
techniques, it was shown that erucic acid binds to one site in the IIA subdomain, mainly through
hydrophobic but also hydrogen bonding.
Wagner et al. (1958) fed a diet containing rapeseed oil with 42% erucic acid to adult male rats for
6 months, and subsequently determined the content of erucic acid in the fractions of neutral lipids and
phospholipids of various organs (heart, liver, kidneys, lung, spleen, intestine, bones and carcass). The
rat strain and concentration of rapeseed oil in the diet were not given. The percentage of erucic acid
among total fatty acids varied between different organs, being in neutral lipids 2.2 in the liver and 4.5
in the heart, and for phospholipids, absent in the liver and 2.4 in the heart. The authors concluded
that none of the examined organs accumulated erucic acid and that neutral fats incorporated more
erucic acid than phospholipids. In another experiment, the same diet was fed to adult male rats for
45 days, followed by a rapeseed oil-free diet for 20 days in order to determine the elimination half-life.
The half-life of erucic acid in the total lipids of various organs (lung, intestine, skin and carcass) and
fat depots (perirenal, mesenterial and genital) ranged from 18 to 31 days and was about the same as
for common fatty acids.
Carroll (1962) reported that the rat adrenal, which was not among the tissues studied by Wagner
et al. (1958), accumulated large amounts of cholesteryl erucate when erucic acid was included in the
diet. In support of this observation, Walker (1972a) reported that greatest deposition of erucic acid
occurred in the adrenals and decreasing amounts were found in the plasma, heart, spleen, kidney,
erythrocytes, testis and brain of male weanling Wistar rats fed a diet containing HEAR oil or a mixture
of ethyl erucate and corn oil (5:1) for 18 weeks. Walker et al. (1972) further reported that female
weanling Wistar rats maintained for 10 weeks on a diet containing a 5:1 mixture of ethyl erucate and
corn oil extensively deposited erucic acid in the cholesteryl ester fraction of adrenals and ovaries,
accounting for up to 30% of the total fatty acids. The authors concluded that this effect was related to
the high activity of these organs for the synthesis of steroidal hormones.
In contrast to the rat studies, no preferential deposition of erucic acid in the tissue lipids from
adrenals and ovaries were noted when 5-week-old swine were maintained for 6 weeks on a diet
consisting of 59% corn and 25% soybean meal, and containing either 10% rapeseed oil or 10% corn
oil (control). The greatest deposition of erucic acid, accounting for more than 7% of the total fatty
acids, was found in plasma and adipose tissue lipids, whereas erucic acid comprised 3–5% of the total
fatty acids in the spleen, adrenal, erythrocyte and heart. Only 1–3% erucic acid was found in the
ovary, liver, kidney and testis (Walker, 1972b).
In all these studies, the amounts of erucic acid deposited in the various tissue lipids were
quantiﬁed. However, because of the chain shortening of erucic acid during b-oxidation, exact ﬁgures
for the initial distribution of erucic acid into different organs after absorption may not to be derived
from the analysis of erucic acid alone. Even radiotracer studies may lead to erroneous results if the
label can be removed during b-oxidation, such as with 14C-erucic acid carrying the label near the
carboxyl group.
The uptake of low concentrations of erucic acid, which did not perturb the normal plasma levels of
fatty acids, into the liver and heart of male Sprague–Dawley rats was determined following infusion of
14-14C-erucic acid (Murphy et al., 2008). A 2.3-fold higher uptake by the liver as compared with the
heart was observed. This higher hepatic uptake was accounted for by a 4.2-fold higher incorporation
of label into neutral lipids of the liver than those of the heart. In the liver, 56% of the label was found
in cholesteryl esters, while in the heart 64% was found in triacylglycerols. Esteriﬁed neutral lipids of
the heart contained 75% of the label as erucic acid and 10% as oleic acid. In contrast, only 25% were
unchanged erucic acid, 10% were oleic acid and 50% were stearic acid in the liver. These data
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indicate different metabolism of erucic acid in the liver (mainly conversion to stearic acid followed by
export in neutral lipid) and heart (mainly incorporation into triacylglycerols).
Newborn Albino rats were kept on a diet containing 10% rapeseed oil (with 43% erucic acid) or
blended canola oil (with 0.4% erucic acid). At the age of 4 months, the plasma, liver, adrenal gland,
retina and brain were collected from both groups, and the fatty acids were determined in various lipid
fractions. Samples from the retina were collected since rat retina is known to accumulate certain C22
polyunsaturated fatty acids, in particular docosahexaenoic acid (DHA), in the phospholipids of the rod
outer segments (Fliesler and Anderson, 1983). Only in the rats receiving rapeseed oil, erucic acid was
incorporated into lipids of the plasma (2.3%), liver (0.6%) and adrenal gland (17.6%) but not of the
retina or brain, suggesting that erucic acid is not distributed into the latter two tissues (Wang et al.,
1992).
There has been a long lived tenet according to which fatty acids do not readily penetrate the
blood–brain barrier and consequently are not used as a source of energy by the brain, because they
are bound to albumin and plasma lipoproteins. However, experimental studies have demonstrated that
non-esteriﬁed fatty acids, readily liberated from albumin or hydrolysed from the glycerol backbone, are
available for passing through the blood–brain barrier (Hamilton, 1998). According to a more recent
hypothesis, fatty acids are not used for energy production in the brain because they have higher
oxygen expenditure and cause more oxidative stress than glucose (Sch€onfeld and Reiser, 2013).
There are contradictory ﬁndings regarding the passage of erucic acid from the blood into the brain.
Poulos et al. (1994) reported that increased levels of erucic acid were found in the fatty acids of the
plasma and liver, but not of the post-mortem brain of adrenoleukodystrophy (ALD) patients treated
with Lorenzo’s oil.35 Similar ﬁndings in ALD patients treated with Lorenzo’s oil were reported by
Rasmussen et al. (1994). Substantial amounts of erucic acid were present in the post-mortem adipose
tissue and liver but not in the post-mortem brain. Likewise, feeding Wistar rats for 18 weeks with corn
oil supplemented with ethyl erucate did not result in increased erucic acid concentrations in the brain
(Walker, 1972a). In contrast, in a later study by Golovko and Murphy (2006), 14C-erucic acid was used
to probe the transfer of erucic acid from plasma into brain. After intravenous infusion of male
Sprague–Dawley rats for 10 min, 0.01% of the plasma radioactivity was taken up by the brain and
incorporated into triacylglycerols, phospholipids and cholesteryl esters. Moreover, about 60% of the
radioactivity in the brain was attributed to eicosenoic and oleic acid. This study demonstrates that
erucic acid crosses the blood–brain barrier to a small extent, is incorporated into speciﬁc lipid pools,
and undergoes b-oxidation in the brain.
The fetal heart utilises glucose as its major energy source, and might therefore be protected from
the cardiotoxic effects of erucic acid. Intrauterine mitochondrial fatty acid oxidation is not believed to
play a major role. However, lethal fetal cardiac myopathy has been described, where impaired
placental fatty acid oxidation has been proposed as an underlying cause (Rakheja et al., 2002; Oey
et al., 2006).
3.3.1.3. Metabolism of erucic acid
As shown in Figure 4, free erucic acid in the blood is transported to the tissues as albumin
complex, while erucic acid present in triacylglycerols of chylomicrons or very low-density lipoproteins
(VLDL) is liberated by lipoprotein lipase located in the epithelial lining of the blood vessels (Feingold
and Grunfeld, 2015). In tissue cells, the general fate of free erucic acid is activation to erucoyl-CoA,
which can be used for the incorporation of erucic acid into triacylglycerols and phospholipids by
esteriﬁcation (route A) or for b-oxidation in mitochondria (route B) or for chain shortening in
peroxisomes (route C). The conversion of erucoyl-CoA to erucoyl-carnitine is required for uptake into
mitochondria. A forth and minor route (not depicted in Figure 4) is the chain elongation of erucic acid
to nervonic acid (24:1 n-9). All four routes are mediated by enzymes. The metabolites resulting from
chain shortening and chain elongation of erucic acid are depicted in Figure 5.
35 Lorenzo’s oil, a drug used for adrenoleukodystrophy (ALD), is comprised of 20% glycerol trierucate (a triacylglycerol with
three erucic acid molecules) and 80% glycerol trioleate.
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The numerous studies aiming at elucidating the metabolism of erucic acid in the heart and liver
have been reviewed by Bremer and Norum (1982). Brieﬂy, rats and other animal species have a limited
capacity to b-oxidise erucic acid (and other fatty acids with more than 18 carbon atoms) in
mitochondria due to a slow oxidation of erucoyl-CoA by the mitochondrial acyl-CoA dehydrogenase.
Moreover, erucoyl-CoA has an inhibitory effect on the oxidation of the CoA esters of other fatty acids.
As a consequence (which is discussed in more detail in Section 3.3.4.1), a diet containing high
amounts of erucic acid causes an accumulation of triacylglycerols (lipidosis) in the heart and other
tissues but not the liver, which is able to export erucic acid as VLDL to the blood plasma.
Because peroxisomes lack a short-chain acyl-CoA oxidase, complete degradation of erucoyl-CoA
does not occur in peroxisomes. Only one or a few b-oxidation cycles take place, leading mainly to
gondoic acid (20:1 n-9) and oleic acid (18:1 n-9) (Osmundsen et al., 1979). However, these products
of peroxisomal degradation of erucic acid can be further b-oxidised in mitochondria.
In mitochondria, each acetyl-CoA molecule obtained by b-oxidation of erucic acid is
dehydrogenated in the mitochondrial citrate cycle to two carbon dioxide molecules with formation of
one ﬂavin adenine dinucleotide (FADH2) and three nicotinamide adenine dinucleotide (NADH)
molecules, which enter the mitochondrial respiratory chain for adenosine triphosphate (ATP)
production. The respiratory chain also utilises the FADH2 and NADH generated during mitochondrial
b-oxidation of erucic acid. Peroxisomes lack the citrate cycle and respiratory chain, and do not form
FADH2 but hydrogen peroxide (H2O2) during b-oxidation. The acetyl-CoA and NADH generated during
chain shortening in peroxisomes are exported to the mitochondria for further utilisation.
nervonic acid  (24:1 n-9) 
erucic acid  (22:1 n-9) 
β-oxidation elongation 
β-oxidation elongation
gondoic acid  (20:1 n-9) 
oleic acid  (18:1 n-9) 
β-oxidation elongation 
Figure 5: Products resulting from chain elongation and chain shortening of erucic acid
Chylo: chylomicrons; VLDL: very low-density lipoproteins; alb: albumin; LPL: lipoprotein lipase; TG: triacylglycerol;
PL: phospholipid; Car: carnitine.
Figure 4: Cellular uptake and fate of erucic acid (EA)
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It appears to be a general feature in all species that the mitochondrial oxidation rate of fatty acids
decreases abruptly when the chain length exceeds 18 carbon atoms. For example, the oxidation rate
of 22:1 acylcarnitines is 30–35% of that of 16:0 or 18:1 acylcarnitines in isolated heart mitochondria
from pigs and oxen (Osmundsen and Bremer, 1978). However, there appear to be species differences
in the ability of heart mitochondria to oxidise carnitine esters of fatty acids of varying chain length.
Buddecke et al. (1976) observed that pig heart mitochondria oxidised erucic acid with ca. 3-fold higher
rates than rat heart mitochondria. Moreover, Osmundsen and Bremer (1978) reported that 22:1 fatty
acids inhibit the tricarboxylic acid cycle in heart mitochondria from the rat but not from the pig. Thus,
overall respiratory depression was somewhat less severe in pigs than in rats.
The low capacity of heart mitochondria for b-oxidation of erucic acid observed in various animal
species has also been demonstrated for humans (Clouet and Bezard, 1979). Mitochondria isolated from
fragments of human heart appendages, removed during surgical intracardiac operations, were
incubated with 14-14C-erucic acid or 10-14C-oleic acid. The radioactive products soluble in perchloric
acid, that result from the b-oxidation, were formed in much lower amounts (about 6- to 10- fold) from
erucic acid than from oleic acid. Activation of fatty acids, the initial step of b-oxidation, was also very
much lower (about 5- to 7-fold) with erucic acid than with oleic acid (Clouet and Bezard, 1979).
However, no information is available on cardiac lipidosis in persons ingesting erucic acid, e.g. patients
receiving Lorenzo’s oil.
The complexity of the metabolism of erucic acid and other fatty acids is increased by the fact that
different organs may use the options of incorporation into lipids, chain degradation and chain
elongation to various extents. This is illustrated by a study reported by Clouet et al. (1980) on the
in vivo conversion of erucic acid into total lipids, mitochondria and microsomes from the liver, kidneys
and heart of rats, 8 min after intravenous injection of albumin-bound 14-14C-erucic acid. In the liver
(containing 15% of the injected radioactivity), oleic acid (18:1 n-9) was the main fatty acid formed
(26% of the 14C recovered). In kidneys (0.53% of the injected radioactivity), the level of nervonic acid
(24:1 n-9) was higher (20%) than that of oleic acid (14%). No appreciable transformation was
encountered in the heart, which contained 0.53% of the injected radioactivity. In the liver, the
microsomes showed higher converted radioactivity (45%) mainly as oleic acid (33%), much higher
than in mitochondria (11%), whereas the amount of total 14C fatty acid was a little higher in the latter
fraction. In kidneys, the mitochondrial and microsomal fractions contained the same percentage of
14C-oleic acid (15%), whereas nervonic acid was recovered in higher proportion, 29% in microsomes
and 20% in mitochondria. In the heart, the mitochondrial and microsomal fractions contained the
same low percentage of 14C-oleic acid and nervonic acid (around 5%).
3.3.1.4. Excretion of erucic acid
Data on the excretion of erucic acid are extremely limited. Only older studies are available which
have focussed on measuring the faecal excretion of erucic acid. As erucic acid can be metabolised by
chain shortening and/or elongation (see Section 3.3.1.3), it would be necessary to use appropriately
radiolabelled erucic acid to account for excreted metabolites.
Ziemlanski et al. (1973) administered a single dose of 0.8 mL of erucic acid ethyl ester
(corresponding to 560 mg erucic acid) or 1.6 mL of rapeseed oil (erucic acid content not given) either
alone or mixed with soybean oil. The time course of faecal excretion of erucic acid was similar after
each dosing regimen, with the major proportion being excreted within 48 h and completion reached
after 4–5 days. About 30% of the dosed erucic acid was accounted for in the 5-day faeces when
erucic acid ethyl ester or rapeseed oil had been given alone, and about 20% when given together with
soybean oil.
3.3.1.5. Summary regarding the absorption, distribution, metabolism and excretion of
erucic acid
Erucic acid is present in food and feed, predominantly as component of triacylglycerols. It is well
absorbed from the gastrointestinal tract to an extent varying between 60% and 100%, depending on
the species. Humans exhibit virtually complete absorption. Like other fatty acids, erucic acid is
distributed to the different organs where it is metabolised by the following major pathways: (1)
incorporation into lipids (mostly triacylglycerols), (2) complete b-oxidation in mitochondria, (3) partial
b-oxidation (chain shortening) in peroxisomes, and (4) chain elongation. In contrast to fatty acids with
18 or less carbon atoms, erucic and other docosenoic acids are poorly metabolised by b-oxidation in
mitochondria and depend on chain shortening in peroxisomes, in particular in rats but also in pigs.
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3.3.1.6. Transfer into food of animal origin
In many of the studies identiﬁed, the levels of erucic acid in food of animal origin were only
reported as percentage of total fatty acids, and therefore, transfer from feed to ﬁnal product could not
be calculated except in milk. The CONTAM Panel noted that several of the studies were reported
40 years or more ago, and therefore, the applicability to current animal genotypes is uncertain.
Meat
Diets supplemented with high (23.7%) or low (2.4%) erucic acid oils were fed to broiler chickens
for 4 weeks (Vogtmann and Clandinin, 1974). There were signiﬁcant differences (p < 0.001) in the
erucic acid contents of different tissues from the broiler chickens; in breast tissue, for example, erucic
acid content were 6.8% and 0.7% of fatty acids in broiler chickens fed the high and low erucic acid
diets, respectively. Feed intakes were not given, and therefore, transfer rates cannot be calculated.
In a subsequent study broiler chickens were fed diets supplemented with oil (15% inclusion in the
diet) from different varieties of LEAR oil, for 8 weeks. Erucic acid contents of the oils ranged from
< 0.1% to 3.5% of total fatty acids. Erucic acid contents ranged from ‘undetected’ to 1.2% of total
fatty acids in spleen from broiler chickens fed a reﬁned oil. The authors concluded that ‘only small
amounts of erucic acid were found in the tissues’ (Vogtmann et al., 1974).
Farnworth et al. (1994) examined the effect on the body composition of piglets as a result of
feeding artiﬁcial milk containing 0%, 2%, 7%, 12% or 20% erucic acid. Digestibility of erucic acid was
high (> 98%), and the erucic acid content of the backfat36 reﬂected the concentrations in the diet. In
the pigs receiving the highest erucic acid diet, the level of erucic acid in backfat was approximately
18% of total fatty acids; when the erucic acid content was reduced to 2%, this level was only 0.6%.
Erucic acid was also deposited in adipose tissue.
B€öhme et al. (2005) undertook a study in which crambe press cake was fed to growing and
fattening pigs (24–120 kg bw). Erucic acid contents in the diets ranged from 0.2 to 7.1 g/kg dry
matter (DM), and the total intake of erucic acid over the growing and fattening periods ranged from
47 to 1,912 g. At the three lowest levels of intake (47, 80 and 173 g erucic acid over the experimental
period), there were no signiﬁcant differences in the erucic acid contents of backfat or intramuscular
fat. At the two highest intakes of erucic acid there was a signiﬁcant (p < 0.05) dose-related increase in
the erucic acid content (as a % total fatty acids) from < 0.1% (control treatment) to 1.5% in backfat
and 0.7% in intramuscular fat.
Milk
B€öhme et al. (2005) examined the transfer of erucic acid from feed to milk. Mid-lactation dairy
cows were fed diets containing 0%, 15% or 30% crambe press cake for 8 weeks. Erucic acid contents
were 0.1%, 1.3% and 2.1% of total fatty acids in milk (p < 0.05). There was a direct and positive
correlation between erucic acid output in milk and erucic acid intake, and from the data provided for
erucic acid intake and milk fat production the CONTAM Panel calculated transfer rates of 100%, 26%
and 16%, respectively.
More recently, Hristov et al. (2011) fed lactating dairy cows diets containing conventional, solvent-
extracted canola meal or high erucic acid (erucic acid 42% of total fatty acids), low-glucosinolate
rapeseed meal. Rumen studies indicated that erucic acid is partially hydrogenated or isomerised in the
rumen, and that the resulting biohydrogenation intermediates and end-product fatty acids are readily
absorbed and utilised in the mammary gland for milk fat synthesis. As a result, replacing conventional
rapeseed meal with HEAR meal resulted in a signiﬁcant increase in erucic acid from 0.07 to 2.33 g/kg
total fatty acid in the milk (p < 0.001).
In both these reports, erucic acid was expressed as % of total fatty acids. In order to convert from
% in total fatty acids to % in milk fat, it is necessary to account for the glycerol present in milk, and
the accepted conversion factor for milk fat is 0.945 (Paul and Southgate, 1978). Adopting this
approach, the erucic acid content of milk ranged from 0.02 to 0.65 g/kg in Hristov et al. (2011), and
from 0.04 to 0.8 g/kg milk in B€öhme et al. (2005).
Eggs
A number of studies have examined the transfer of erucic acid from feed to the fatty acids in egg
yolks. Lall and Slinger (1973) fed laying hens diets supplemented with 10% or 20% of HEAR and LEAR
36 The panniculus adiposus along the back of a pig.
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oils (containing approximately 32% and 1.2% erucic acid, respectively). While the total lipid content of
the yolk was not inﬂuenced by the type or level of dietary fat, the addition of the different rapeseed
oils altered the fatty acid composition of egg yolk. The average erucic acid content of yolk fat of hens
fed 10% and 20% of the HEAR oil was 0.6%, but was 0.2% in yolk fat of eggs from laying hens fed
the LEAR oil.
Vogtmann et al. (1974) examined the effects of including 5% or 15% of LEAR and HEAR oils on
the total lipid and fatty acid contents of egg yolks. The erucic acid content of egg yolk fatty acids was
0.2% in eggs from laying hens fed 15% of the HEAR oil, but was < 0.1% in the fatty acid of egg yolks
of laying hens fed the LEAR oil. Based on other changes in the fatty acid contents of the egg yolks, the
authors concluded that in the laying hens a partial degradation of erucic acid occurs.
Honey
The CONTAM Panel considered the transfer of erucic acid from pollen into honey. Evans et al.
(1988) reported the fatty acid composition of pollen and seeds from three cultivars of B. napus,
including one cultivar high in erucic acid. Only traces of erucic acid (< 2.0% of the fatty acids) were
found in the pollen. Usually, the total lipid content of pollen is less than 10% (Nicolson, 2011),
however, also higher levels have been reported (e.g. 23.8% of dry weight, Evans et al., 1988). In
addition, it should be noted that the pollen content in honey is low. Puusepp and Koff (2014) reported
an average concentration of 10,000 grains/g honey and considering that 2,000 pollen grains weigh
1 mg (Porter, 1981), the pollen content in honey is around 0.5%. Given the low amounts of pollen in
honey, the low lipid content in pollen and the low fraction of erucic acid in the lipid fraction of the
pollen, the CONTAM Panel concluded that the transfer of erucic acid from pollen into honey is
negligible.
Fish
Torstensen et al. (2004) fed Atlantic salmon diets in which ﬁsh oil was replaced by 25%, 50%, 75%
or 100% rapeseed oil, giving erucic acid (22:1 n-9) contents ranging from 2.0% (100% ﬁsh oil) to
0.5% (100% rapeseed oil). Levels of erucic acid in both red and white muscle and livers declined with
declining levels in the diet.
Summary
There is evidence that erucic acid present in feed is transferred to products of animal origin and a
dose-related increase in erucic acid in food of animal origin has been shown. With the exception of the
study reported by B€öhme et al. (2005), it has not been possible to estimate transfer rates from feed to
food of animal origin. In ruminants, erucic acid is also partially hydrogenated or isomerised in the
rumen.
3.3.2. Toxicity in experimental animals relevant for human risk assessment
3.3.2.1. Acute toxicity (single dose)
Groups of ﬁve male and female Wistar rats received a single erucic acid dose of 5 g/kg bw as a
25% suspension in water by gastric intubation (Henkel KGaA, 1981a). The animals exhibited a rough
fur and reduced motor activity shortly after dosing. These effects were slight and disappeared within
24 h. All animals gained body weight and survived an observation period of 14 days without symptoms
of toxicity. The histological examination of internal organs did not reveal any abnormalities except an
acute inﬂammation of the intestine. The authors concluded that the oral LD50 of erucic acid for male
and female Wistar rats is > 5 g/kg bw. Although the study was conducted according to OECD guideline
401, there was no control group and the organs for histological examination were not speciﬁed.
3.3.2.2. Repeated dose toxicity
The animal species most widely used for studying the toxicity of erucic acid is the rat. In most
studies, rapeseed or mustard oil with a high or low content of erucic acid, present in the fraction of
triacylglycerols, has been used rather than glycerol trierucate or erucic acid per se. It should be noted
that several studies used rapeseed oils high in erucic acid while rapeseed oil available on the European
market for dietary use contains usually extremely low levels (less than 0.5%) of erucic acid. Results
reported in Sections 3.3.2.2, 3.3.2.4, 3.3.2.5 and 3.3.5 for rapeseed oil are therefore not
representative for rapeseed oils containing low levels of erucic acid that are available on the European
market for dietary use.
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A. Studies including only low erucic acid rapeseed oils in experimental animals
As deﬁned by the Codex Alimentarius Commission LEAR oils contain less than 5% erucic acid
(Codex Alimentarius Commission, 1979). Their toxicity has been extensively reviewed by Kramer and
Sauer (1983b). The LEAR oil presents a particular fatty acid composition: it is rich in oleic acid (18:1 n-9),
similarly to peanut and olive oil, and presents also a relatively high content of linolenic acid (18:3 n-3),
similarly to soybean oil (Kramer et al., 1979a). Typical ranges of variation for both fatty acids,
considering broad variation for cultivar and environmental conditions, are between 54% and 71% for
oleic acid and between 3% and 14% for linolenic acid (Seberry et al., 2006, 2014). The digestibility of
LEAR oil in rats is very high, approaching 100%.
A large body of evidence indicates that LEAR oils do not cause myocardial lipidosis in rats; however,
a high incidence of myocarditis in male rats is reported on prolonged feeding of this rapeseed oil. The
extensive literature review by Kramer and Sauer (1983b) allows concluding that LEAR oils consistently
produce a higher incidence of lesions in rats than other oils. The severity of the lesions (number of
lesions per heart) is also, in general, signiﬁcantly higher in rats fed LEAR oils than other oils. Analysis
of published data (Kramer and Sauer, 1983b) in rats indicate that, of the fatty acids in vegetable oils,
18:1, 18:3, 20:1 and 22:1 promote the occurrence of myocardial lesions whereas 16:0, 18:0 and 18:2
have a protective effect. Therefore, the fatty acid composition (particularly the presence of oleic acid
and linolenic acid) of LEAR oils may account for the incidence of myocarditis induced in rats by this
vegetable oil. Pigs, dogs, mice and non-human primates do not respond to dietary LEAR oils like the
rat, showing heart lesions that are in general not related to fat and likely of different aetiology.
Effects on the liver (e.g. morphological alterations) and platelet number have been reported in
piglets (Cullen et al., 1996; Innis and Dyer, 1999), but as in the case of cardiotoxicity these effects
cannot be ascribed to erucic acid because of the fatty acid composition of LEAR oils.
Therefore, the CONTAM Panel concluded that studies using only LEAR oils cannot be used for the
risk assessment of erucic acid.
B. Studies including oils high in erucic acid (> 5%)
Rat
The studies in rats with only high erucic oils or with both high and low erucic acid oils are described
in Appendix G, Table G.1 (including the doses). The text below summarises the toxic effects observed
in these studies.
It is to be noted that in these experiments, rats were fed diets containing a high amount of fat
(20–30%), which already may have an effect on the rats compared to rats fed standard (low-fat)
diets: e.g. reduced food consumption, increase in body weight, modiﬁcations of levels of some
nutriments, induction of signs of myocardial lipidosis (Abdellatif and Vles, 1973a; Engfeldt and
Gustafsson, 1975; Ziemlanski et al., 1975; Kramer et al., 1979b; Kramer et al., 1992; Vaskonen et al.,
1996).
Cardiac lipidosis
The heart is the principal target organ of toxic effects following short or long-term exposure of rats
to diets containing erucic acid. Myocardial lipidosis is produced in rats fed diets containing rapeseed oil,
mustard oil or methyl erucate (e.g. Beare-Rogers et al., 1971; Rocquelin et al., 1975; Kramer et al.,
1992). Lipidosis appears early after feeding (e.g. Abdellatif and Vles, 1970a,b, 1973a; Houtsmuller
et al., 1970; Beare-Rogers et al., 1971; Ziemlanski et al., 1975); lipid droplets may be detected in
myocardial cells by electron microscopy in rats fed HEAR oil as early as 3 h after feeding (Ziemlanski
et al., 1973). Myocardial lipidosis reaches a peak 3–7 days after onset of feeding and regresses
thereafter. The severity and duration of this alteration are directly related to the erucic acid content of
the diet and the duration of exposure (Corner, 1983; Kramer et al., 1988). Myocardial lipidosis
regresses following long-term administration of high doses of erucic acid, but still remains above that
found in control animals at the end of the exposure period (e.g. Beare-Rogers et al., 1972b; Abdellatif
and Vles, 1973a). In addition, Kramer et al. (1988) have shown that lipidosis induced in rats after
1 week exposure to a high-fat/high erucic acid diet was reversible to nearly control levels within
1 week when changing to a low-fat diet without erucic acid. One of the possible mechanisms for the
myocardial triglyceride accumulation and its regression is an increased ability of the heart to oxidise
erucic acid to shorter chain fatty acids (see Section 3.3.4) (Kako and Vasdev, 1979; Norseth et al.,
1979). Electron microscopic examinations showed that lipid droplets were closely associated with
mitochondria. Houtsmuller et al. (1970) have described the impaired oxidative capacity of the heart
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mitochondria after exposure of rats for 6 weeks to HEAR oil. Mitochondrial damage
(megamitochondria, mitochondrial proliferation, increase in the average volume, distortion of shape,
degeneration of crista), and disorganisation of myoﬁbrils have been reported after exposure of male
rats to rapeseed oil for several months (Bhatnagar and Yamashiro, 1979; Yamashiro and Clandinin,
1980). Charlton et al. (1975) reported that cardiac lipidosis in rats fed a variety of rapeseed oil was
more severe in the ventricular walls and interventricular septum than in the atrial walls. Myocardial
lipidosis is reported to reduce the contractile force of the heart muscle. ten Hoor et al. (1973) showed
that myocardial function of rats fed HEAR oil for a short term (i.e. 3 days) is reduced. They suggested
that the decreased contractile force of the heart muscle may be related to an impaired mitochondrial
function that decreased capacity to oxidise substrate and a decreased rate of ATP synthesis. Other
authors reported no functional changes (Kako and Vasdev, 1979; Kako et al., 1980). Heart lipids of rats
exposed to HEAR oil were rich in erucic acid. Speciﬁc accumulation of triacylglycerols as well as an
increase in cardiac free fatty acids was observed in the heart of rats fed HEAR oils (Kramer et al.,
1992). Cardiac triacylglycerols are readily mobilised for energy production or serve as phospholipids
precursors (Kramer and Sauer, 1983a). Cardiac lipidosis was not observed, or only traces, in rats fed
lard, sunﬂower, corn or peanut oil. The presence of intracellular fat droplets was also observed in
skeletal muscles of rats fed HEAR oil. Pale heart and muscles were described in rats fed HEAR oil
(Corner, 1983).
It has been shown that myocardial lipidosis of rats fed HEAR oil, partially hydrogenated HEAR oil,
herring oil or partially hydrogenated herring oil is correlated with the amount of docosenoic acids37 (in
particular erucic acid, cetoleic acid and brassidic acid) in cardiac lipids (Beare-Rogers et al., 1972a).
Studies have also shown that greater lipid deposition occurs in weanling rats fed rapeseed oil than in
similarly treated older rats.
The CONTAM Panel considered that lipidosis is a relevant effect for the risk assessment of erucic
acid.
Degenerative lesions in the heart
Ziemlanski et al. (1975) have shown that exercise contributes to the utilisation of great surplus of
myocardial erucic acid. Myocardial fatty degeneration was less intense and the erucic acid percentage
of total fatty acids in the heart was lower in trained rats fed a diet containing very high levels of erucic
acid than in untrained rats. Training was also found to reduce the growth rate of the animals.
After 2–4 weeks feeding with diets containing rapeseed oil, degenerative lesions of cardiac
muscular ﬁbres appear in rats, followed by myocardial necrosis (death of myocardial cells), removal of
the necrotic cellular debris by macrophages and repair of the lost muscle by a ﬁbrous connective tissue
scar (ﬁbrosis, observed mainly from 16 weeks feeding) (Ziemlanski et al., 1975). Myocardial necrosis
may occur in rats subjected to many different nutritional and metabolic conditions and is inﬂuenced by
many factors (age, sex, strain, source); the male being more severely affected (Kramer et al., 1988)
and at an earlier age. Cardiac injury might be due to an interaction of male sex hormones with speciﬁc
dietary fat components. Kramer et al. (1988) have shown that growth rate is also involved in the
aetiology of myocardial necrosis in rats; small male showing signiﬁcantly less myocardial necrosis than
heavier rats. Myocardial lesions have been observed in the hearts of rats fed rat chow, control oils
such as corn, peanut, olive, soybean or various marine oils. Therefore, myocardial necrosis is
considered to be a spontaneous idiopathic lesion in the male rat. Experiments done by Innis and
Clandinin (1980) have shown that fundamental physiological differences in the proﬁle of fatty acids
(saturated and essential fatty acids) reaching the heart occur between young growing male rats fed
for 1 week and those fed for 4 weeks and between male and female rats fed identical fats for the
same length of time. In females greater movement of fatty acid through hepatic and extrahepatic
tissue may result in modiﬁcation of plasma fatty acids. These results suggest that physiological
differences in whole body fat metabolism unrelated to plasma fatty acids determine strain differences
in timing and severity of rapeseed oil-induced cardiac pathology. Charlton et al. (1975) reported that
cardiac necrosis and ﬁbrosis in rats fed a variety of rapeseed oils was more severe in the ventricular
walls and interventricular septum than in the atrial walls. Acute and chronic lesions are sometimes
present in the same heart, suggesting that focal necrosis does not occur at one time but is continuous
or recurrent during at least part of the feeding trials. In some experiments, higher incidence and
severity of myocardial necrosis have been observed in rats fed HEAR oil compared to control oils or
37 Docosenoic acid is the group name for all fatty acids with 22 carbon atoms and one double bound regardless of the position
of the double bound and cis or trans conﬁguration; e.g. erucic acid, cetoleic acid and brassidic acid.
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LEAR oil (Hung et al., 1977). Several hypotheses have been proposed to explain the aetiology of the
focal myocardial necrosis and ﬁbrosis seen in male rats following feeding with various rapeseed or
herring oils. Some authors considered that erucic acid alone was responsible for the production of the
focal necrosis (Abdellatif and Vles, 1973a; Engfeldt and Brunius, 1975b; Astorg and Cluzan, 1976).
However, the results of several studies suggested that the increased incidence of myocardial necrosis
was the result of a fatty acid imbalance (relative abundance of saturated and/or unsaturated acids) for
the growing male albino rat (Kramer et al., 1973, 1975; Hulan et al., 1977). Common C16 and C18
fatty acids found in most vegetable oils appear to be involved in cardiac necrosis of the rat (Kramer
et al., 1975). According to Kramer et al. (1988), the development of myocardial necrosis appears to be
caused by a combination of factors such as an alteration of cardiac phospholipids and/or their fatty
acid composition (saturated fatty acids, C22 n-3 Polyunsaturated fatty acids (PUFAs) and long chain
monoenes of 20:1, 22:1 and 24:1). Several studies have shown that there is no apparent relationship
between the number of lesions per heart and the amount (accumulation) of cardiac triacylglycerols
and free fatty acids or the concentration of erucic acid in the cardiac triacylglycerols or free fatty acids
in the heart of Sprague–Dawley rats (Kramer and Hulan, 1978; Kramer et al., 1979b).
The CONTAM Panel concluded that, from these studies with oils, myocardial necrosis cannot be
speciﬁcally linked to erucic acid, and therefore, myocardial necrosis is not a suitable endpoint for risk
assessment.
Other cardiac endpoints
Lisciani et al. (1989) have shown that the exposure of Wistar male rats for 10 days to erucic acid
(11.4 g/kg bw per day) results in an earlier occurrence of ventricular ﬁbrillation, pulmonary oedema
(increased incidence) and cardiac arrest compared to the control group after being injected with
adrenaline until cardiac arrest. The development of pulmonary oedema was the result of the
inadequacy of cardiac output to counterbalance the increase in vascular resistance induced by
adrenaline. A diet rich in erucic acid was more arrhythmogenic and the heart was less efﬁcient.
However, no effect on the electrocardiogram (ECG) was observed after feeding rats with HEAR oil for
8 weeks (Berglund, 1975) or with HEAR oil or erucic acid for 26 weeks (de Wildt and Speijers,
1984). So, in spite of gross morphological changes, no disturbances seemed to occur within the
conductance system of the affected heart. Although focal myocardial ﬁbrotic lesions was induced by
HEAR oil after 24–26 weeks feeding, no changes were noted with respect to the intrinsic myocardial
contractibility in vitro and in vivo. After inotropic intervention, only the HEAR oil fed rats showed less
contractile reserve capacity. This was not observed in the erucic acid-treated rats which do not show
epicardiac ﬁbrotic lesions. The authors concluded that rapeseed oil and not erucic acid is responsible
for loss of contractile reserve capacity without changes in the myocardial conductance system and
that erucic acid might interfere with the peripheral vascular system, reducing vascular reactivity. They
showed also that erucic acid alone appears to be responsible for an impaired vasoconstrictor
response towards noradrenaline. It appears also that a fat rich diet might result in reduced
myocardial function during a state of energy demand coupled with a blood pressure decrease
(de Wildt and Speijers, 1984).
When the hearts taken from rats fed for 10 days with a normal or erucic acid diet (12 g/kg bw per
day) were perfused aerobically with an isovolumic preparation, no difference was observed in
mechanical activity (heart weight, rate at which the isolated heart beat or the coronary perfusion
pressure) between the two groups of rats. However, when pressure-volume curves were determined in
the paced hearts, the pressure developed by hearts from erucic acid fed rats was reduced, indicating
that erucic acid causes systolic as well as diastolic dysfunction (Pasini et al., 1992a,b).
Stewart et al. (1993) reported that the fat accumulation that occurs in isolated perfused hearts of
rats fed diets rich in high erucic acid rapeseed oil does not interfere with the cardiac high energy
phosphate metabolism or contractile function. However due to the limitations of the study (e.g. small
number of animals, rate pressure product has been shown not to correlate with cardiac workload) by
Aksentijevic et al. (2016), it was not further considered.
Non-cardiac effects
Other effects observed in rats exposed to HEAR oil are listed below:
• decreased feed intake, weight gain from about 6–8 g/kg bw per day (4–16 weeks feeding)
(e.g. Craig et al., 1963; Beare-Rogers et al., 1971; Ziemlanski et al., 1975; Hung et al., 1977;
Chun et al., 1988);
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• changes in the liver (increased weight, fat accumulation, change in lipid composition,
accumulation of erucic acid, hepatocytes vacuolation, mononuclear cell aggregation) from
about 4 g/kg bw per day (Ziemlanski et al., 1972a,b, 1975; Kramer et al., 1979b);
• changes in the kidneys (increased weight, degenerative changes, tubular dilatation, vacuolation
of tubular epithelium, casts, scar formation) from about 6 g/kg bw per day (Abdellatif and
Vles, 1970b, 1971b, 1973a);
• changes in skeletal muscles (fatty inﬁltration) from about 13 g/kg bw per day (Abdellatif and
Vles, 1970b, 1973a);
• changes in adrenal (lipidosis, enlargement of cortical cells, modiﬁcation of activities) from
about 4 to 6 g/kg bw per day (Abdellatif and Vles, 1971b, 1973a; Ziemlanski and Budzynska-
Topolowska, 1978b);
• increased testis weight at about 4 g/kg bw per day (Ziemlanski and Budzynska-Topolowska,
1978b).
Studies relevant for hazard characterisation
Due to the high number of studies available (see Appendix G, Table G.1), the CONTAM
Panel deﬁned four criteria for the identiﬁcation of studies that are suitable for hazard characterisation,
namely:
• testing of several doses with a wide dose-range;
• erucic acid being reported as the main source of variation in fatty acid composition of the diet;
• possible identiﬁcation of a no observed adverse effect level (NOAEL)/lowest observed adverse
effect level (LOAEL);
• observation of myocardial lipidosis as relevant toxic effect.
From the studies described in Appendix G, Table G.1, the CONTAM Panel identiﬁed six studies that
met these criteria. These studies are summarised in Table 11 and are described in more detail below.
In a study by Kramer et al. (1992), young male Sprague–Dawley rats (10/group) were fed for
1 week diets containing 20% by weight fat/oil mixtures with different levels of erucic acid. The test oil
mixtures were prepared by mixing canola oil, HEAR oil and cocoa butter to give oils with low (2.4% or
2.9%) and medium (8.7% or 10.1%) erucic acid content, each with a low (8%) or a high content
(35%) of total saturated fatty acids. In addition, HEAR oil (42.9% erucic acid; high erucic acid group)
and corn oil (control group) were tested. Based on the information available, the CONTAM
Panel calculated the following doses of erucic acid: 0, 0.6–0.7, 2.1–2.4 and 10.3 g/kg bw per day using
the default factor of 0.12 for a subacute study in rats (EFSA Scientiﬁc Committee, 2012). There were
no signiﬁcant differences in weight gain of rats fed the four oil mixtures and corn oil; however, rats fed
a diet with HEAR oil gained signiﬁcantly less weight. The heart weights were similar for all groups.
Rats fed corn oil showed traces of myocardial lipidosis by histological staining (incidence: 6/10, severity
3  1.2). A signiﬁcant increase in severity of myocardial lipidosis as shown histologically and by an
accumulation of erucic acid in heart lipids was observed at about 2.1 g/kg bw per day. Incidences of
lipidosis were 8/10 & 10/10 in the low erucic acid groups, 10/10 & 10/10 in the medium erucic acid
groups and 10/10 in the high erucic acid group. The severity (area %) was: 14  5.6 & 13  4.8,
56  9.0 & 44  5.6 and 100%, respectively. The areas most affected were the right and left
ventricles near the base of the heart. Extensive myocardial lipidosis was observed throughout the
whole heart in rats fed diets with HEAR oil. No increase in cardiac triacylglycerol was noted except in
the rats fed the highest dose. No changes in myocardial lipid content was shown histologically by the
content of cardiac triacylglycerol or the erucic acid content of triacylglycerol at 0.6–0.7 or 2.1–2.4 g/kg
bw per day. A better correlation was noted between the histological staining method and the erucic
acid content in cardiac triacylglycerol than with the total cardiac triacylglycerol content. The erucic acid
content was the highest in cardiac triacylglycerol and free fatty acids. An increase in saturated fatty
acids in the diet, did not change the incidence and/or severity of myocardial lipidosis at 0.6–0.7 or
2.1–2.4 g/kg bw per day. The CONTAM Panel identiﬁed from this study a NOAEL of 0.7 g/kg bw per day
based on the increased severity of myocardial lipidosis at 2.1 g/kg bw per day (Kramer et al., 1992).
Beare-Rogers et al. (1971) reported two experiments of which one was identiﬁed by the CONTAM
Panel based on the criteria described above. Varying levels (0%, 2.5%, 5%, 10%, 15% or 20% by
weight) of rapeseed oil (containing 29.7% erucic acid) were fed for 1 week to weanling male rats
(15/group; strain not reported) to produce maximal fat deposition. Other rats were fed diets
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containing 10% or 20% canbra oil38 (containing 2.9% erucic acid). Based on the information provided
by the authors, the CONTAM Panel calculated doses of 0, 0.3, 0.7, 0.9, 1.8, 3.6, 5.3 or 7.1 g/kg bw
per day, respectively when applying a default factor of 0.12 (EFSA Scientiﬁc Committee, 2012).
Deposition of total fatty acid and erucic acid in the heart was absent at 0.3, 0.7, 0.9 and 1.8 g/kg bw
per day but increased greatly in rats exposed to 3.6 g/kg bw per day or more. Accumulation of fatty
acids occurred mainly as triacylglycerols. The two highest erucic acid doses were associated with
deposition of fat globules within myocardial cells and between the myoﬁbrils. Other changes were
interstitial oedema, myocytolytic changes in the cardiac muscle cells and some focal areas of necrosis.
The CONTAM Panel identiﬁed a NOAEL of 1.8 g/kg bw per day based on deposition of total fatty acid
and erucic acid in the heart. The NOAEL for myocardial lipidosis was 3.6 g/kg bw per day.
In a study by Kramer et al. (1988), male Sprague–Dawley rats (3 weeks of age) were fed a low-fat
diet (5% by weight corn oil and 45% starch) for 14 weeks followed by high-fat diets (20% by weight
rapeseed oil and 30% starch) for 1 week containing graded levels of erucic acid: 1%, 10%, 20%,
30%, 40% and 50%. The CONTAM Panel calculated erucic acid doses in the diet of 0, 0.1, 1.6, 4.1,
5.2, 7.0 and 8.8 g/kg bw per day, respectively, when applying a default factor of 0.12 (EFSA Scientiﬁc
Committee, 2012). Some rats within each group were returned to the low-fat diet for 1 week after the
test period. For comparison, one group of 3-week-old male rats were fed the high-fat 50% erucic acid
diet for 15 weeks. Growth depression and reduced feed intake was noted in rats fed diets rich in
erucic acid. However, the results were confounded by an increase in body weight resulting from the
switch from a diet containing 5% fat to one containing 20% fat. The growth depression effect of
erucic acid was removed on return to a diet without erucic acid. Within 1 week of feeding rapeseed oil
diets, myocardial lipidosis was induced in adult rats. A dose-related increase in severity was observed
(relative lipidosis grading: no fat stain, very slight, slight, moderate, moderate and marked). This
increase was reversible after return to low-fat diet without erucic acid (nearly control level). The switch
also involved a reduction in the level of fat in the diet from 20% to 5% by weight, which might have
expedited the regression of myocardial fat inﬁltration. Continuous feeding of the same HEAR oil diet
reduced the severity of myocardial lipidosis signiﬁcantly (moderate) compared to rats fed this diet for
only 1 week. The relatively high residual lipidosis in male rats fed HEAR oil for 15 weeks may be
explained by the high dietary concentration of erucic acid. A dose-related increase in the incidence of
myocardial necrosis (not reported in control, 7/30, 9/30, 17/30, 15/30, 9/30 and 16/30, respectively)
but not in severity was seen. The response to dietary erucic acid, however, was not linear. Long-term
feeding of HEAR oil resulted in a much higher incidence and severity of myocardial necrosis (incidence:
20/20; severity: 18 rats with more than 6 lesions/heart) than the 1-week exposure. Continued feeding
of a diet rich in erucic acid may have increased the rat’s capacity to metabolise erucic acid as evidence
by a lower level of erucic acid and higher levels of 20:1 n-9 and 18:1 n-9 compared with male rats fed
the same diet for only 1 week. Based on their observations, the authors suggested that the
development of myocardial necrosis appears to be caused by a combination of factors such as an
alteration of cardiac phospholipids and/or their fatty acid composition (saturates, C22 n-3 PUFAs and
long chain monoenes of 20:1, 22:1 and 24:1). The CONTAM Panel identiﬁed a NOAEL of 1.6 g/kg bw
per day based on increased severity of myocardial lipidosis at 4.1 g/kg bw per day.
Abdellatif and Vles (1970a) performed a dose–response study in which Wistar male rats (3-week-
old; 12/group) were given 0%, 5%, 10%, 15%, 20%, 25% or 30% by weight rapeseed oil (46%
erucic acid) for 2 weeks. The CONTAM Panel calculated erucic acid doses in the diet of 0, 2.6, 5.5, 8.8,
12.6, 17.0, 22.1 g/kg bw per day, respectively, when applying a default factor of 0.12 (EFSA Scientiﬁc
Committee, 2012). Growth rate slightly increased as erucic acid dose raised from 2.6 to 5.5 g/kg bw
per day but decreased with further increases in rapeseed oil. An erucic acid dose of 5.5 g/kg bw per
day was found as the minimum level to elicit fatty accumulation in the heart and in the skeletal
muscles, which increase in severity with increasing doses. Hypertrophy of the adrenal cortical cells was
observed at doses from 12.6 g/kg bw per day. The CONTAM Panel identiﬁed a NOAEL of 2.6 g/kg bw
per day based on myocardial lipidosis.
In a study by Beare-Rogers et al. (1972b) male weanling COBS® rats (10–12/group) were fed diets
containing 20% by weight fat with 0%, 2.5%, 5%, 10%, 15% or 20% rapeseed oil (38.1% erucic
acid), corresponding to erucic acid doses of 0, 0.9, 1.7, 3.4, 5.1 and 6.9 g/kg bw per day for
1–16 weeks. Doses were calculated using a default factor of 0.09 (EFSA Scientiﬁc Committee, 2012).
Other rats received 0–15% by weight partially hydrogenated rapeseed oil (35.2% 22:1) or 0–15% by
weight partially hydrogenated herring oil (31.3% 22:1). Cardiac lipid (fatty acids) accumulation was
38 Name previously used to refer to LEAR oil in Canada; currently canola is used.
Erucic acid in feed and food
www.efsa.europa.eu/efsajournal 46 EFSA Journal 2016;14(11):4593
noted in rats fed rapeseed oil and reached a peak at 1 week and decreased thereafter. The incidence
of hearts positive for fat stain were 0/10, 0/10, 0/10, 5/10, 9/10 and 10/10 in the groups receiving
doses of 0, 0.9, 1.7, 3.4, 5.1 and 6.9 g/kg bw per day, respectively. The accumulation of fatty acids
appeared to be related to the concentration of docosenoic acid (22:1). The triacylglycerol fraction
accounted for most of the deposited fat and contained a high concentration of docosenoic acid. After
16 weeks, degenerative lesions (necrosis and ﬁbrosis) were observed in rats receiving rapeseed oil
(0/12, 0/12, 3/12, 3/12, 6/12 and 9/11, respectively). Similar incidences of lesions were observed in
rats fed with partially hydrogenated rapeseed oil or partially hydrogenated herring oil. The CONTAM
Panel identiﬁed from this study a NOAEL of 0.9 g/kg bw per day based on degenerative lesions. The
NOAEL for myocardial lipidosis was 1.7 g/kg bw per day.
Abdellatif and Vles (1973a) fed Sprague–Dawley rats (3-week-old; 8/group/sacriﬁce time)
semisynthetic diets containing 20% by weight fat with different levels of rapeseed oil (0%, 2.5%, 5%,
7.5%, 12.5% or 15%). The diets were made isocaloric in fat by addition of sunﬂower seed oil. Based
on the information available, the CONTAM Panel calculated the following doses of erucic acid: 0, 1.0,
2.0, 3.0, 4.0, 5.0 and 5.9 g/kg bw per day using the default factor of 0.09 (EFSA Scientiﬁc Committee,
2012). The rats were killed after 3 and 6 days and 32 weeks. The growth rate was lower in rats fed
5.9 g/kg bw per day. Signiﬁcant differences in the absolute and relative weights of various organs
where only observed when the erucic acid dose was ≥ 3.0 g/kg bw per day (spleen, kidneys from
3.0 g/kg bw per day and thyroid, heart, testis and liver at the highest dose). All animals fed rapeseed
oil showed lipidosis of the heart, skeletal muscle, diaphragm and adrenals after 3 or 6 days and
decreased thereafter. The lipidosis became more severe as the level of rapeseed oil increased. After
32 weeks, diet-related changes were observed in the kidneys (slight tubular dilatation and increased
debris in the lumina, especially in rats fed 5.9 g/kg bw per day), adrenals (enlargement of the cortical
cells from 2.0 g/kg bw per day) and the heart. The cardiac changes consisted of minimal lipidosis, foci
of myocytolysis showing mononuclear cell proliferations, thickening of the reticular sheath around
individual muscle ﬁbres, increase in the interstitial connective tissue elements and aggregates of
Anitskow cells. Minimal degrees of these changes were observed in control animals. The incidence and
severity of the heart changes increased with the level of erucic acid, especially at doses above 2.0 g/kg
bw per day. Fibrosis was already observed at the lowest dose of erucic acid. The CONTAM
Panel identiﬁed a LOAEL of 1.0 g/kg bw per day based on myocardial lipidosis and ﬁbrosis.
From the identiﬁed studies, the CONTAM Panel concluded that the lowest NOAEL for lipidosis was
0.7 g/kg bw per day in a 7 day feeding study in young male Sprague–Dawley rats reported by Kramer
et al. (1992). The CONTAM Panel noted that this NOAEL is below the doses causing non-cardiac
effects.
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Pigs
The studies in pigs with high erucic acid oils or studies with both high and low erucic acid oils are
described in Appendix G Table G.2. The text below summarises the toxic effects observed in these studies.
In pigs, the heart is also the principal target organ of toxicity following exposure to erucic acid. A
dose–response relationship between the level of erucic acid in the diet and the severity of myocardial
lipidosis has been observed (Opstvedt et al., 1979; Kramer et al., 1990). The severity of lipidosis was
higher in newborn than in weaned pigs. Kramer et al. (1990) suggested that the immature
myocardium may be less able to metabolise long-chain fatty acids, making neonates especially prone
to myocardial lipidosis, albeit transiently.
Foci of myolysis or necrosis with macrophage or leukocyte inﬁltration were observed in hearts of
pigs fed HEAR oil, other vegetable oils and marine oils (Friend et al., 1975, 1976; Svaar et al., 1980).
However, incidence and severity of necrosis were independent of the erucic acid concentration and
type of oil diet. In contrast, these lesions were not observed when using a conventional diet (e.g.
standard chow or diet containing lard), indicating that diets containing high oil levels are not well
tolerated by pigs. Increased total mitochondrial volume due to an increase in number and size of
mitochondria was reported in male pigs fed rapeseed oil for more than 30 days, followed by
degenerative changes after 60 days feeding and even complete disappearance (Vodovar et al., 1977).
Haematological effects (decrease in platelets counts, increased platelet volume, higher bleeding time)
were reported in newborn Yorkshire piglets exposed for 4 weeks to HEAR oil (Kramer et al., 1998). Liver
morphological alterations such as increased number of tortuous cisternae of rough surfaced endoplasmic
reticulum, signet ring-shaped mitochondria and cytoplasmic lacunae were observed in pigs fed rapeseed
oil. Bile canalicular lamina occluded by swollen microvilli and/or globules of a lipid-like material were also
seen. These changes represent functional modiﬁcations of hepatocytic metabolism in response to oil
supplementation (Friesen and Singh, 1981), and therefore, they are very unlikely to be due to erucic acid.
Based on these observations, the CONTAM Panel considered that lipidosis is a relevant effect for
the risk assessment of erucic acid.
Studies relevant for hazard characterisation
Due to the high number of studies available (see Appendix G, Table G.2), the CONTAM Panel deﬁned
four criteria for the identiﬁcation of studies that are suitable for hazard characterisation; namely
• testing of several doses with a wide dose-range;
• erucic acid being reported as the main source of variation in fatty acid composition of the diet;
• possible identiﬁcation of a NOAEL;
• observation of myocardial lipidosis as relevant toxic effect.
From the studies described in Appendix G, Table G.2, the CONTAM Panel identiﬁed one study that met
these criteria. The identiﬁed study is summarised in Table 12 and is described in more detail below.
Kramer et al. (1990) fed newborn Yorkshire male and female piglets sow milk (corresponding to an
erucic acid dose of 0.09 g/kg bw per day) or milk replacer diets containing rapeseed oil with different
levels of erucic acid or soybean oil from birth to 2 weeks of age. Dietary oils with 2.3%, 4.7%, 7.0%,
11.7% and 20.7% erucic acid were prepared by mixing appropriate amounts of canola (0.8% erucic
acid) and HEAR (42.9% erucic acid) oils. Based on the information provided by the authors, the
CONTAM Panel calculated doses of 0, 0.1, 0.3, 0.7, 1.1, 1.8, 3.0 or 5.1 g/kg bw per day. Animals were
initially fasted for 8 h and then fed every 2 h at the rate of solid intake equivalent to 7% of body
weight per day. Piglets have been successfully reared with milk replacers; they grew as well as piglets
left with the sow. There were no signiﬁcant diet effects on body weight. Newborn piglets showed no
myocardial lipidosis, but lipidosis appeared with consumption of sow milk and disappeared by 7 days
of age. Milk replacer diets containing soybean oil or rapeseed oil mixtures with up to 4.7% erucic acid
in the oil (doses up to 0.7 g/kg bw per day) gave trace myocardial lipidosis. Doses of 1.1 g/kg bw per
day or more caused deﬁnite dose-related myocardial lipidosis in newborn piglets, with a maximum
after 1 week on diet. This may be related to the low capacity of the fetus to oxidise fatty acids which
increased rapidly after birth (Werner et al., 1983). The authors indicated that the severity of the
lipidosis was greater than observed previously by Opstvedt et al. (1979) and Kramer et al. (1975) with
weaned pigs. Focal myocardial necrosis was not observed in any of the piglets fed sow milk or any of
the milk replacer diets. There were no signiﬁcant differences among diets in cardiac lipid classes
except for triacylglycerol which increased in piglets fed rapeseed oil with the highest content of erucic
acid. The CONTAM Panel identiﬁed a NOAEL of 0.7 g/kg bw per day based on lipidosis.
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In summary, increased myocardial lipidosis is observed in newborn pigs at erucic acid doses of
1.1 g/kg bw per day and the CONTAM Panel identiﬁed a NOAEL of 0.7 g/kg bw per day for this
endpoint.
Monkeys
The studies in monkeys with high erucic acid oils or studies with both high and low erucic acid oils
are described in Appendix G Table G.3. The text below summarises the toxic effects observed in these
studies.
Pronounced myocardium lipidosis as well as increased size of mitochondria were observed in
monkeys exposed to HEAR oil and to partially hydrogenated herring oil (e.g. Ackman and Loew, 1977;
Loew et al., 1978; Schiefer et al., 1978). In some studies, foci of mononuclear cell inﬁltration were
observed, but they were not speciﬁc to animals fed HEAR oil. Lipidosis was also observed in skeletal
muscles. The erucic acid level in heart total lipids and in triacylglycerols increased in monkeys exposed
to HEAR oil. There was no indication of gross myocardial changes indicative of myocardial
enlargement, cardiac failure or myocardial ischemia. No adverse effect was observed on blood
coagulation. No myocardial damage was associated with feeding rapeseed oil. In a study where adult
male monkeys were fed diets containing mustard oil for 1 year, sarcoplasmic vacuolation of right and
left ventricular myocardium was shown as well as myocardial ﬁbrosis (Gopalan et al., 1974). The
relevance of these studies is limited due to the low number of doses and animals tested.
From the studies described in Appendix G, Table G.3, no study was identiﬁed in which a wider
dose-range was studied. Therefore, none of the studies were considered relevant for the risk
assessment of erucic acid.
Other animal species
The studies in mice, rabbits and gerbils with high erucic acid oils or studies with both high and low
erucic acid oils are described in Appendix G Table G.4. The text below summarises the toxic effects
observed in these studies.
In mice, a signiﬁcant increase in the heart weight and liver was observed in animals fed rapeseed
oil containing high levels of erucic acid for 5 weeks (Lei et al., 2010). Long-term exposure of rabbits to
high levels of erucic acid resulted in increases in total serum lipids, cardiac interstitial ﬁbrosis
associated with vacuolar changes and disarrangement and dissociation of the myoﬁbrils. In the liver,
portal ﬁbrosis (cirrhosis) was seen, sometimes associated with hyperplasia of the bile ducts and/or the
ductular cells. Atherosclelerotic changes were also observed in the thoracic aorta of some rabbits
(Abdellatif and Vles, 1971b). After 1 week feeding of gerbils, more cardiac fatty acids deposits
including erucic acid were observed in animals fed high erucic acid levels than in control animals or
animals fed a low erucic acid level. Young gerbils were particularly susceptible to the deposition of
fatty acids from rapeseed oil (Beare-Rogers and Nera, 1972).
From the studies described in Appendix G, Table G.4, no study was identiﬁed in which a wide dose-
range was studied. Therefore, none of the studies were considered relevant for the risk assessment of
erucic acid.
Summary
The heart is the principal target organ following short-term or long-term exposure of rats, pigs,
monkeys, rabbits and gerbils to diets with oils containing erucic acid. The most common and sensitive
effect observed in all species is myocardial lipidosis. Lipidosis is transient and reversible: it develops
very quickly (a few hours after starting exposure), reaches a peak after 3–7 days and regresses
thereafter, even during continued feeding of high erucic acid diets. Species differences appear to exist
with respect to responses to erucic acid-containing oils. Studies in rats and, newborn and weanling
pigs showed an association between the level of erucic acid in the diet and the severity of myocardial
lipidosis. In rats, increased myocardial lipidosis is observed at doses of 1 g erucic acid/kg bw per day
or higher. In newborn pigs, increased myocardial lipidosis is observed at a dose of 1.1 g erucic acid/kg
bw per day. The overall NOAEL for lipidosis was 0.7 g/kg bw per day in a 7-day feeding study in young
rats and in a 2-week feeding study in newborn piglets. Adult pigs are able to tolerate higher levels of
erucic acid than young animals. These results suggest that the immature myocardium and/or liver may
be less able to metabolise erucic acid, making neonates especially prone to myocardial lipidosis, albeit
transiently. Myocardial lipidosis is reported to reduce the contractile force of the heart muscle.
Mitochondrial damage (megamitochondria, mitochondrial proliferation, increase in the average volume,
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distortion of shape, degeneration) and disorganisation of myoﬁbrils has been reported after exposure
of rats, pigs, monkeys or rabbits to high doses of erucic acid.
Myocardial necrosis and ﬁbrosis have been observed in rats and occasionally in other species after
erucic acid exposure via rapeseed oils for 4 or more weeks. However, these effects were also observed
in animals fed oils not containing erucic acid and the incidence and severity were independent of the
erucic acid dose and the type of oil diet. Myocardial necrosis in rats is inﬂuenced by many factors such
as age, sex, strain and breeding source. The results of several studies suggest that factors other than,
or in addition to, erucic acid are responsible for the increased incidence of lesions observed in rats fed
with oils high in erucic acid, e.g. fatty acid imbalance. Therefore, the CONTAM Panel considered
necrosis observed in these studies not a suitable endpoint for the risk assessment. A causal link
between myocardial lipidosis and myocardial lesions has not been established.
3.3.2.3. Genotoxicity
No genotoxicity studies on erucic acid were identiﬁed in the literature. Negative results in in vitro
genotoxicity assays (Ames test in Salmonella Typhimurium and DNA damage and repair assays in
Bacillus subtilis) are claimed for erucic acid in a compilation of data from the European Chemicals
Bureau (European Commission, 2000). One of the study reports was made available by the data owner
(Henkel KGaA, 1981b). However, because of the lack of raw data these studies cannot be used for the
evaluation of erucic acid genotoxicity. Therefore, no conclusion can be drawn on its genotoxic
potential.
3.3.2.4. Carcinogenicity
In general, it is difﬁcult to identify the effect of individual fatty acids e.g. on cancer incidence, as
the diet always contains a complex natural fat or oil as the source of fatty acids. Experimental studies
on mice have been conducted to clarify the role of main fatty acids by selecting different fats, oils and
their mixtures in order to have sufﬁciently wide ranges for individual fatty acids in 20 different diets
(Tinsley et al., 1981), which were given to mice for 27 weeks. Statistical methods were used to further
isolate the effects of individual fatty acids on the incidence and development of mammary tumours in
C3H mice. The results indicated that most fatty acids have little effect on tumour incidence. Increased
incidences were found for linoleic acid (18:2 n-6) and stearic acid (18:0). In this experimental setting,
there was a suggestion that erucic acid reduced tumour incidence but it cannot be excluded that this
effect could be due to some other constituent of the rapeseed oil.
Carroll and Khor (1971) reported a promoting effect on 7,12-dimethyl-benz[a]anthracene-induced
mammary adenocarcinomas when rats were kept on a diet containing 10–20% corn oil. Experiments
were conducted with different fats and oils including rapeseed oil (34.5%) fed at the 20% level
(corresponding to an erucic acid dose of 6.2 g/kg bw per day using a default factor of 0.09 (EFSA
Scientiﬁc Committee, 2012)). In general more tumours per rat were observed when unsaturated fats
were fed. Rapeseed oil was the exception and the low yield of tumours with this oil was explained by
the authors as likely related to the high content of 20:1 and 22:1 fatty acids.
In summary, the studies currently available do not allow drawing conclusions on the carcinogenicity
of erucic acid.
3.3.2.5. Developmental and reproductive toxicity
In the study by Carroll and Noble (1957) male rats were given a diet of powdered Master Meal with
a supplement of 10% or 15% by weight of erucic acid or 25% rapeseed oil (containing approximately
50% by weight of erucic acid in the triacylglycerols). Based on the available information and using a
default factor of 0.09 (EFSA Scientiﬁc Committee, 2012), the CONTAM Panel calculated erucic acid
doses of 9.0 and 13.5 g/kg bw per day for the erucic acid groups and 11.3 g/kg bw per day for the
rapeseed oil group. The fertility of the animals was monitored and, after different periods on the diet,
animals were killed and the testes, seminal vesicles and prostate were analysed at autopsy. The
fertility of the males receiving 13.5 g/kg bw per day for approximately 3 months was markedly
affected and after 5 months, mating rarely occurred. No effects on fertility were observed when the
feeding was with diet supplemented with 15% oleic acid or 25% rapeseed oil (11.3 g/kg bw per day).
The authors hypothesise that the presence of other fatty acids in the rapeseed oil might have
moderated the effects of erucic acid. The weight of the testes was markedly increased in the growing
animals fed with the erucic acid-supplemented diet while no effects were observed in adult animals
maintained with the same diet. The weight of the seminal vesicles and prostate appeared normal.
Histological alterations were observed in the spermatogenic cells of the testes with increasing
Erucic acid in feed and food
www.efsa.europa.eu/efsajournal 55 EFSA Journal 2016;14(11):4593
degenerative changes after 3 months on the erucic acid-supplemented diets. Conversely, no changes
were observed in the tubules of adult rats fed with this diet for 4 months. The morphological changes
were permanent and irreversible. Moreover, they were conﬁned to the tubular epithelium and were not
associated with alterations of the Leydig cells neither with effects on male sex hormones secretion.
Since the testis is rich in highly unsaturated fatty acids, the erucic acid may act by competing with
fatty acids essential for normal testicular function, however on the basis of the available data the
mechanism remains speculative. In the same study the feeding of the erucic acid supplement to the
mother for more than 8 weeks resulted in poor survival of the young but since the supplement with
oleic acid showed the same effect this cannot be considered speciﬁc for erucic acid. The animals which
died after parturition or were killed showed only occasionally changes in endocrine organs. As in the
case of the male rats prolonged feeding caused impairment of the reproductive process.
In a following study Beare et al. (1959) were unable to reproduce the effects on spermatogenesis
reported by Carroll and Noble (1957). Male Wistar rats fed for 9 weeks a diet containing 20% Golden
rapeseed oil (42.7% erucic acid in the oil; equivalent to a dose 7.7 g erucic acid/kg bw per day using
the default factor of 0.09 for a subchronic study (EFSA Scientiﬁc Committee, 2012)), successfully sired
3 L and showed no abnormalities when scariﬁed at 11 months of age. However the authors noted that
in their experimental setting the diet administered to rats contained a signiﬁcant fraction of linoleic
acid and a lower level of erucic acid than that employed by Carroll and Noble (1957) where erucic acid
was the only fatty acid added to a low-fat diet.
In the study by Rose and Bell (1982) female Swiss mice were fed a puriﬁed diet containing 20% of
different types of fats and oil. The tested fats and oils were lard/corn oil (0% erucic acid), LEAR (0.1%
erucic acid), stinkweed oil (41% erucic acid) and screening oils with different erucic acid content
(2.8%, 5.8% and 5.2%). Based on the available information and using a default factor of 0.2 (EFSA
Scientiﬁc Committee, 2012), the CONTAM Panel calculated erucic acid doses of 0, 0.04, 1.1, 2.1, 2.3
and 16.4 g/kg bw per day. This diet was given for a 2-week preliminary period and then during 18
days of gestation. No evidence of teratogenic effects was reported when LEAR oil (0.04 g/kg bw per
day) was incorporated into the diet. Feed consumption levels were reduced in some cases, perhaps
due to reduced palatability, thus accounting for decreased reproductive performance. Mice fed the
LEAR diet had a decreased incidence of cleft palate in their fetuses as compared with mice fed the
lard:corn oil control diet.
In the study by Reyes et al. (1995) pregnant rats and hamsters were fed for 90 days prior to
mating and until the last day of pregnancy with diets containing either 25% rapeseed oil rich in erucic
acid (41.5%) or corn oil (0.5% erucic acid). Based on the available information and using a default
factor of 0.09 (EFSA Scientiﬁc Committee, 2012), the CONTAM Panel calculated erucic acid doses of
0.1 and 9.3 g/kg bw per day. Mating was successful for both rats and hamsters. The number and
weight of fetuses were similar when animals were fed either rapeseed or corn oil. No morphological
abnormalities were observed in any of the fetuses. Histological examination conducted the last day of
pregnancy (day 20 for rats and day 14 for hamsters) showed no morphological abnormalities in the
liver, heart, kidneys and adrenals. Mild myocardial lipidosis was observed in pregnant hamsters fed
both oils. The dietary proﬁle was reﬂected in the fatty acid composition of the liver, heart and kidney.
Erucic acid was found in the highest proportion in the heart (14%) of animals fed rapeseed oil.
Pregnancy induced changes in bile secretion in rats and hamsters irrespective of the diet administered.
In summary, no major adverse reproductive and developmental effects were associated with
feeding female rats, mice and hamsters with erucic acid-containing diets prior to mating and during
pregnancy. There is one limited report of affected fertility of male rats maintained under prolonged
feeding with an erucic acid-supplemented diet but since these observations were made only in one
study and one species (i.e. rat), the results should be conﬁrmed in order to be used in risk
assessment.
3.3.3. Observations in humans
Few studies have determined esteriﬁed erucic acid levels (in phospholipids and neutral lipids) in
human plasma, however no studies were identiﬁed that discriminate between albumin bound and
unbound fractions of unesteriﬁed fatty acids.
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3.3.3.1. Biomonitoring studies
The NHANES food database reports mean serum concentrations for esteriﬁed erucic acid of
3.4 lmol/L (95% CI: 2.77–3.79) in a 1,845 sample subset of the large cohort.39
In a recent report, average concentrations of 61 fatty acids including esteriﬁed erucic acid in
plasma of young (age ranging from 20 to 29 years), healthy and ethnoculturally diverse Canadians
consuming their usual diet were studied. Participants were recruited between September 2004 and
July 2009. The authors found mean plasma erucic acid levels of 3.9 lmol/L (range: trace – 48.0 lmol/L).
The study was part of the cross-sectional Toronto Nutrigenomics and Health Study. The total
population studied was 826 (327 males and 499 females) (Abdelmagid et al., 2015).
3.3.3.2. Epidemiological studies
Epidemiological studies on potential adverse effects of dietary erucic acid intake are scarce and only
a limited number of independent studies were identiﬁed. These studies are however, large case–
control studies. Negative controls were employed to estimate potential bias.
Cardiovascular effects
Imamura et al. (2013) studied the association between plasma phospholipid long-chain
monounsaturated fatty acids (LCMUFAs) (20:1, 22:1 and 24:1), used as biomarker of exposure, and
the incidence of congestive heart failure. This association was studied in two independent cohorts; the
Cardiovascular Health Study (CHS; 3,694 subjects; mean age 75.2  5.2 years) and the
Atherosclerosis Risk in Communities Study (ARIC; 3,577 subjects; mean age 54.1  5.8 years). To
determine whether the associations were myocardium speciﬁc, incident stroke was used as a negative
control outcome. In addition, the authors evaluated intake levels based on consumption data obtained
in the NHANES 2003–2010 study (Ervin et al., 2004; U.S. Department of Agriculture - Agricultural
Research Service40) and on dietary consumption data collected in both CHS and ARIC cohorts.
The level of 22:1 plasma phospholipids (expressed as per cent of total fatty acids) were
0.03  0.01% and 0.01  0.03% in the CHS and ARIC cohorts, respectively. These levels were much
lower than the levels of 24:1 which were 1.96  0.44% and 0.57  0.17% in the CHS and ARIC
cohorts, respectively. The level of 22:1 was below the LOD (0.01%) in 43% of the subjects of the
ARIC cohort.
In both cohorts, higher circulating levels of 22:1 and 24:1 plasma phospholipids were positively
associated with an increased incidence of congestive heart failure, which suggests the possible
cardiotoxicity of LCMUFAs in humans. Since dietary 22:1 is elongated to 24:1 in humans, the authors
suggested that the experimentally observed cardiotoxicity from 22:1 could be partly attributed to 24:1.
Many different foods contribute to the LCMUFA exposure and the authors concluded that the potential
cardiotoxicity of LCMUFAs cannot be attributed to any single food but depends on the overall exposure
to LCMUFAs.
Matsumoto et al. (2013) studied the association between coronary artery disease (CAD) and red
blood cell monounsaturated fatty acids (MUFA) levels. CAD is characterised by the accumulation of
plaques in the coronary artery, which ﬁnally occlude the artery resulting in coronary heart disease
(CHD). In the study by Matsumoto et al., CAD was deﬁned as a non-fatal myocardial infarction, fatal
myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft,
coronary death and sudden death.
A prospective, nested, case–control study was performed in which 1,000 cases of incident CAD and
1,000 control subjects matching age, year of birth and time of blood collection were selected from a
cohort of US male physicians (the Physicians’ health study). The concentrations of different
monounsaturated fatty acids were measured from erythrocytes. All cardiovascular events in the
Physicians’ health study have been adjudicated by an endpoint committee. The diagnosis of myocardial
infarction was conﬁrmed by using WHO criteria. Revascularisation procedures were conﬁrmed by
hospital records.
The authors identiﬁed an inverse association between red blood cell 22:1 n-9 levels and CAD after
adjustment for multiple comparisons (odds ratio: 0.83 (95% conﬁdence interval: 0.72, 0.95;
p = 0.0086). Red blood cell cis 18:1 n-9 and 24:1 n-9 levels were not associated with CAD risk.
39 http://www.cdc.gov/nchs/nhanes.htm/
40 U.S. Department of Agriculture, Agricultural Research Service. 2009. USDA National Nutrient Database for Standard Reference,
Release 22. Nutrient Data Laboratory Home Page. http://www.ars.usda.gov/ba/bhnrc/ndl
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Based on the study by Imamura et al. (2013) it can be concluded that higher levels of 22:1 fatty
acids in plasma phospholipids have been associated with higher incidence of congestive heart failure in
two independent cohorts. In another cohort, higher circulating levels of erucic acid in erythrocytes
have been associated with lower incidence of coronary heart disease (Matsumoto et al., 2013).
Cancer
Sczaniecka et al. (2012) studied the association between breast cancer and dietary intake of
speciﬁc fatty acids in post-menopausal women. The participants were female members of the
VITamins And Lifestyle Cohort, previously described by White et al. (2004). After applying speciﬁc
exclusion criteria, 30,252 women entered the study; 772 cases and 29,480 controls. Dietary
consumption data were obtained by semi quantitative food frequency questionnaire speciﬁcally
modiﬁed to facilitate the fatty acid intake estimations. During the years 2000–2002, study subjects
reported usual frequency and portion size of 120 foods and beverages consumed during the year
before baseline with the help of photographs of portion sizes. The consumption data were converted
to intake of speciﬁc fatty acids by using Minnesota Nutrient Data System for Research.41
The intake of total MUFAs (highest vs. lowest quintile hazard ratio: 1.61, 95% conﬁdence interval:
1.08–2.38, p = 0.02) was associated with an increased breast cancer risk. The CONTAM Panel noted
that for erucic acid, both an association with a reduced and an increased breast cancer risk was
reported.
The authors concluded that ‘although further study of speciﬁc fatty acids is needed, this study
provides further support for the hypothesis that fat consumption is associated with breast cancer risk
and suggests that risk varies by type of fatty acid’. From this study, the CONTAM Panel concluded that
the evidence is not strong enough to draw conclusions regarding the association between erucic acid
and breast cancer. The estimation of the erucic acid exposure was based on a food frequency
questionnaire but no biomarker for exposure was used.
Ukoli et al. (2010) studied the association between prostate cancer and dietary fat using a case–
control study. Two genetically related populations were included, namely African Americans (48 cases
and 96 controls) and Africans (66 cases and 226 controls).
Signiﬁcant differences were observed for 13 out of 21 circulating fatty acids in cases compared to
the controls in both populations. No association was found between the level of erucic acid and the
risk of prostate cancer in Africans (odds ratio = 1.06 (95% conﬁdence interval: 0.52–2.16); adjusted
odds ratio = 0.94 (95% conﬁdence interval: 0.40–2.20)), however an association was shown in African
Americans (odds ratio = 2.95 (95% conﬁdence interval: 1.01–8.60); adjusted odds ratio = 3.96 (95%
conﬁdence interval: 1.05–14.9)). Also for other fatty acids (e.g. DHA, nervonic acid and arachidonic
acid (20:4 n-6)) such an association was observed. The association between plasma fatty acid proﬁles
and prostate cancer is therefore not speciﬁc to erucic acid.
In summary, two studies on the possible association between cancer and erucic acid exposure were
identiﬁed but no conclusion can be drawn due to the intrinsic limitations or lack of speciﬁcity of the
outcome.
3.3.3.3. Adverse effects due to therapeutic use
Lorenzo’s oil is an erucic acid-containing drug used to treat patients with ALD, which is an inherited,
X-linked, peroxisomal disease (OMIM database 30010042) leading to total disability by motor deﬁcits,
dementia, impaired vision and hearing (Moser, 1997). Characteristic to the disease are myelopathy,
peripheral neuropathy and cerebral demyelopathy. In ALD patients, the genetic defect resides in the
ABCD1 gene encoding for a peroxisomal membrane transporter for very long-chain fatty acids (Mosser
et al., 1993; van Roermund et al., 2011). ALD is the only disease associated with deﬁciency of a
peroxisomal ABC transporter. Diagnosis of ALD is conﬁrmed by increased levels of very long-chain fatty
acids (> 20 carbon chain length) in the circulation.
Lorenzo’s oil inhibits the activity of the enzyme ELOVL1 (elongation of very long-chain fatty acid),
the primary enzyme responsible for the synthesis of saturated and monosaturated very long-chain fatty
acids (VLCFAs), by a mixed inhibition mechanism, rather than by competitive inhibition. Lorenzo’s oil
reduce the saturated VLCFA level in the plasma of X-ALD patients. The optimal inhibition requires both
erucic acid and oleic acid, as erucic acid alone does not inhibit ELOVL1 signiﬁcantly (Sassa et al., 2014).
41 http://www.ncc.umn.edu/products/ndsr.html
42 http://www.omim.org
Erucic acid in feed and food
www.efsa.europa.eu/efsajournal 58 EFSA Journal 2016;14(11):4593
The clinical use of the drug has been reported to be beneﬁcial to presymptomatic patients, but has
very minor effect if administered after onset of the disease (Berger and G€artner, 2006).
Doses of Lorenzo’s oil are expressed, depending on the publication, in different ways. Rasmussen
et al. (1994) reported typical intakes of 2.5–4 tablespoons (15 mL/tablespoon) per day. This is
equivalent to 0.09–0.14 g erucic acid/kg bw per day assuming a body weight of 70 kg and
0.27–0.44 g erucic acid/kg bw per day assuming a body weight of 23 kg for children between 3 and
10 years old.43 In the study by Deon et al. (2006) the patients were treated with a higher dose of
2–3 mL of Lorenzo’s oil/kg bw per day (adjusted individually) corresponding to 0.34–0.51 g erucic
acid/kg bw per day.44 Many authors e.g. Zinkham et al. (1993) expressed the dose as a percentage of
the daily caloric intake, typically 20%. A dose of 20% of caloric intake is estimated to correspond
approximately to 2–3 mL/kg bw per day of Lorenzo’s oil, i.e. 0.4–0.6 g/kg bw per day of erucic acid
(Moser et al., 2005).
The therapeutic uses of Lorenzo’s oil have been reported to induce haematological effects. In a
clinical trial, ALD patients received either no supplemental oil (n = 13), only glycerol trioleate
(45–90 mL per day) (n = 12) or Lorenzo’s oil (37.5 to 60 mL/day corresponding to an erucic acid dose
of 0.09–0.14 g/kg bw per day as calculated above) (n = 13) for 6 months. In addition, the results
were compared with 33 healthy controls, which were on their customary diet. The group receiving
Lorenzo’s oil showed a statistically signiﬁcant decrease of about 1.5-fold in platelet counts after
6 months. The authors reported a strong inverse relationship between platelet counts, and erucic acid
and other n-9 fatty acid levels (Kickler et al., 1996). In addition, megathrombocytes were observed in
the group treated with Lorenzo’s oil. Appearance of such giant thrombocytes indicates accelerated
thrombocyte turnover. Zierz et al. (1993) reported decreased number of platelets (thrombocytopenia)
in three of ﬁve patients with different phenotypes of ALD treated daily during 1 year with 60–70 g/day
of Lorenzo’s oil providing 11.6–13.5 g erucic acid/day (equivalent to 0.17–0.19 g/kg bw per day
assuming a body weight of 70 kg). In this study the platelet count showed about a 4-fold decrease
when exposed to a daily dose of 15 g of Lorenzo’s oil for 2 months compared to baseline. One case
report described an ALD patient treated with varying doses of Lorenzo’s oil (0–20% of daily caloric
intake; no indication of the dose on mg/kg bw per day basis), in which the treatment resulted in
increases of bleeding time, while platelet function seemed to be normal (Chai et al., 1996). Zinkham
et al. (1993) reported data from 17 ALD patients, who had thrombocytopenia resulting from 6 month
treatment with Lorenzo’s oil. The amount of Lorenzo’s oil provided 20% of calculated daily caloric
intake and the erucic acid dose was not indicated. The thrombocytopenia persisted still after
12 months after the treatment. No uniform platelet-aggregation patterns were found.
Depression of natural killer cells and lymphocytopenia were studied in 27 ALD patients treated with
Lorenzo’s oil, in 14 ALD patients without the treatment and 26 healthy individuals. The patients
received 20% of their total calories as Lorenzo’s oil and the duration of the treatment ranged from
4.5 months to 3.2 years. The dose was not indicated on mg/kg bw or per day basis. While lymphocyte
proliferation in response to mitogens (phytohaemagglutinin and concanavalin A) in untreated ALD
patients was within normal intervals, it was signiﬁcantly higher in patients treated with Lorenzo’s oil. It
was concluded that long-term side-effects on cellular immunoreactivity should be followed in ALD
patients treated with Lorenzo’s oil (Barmaki Pour et al., 2000).
In summary, the therapeutic use of erucic acid results in haematological effects, most notably
thrombocytopenia and morphological alterations of thrombocytes, at doses of about 0.1 g/kg bw per
day. It results also in increased lymphocyte reactivity to mitogens. Erucic acid induced lipidosis has not
been described in humans.
3.3.4. Mode of action
In all experimental studies with repeated dosing of high erucic acid-containing oils to rats, pigs,
monkeys and other experimental animals, effects have most often been observed in the heart and less
frequently in the liver and adrenals (see Section A. Studies including only low erucic acid rapeseed oils
in experimental animals and Appendix G, Tables G.1, G.2, G.3 and G.4). Thus, the heart appears to be
the most susceptible organ for adverse effects of erucic acid.
43 This calculation is based on the assumption of a density of 0.9 kg/L, a body weight of 70 kg and a table spoon content of
about 15 mL. The reported intakes correspond to 34–55 g of Lorenzo’s oil per day or 7–11 g glycerol trierucate per day or
6–10 g erucic acid per day.
44 The reported intakes correspond to 1.8–2.7 g of Lorenzo’s oil/kg bw per day or 0.36–0.55 g glycerol trierucate/kg bw per day.
This calculation is based on the assumption of a density of 0.9 kg/L.
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The major cardiac effects, observed when feeding an erucic acid-containing diet to experimental
animals, are the early but transient accumulation of lipid droplets within myocytes, i.e. lipidosis, and
the later death of myocardial cells (necrosis) followed by the removal of necrotic cellular debris by
macrophages and repair by ﬁbrosis (see Section B. Studies including oils high in erucic acid (< 5%)).
Whereas the occurrence of a transient cardiac lipidosis is clearly associated with the dietary exposure
to erucic acid, the aetiology of cardiotoxic effects such as necrosis and ﬁbrosis is less clear and may
involve factors other than erucic acid, e.g. imbalance of fats or lack of essential nutrients (Sauer and
Kramer, 1983a). In humans, thrombocytopenia and morphological alterations of thrombocytes have
been observed upon therapeutic use of Lorenzo’s oil (see Section 3.3.3.3). Haematological effects have
also been observed in experimental animals fed with HEAR oils, e.g. in pigs (Kramer et al., 1998). The
mechanism for erucic acid induced thrombocytopenia is not known.
3.3.4.1. Cardiac lipidosis
Both male and female rats of various strains accumulate triacylglycerols within cardiac myocytes as
lipid droplets or membrane inclusions when kept on a diet with erucic acid for several days. Myocardial
lipidosis involves primarily an increase in triacylglycerols while the levels of phospholipids and
cholesterol remain fairly constant (Houtsmuller et al., 1970; Beare-Rogers et al., 1972b). Early studies
reported an increase in cardiac free fatty acids, but these ﬁndings appear to be an artefact caused by
hydrolysis of lipids due to inappropriate extraction techniques (Kramer and Hulan, 1978). The
incorporation of erucic acid into cardiac lipids is highest in triacylglycerols and moderate in certain
phospholipids such as phosphatidylcholine and phosphatidylethanolamine (Kramer et al., 1979b;
Yasuda et al., 1980). Lipidosis develops very quickly (a few hours after starting the exposure), reaches
a maximum after 3–7 days (depending on the dose), and decreases or disappears after about 4 weeks
in rats even when kept on a high erucic acid diet (Sauer and Kramer, 1983a).
The major reason for the development of cardiac lipidosis is thought to be an imbalance of uptake
and utilisation of fatty acids (Sauer and Kramer, 1983b). If the heart is supplied with fatty acids such
as palmitic, stearic and oleic acid, as present in common dietary lipids, b-oxidation and ATP production
in mitochondria proceeds smoothly as described in Section 3.3.1.3. However, after changing to a high
erucic acid diet, the supply of erucic acid to the heart via the blood increases, and the mitochondrial
b-oxidation is not able to cope with the high inﬂux for two reasons. Firstly, erucic acid is only poorly
b-oxidised in rat heart mitochondria, and secondly, erucic acid inhibits the mitochondrial b-oxidation of
other fatty acids (see Section 3.3.1.3). Obviously, b-oxidation in peroxisomes is not sufﬁcient to handle
the high level of erucic acid. As a consequence, the inﬂux of free erucic and other fatty acids into the
heart exceeds their utilisation for b-oxidation and ATP production. Because elevated levels of free fatty
acids are toxic, they are converted to triacylglycerols and stored as lipid droplets in myocytes, giving
rise to the observed cardiac lipidosis. Lipidosis, although less pronounced than in the heart, is also
observed in other organs of the rat shortly after exposure to erucic acid, but not in the liver, probably
because the liver can efﬁciently export erucic acid-containing triacylglycerols as VLDLs (Bremer and
Norum, 1982).
The mode of action for cardiac lipidosis outlined for rats exposed to erucic acid is also consistent
with observations made with structurally related fatty acids and with other species of experimental
animals. Oils containing other monounsaturated fatty acids with 20 or more carbon atoms also induce
transient cardiac lipidosis in rats and are poor substrates for mitochondrial b-oxidation (Sauer and
Kramer, 1980).
Based on in vitro data, the pig heart appears to be somewhat more efﬁcient in the b-oxidation of
erucic acid compared to the rat heart. The primary reason for this is believed to reside in the chain
length preference of the mitochondrial b-oxidation system, which is much better deﬁned in rats (sharp
drop of oxidation rate if C > 18) than in pigs, and to the fact that 22:1 fatty acids inhibit the
tricarboxylic acid cycle in heart mitochondria of rats but not of pigs (Buddecke et al., 1976;
Osmundsen and Bremer, 1978). Induction of cardiac lipidosis in humans after ingestion of high erucic
acid diets has not been reported to date.
As mentioned above, cardiac lipidosis is a reversible and transient phenomenon in rats. It regresses
after termination but also upon continuation of the high erucic acid diet. Numerous studies suggest
that the major reason for this adaptation resides in the induction of the peroxisomal b-oxidation
system of the liver and also in the heart, whereas the mitochondrial b-oxidation systems appear not to
be induced in both organs (Sauer and Kramer, 1980; Bremer and Norum, 1982). As a high proportion
of the dietary fat (estimated to be at least 50%) passes through the liver, an enhanced hepatic
peroxisomal b-oxidation of erucic acid would lower the inﬂux of this fatty acid to the heart and
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eventually lead to the regression of cardiac lipidosis, facilitated by the rapid turnover (estimated to be
about 5 h) of cardiac triacylglycerols.
Consistent with the concept of peroxisomal induction is the observation that the cardiac lipidosis
induced by a high erucic acid diet in young rats is markedly reduced by simultaneous feeding of
peroxisome proliferators such as cloﬁbrate (Christiansen et al., 1979). Cloﬁbrate is an agonist of
peroxisome proliferator-activated receptor-alpha (PPARa), which together with other PPARs
orchestrates many aspects of fatty acid metabolism and storage in the heart and other organs (Hihi
et al., 2002).
3.3.4.2. Cardiac effects other than lipidosis
In addition to cardiac lipidosis, cardiac necrosis and ﬁbrosis have been observed in the heart
following feeding of high erucic acid diets. As these effects cannot be speciﬁcally ascribed to erucic
acid (see Section 3.3.2.2), they will not be discussed in more detail.
Dietary exposure to high levels of erucic acid has an effect on cardiac mitochondria. One of the
putative molecular targets is cardiolipin, which is an acidic lipid found exclusively in mitochondria. It is
localised in the inner membranes and required for the mitochondrial b-oxidation of fatty acids and also
for the structural organisation of the respiratory chain (Mileykovskaya and Dowhan, 2014). Cardiolipin
has a strong preference for linoleic acid in most mammalian tissues. In rats, dietary supplementation
with erucic acid or glycerol trierucate results in accumulation of erucic acid in cardiolipin (Blomstrant
and Svensson, 1974; Dewailly et al., 1978). However, it remains to be clariﬁed whether replacement of
some of the linoleic acid by erucic acid alters mitochondrial functions.
Mitochondria are dynamic structures with a rapid turnover, having a half-life in normal rat
myocardium of about 14 days (Stotland and Gottlieb, 2015). They are not only involved in ATP
production but also in specialised functions, e.g. in the regulation of apoptosis. In several experimental
studies, substantially enlarged mitochondria (‘megamitochondria’) have been found in the rat heart
after feeding a high erucic acid diet (Bhatnagar and Yamashiro, 1979), which may release cytochrome
c with subsequent activation of caspases and initiation of apoptosis.
3.3.4.3. Summary
The major effect observed after erucic acid exposure of experimental animals is transient lipidosis
arising mainly from the poor b-oxidation of erucic acid in mitochondria. The reversibility of this effect
appears to be due to the enhanced peroxisomal chain shortening mediated by PPARs.
3.3.5. Adverse effects in livestock, ﬁsh and companion animals
Many studies have been reported in which the effects of erucic acid intake by farm and companion
animals and ﬁsh have been examined. The objective of many of the studies has been to examine
upper limits to levels of erucic acid-containing feeds – predominantly rapeseed meal – in livestock
diets. However, interpretation of the results is difﬁcult because the level of erucic acid has not been
reported, and/or because where adverse effects have been reported they may be confounded by the
presence of other antinutritive factors in meal, particularly glucosinolates.
3.3.5.1. Ruminants
In common with other livestock, there have been very few studies that have examined speciﬁcally
the adverse effects of erucic acid per se. For most ruminant livestock, rapeseed meal is the main
source of exposure to erucic acid, and many studies have been reported in which the effects of
replacing other vegetable proteins with rapeseed meal have been examined. From an extensive review
of published studies, Hill (1991) concluded that low-glucosinolates rapeseed meal could replace
soybean meal with no adverse effect on milk yield or milk composition, a conclusion supported by
Huhtanen et al. (2011) who demonstrated that milk production was as good as, or better, in diets
where rapeseed meal replaced soybean meal. Although some adverse effects on reproduction
efﬁciency in heifers have been reported following long-term feeding of high levels of rapeseed meal
(Lindell, 1976; Lindell and Knutsson, 1976; Ahlstr€om, 1978; Emanuelson et al., 1993; Ahlin et al.,
1994), Emanuelson (1994) concluded that this was due to the presence of glucosinolates rather than
erucic acid.
The seeds of Crambe abyssinica have the highest erucic acid content of all the oil seeds, and
B€öhme et al. (2005) used the meals from both crambe press cake (80.6 g erucic acid/kg DM) and
solvent-extracted crambe seed meal (14.6 g erucic acid/kg DM) to examine the effect of erucic acid on
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feed intake and milk production by lactating dairy cows. The cake and meal were included at 0%,
15% or 30% of the non-forage part of the ration DM and fed to 30 mid-lactation dairy cows (10 cows
per treatment), resulting in erucic acid contents ranging from 0.1 to 24 g/kg DM for the crambe press
cake ration and 0.1 to 3.9 g/kg DM for the crambe seed meal ration. Erucic acid intakes were 0.5,
46.2 and 108 g per day on the crambe press cake-supplemented diets and 0.6, 11.1 and 20.0 on the
crambe seed meal diets. These intakes correspond to doses ranging from 0.00092 to 0.166 g erucic
acid/kg bw, assuming a live weight of 650 kg. At 30% inclusion in the crambe press cake and crambe
seed meal diets, intake of the non-forage feeds decreased by about 10%, but this was compensated
for by an increase in forage intake. As a result, energy intake between groups was similar. At the
highest level of inclusion on both the crambe press cake and crambe seed meal diets there was a
reduction in milk yield, but this failed to reach statistical signiﬁcance.
Hristov et al. (2011) fed high erucic acid low-glucosinolate rapeseed meal (42 g erucic acid/100 g
total fatty acid) to eight multiparous Holstein lactating dairy cows. The erucic acid concentration in the
diet was 9.6 g/kg DM. This concentration corresponds to a dose of 0.42 g/kg bw per day, based on a
feed intake of 28.3 kg DM per day and a default live weight of 650 kg. Both DM intake and milk yield
were signiﬁcantly reduced by 8.4% and 4.4%, respectively (p = 0.001 and 0.047, respectively)
compared to cows fed conventional solvent-extracted rapeseed meal (erucic acid not detected),
although the feed efﬁciency for fat-corrected milk was increased by feeding the high erucic acid feed
compared with the control. The inclusion of high-oil seed meals in the diet lowered rumen acetate
concentration and the molar acetate:propionate ratio.
Based on the study of B€öhme et al. (2005) it would appear that an erucic acid intake of 0.17 g/kg
bw per day may have no adverse effect on milk yield, while intakes of 0.4 g erucic acid/kg bw per day
may result in reductions in feed intake and milk yield (Hristov et al., 2011). However, the possible role
of glucosinolates or other antinutritional factors in the meal could not be ruled out. The CONTAM
Panel concluded that there were insufﬁcient published data from which to derive a reliable NOAEL.
3.3.5.2. Pigs
Toxic effects in pigs
A description of the toxic effects caused by erucic acid in pigs is given in Section 3.3.2 and
Appendix G, Table G.2. The CONTAM Panel identiﬁed a NOAEL of 0.7 g/kg bw per day from the study
by Kramer et al. (1990) for increased myocardial lipidosis in newborn piglets exposed for 2 weeks.
Production-related effects in pigs
A number of studies have been undertaken in which production-related effects in pigs following
dietary supplementation with rapeseed oil were reported.
Kramer et al. (1998) fed newborn piglets sows milk or one of four milk replacer diets supplemented
with vegetable oils including HEAR. Erucic acid doses were 0, 0.02, 0.35, 0.39 and 3.5 g/kg bw per
day (see Appendix G, Table G.2. for more information). After 4 weeks on experiment the weight gain
of the pigs on the erucic acid free soybean oil treatment was signiﬁcantly (p < 0.05) higher
(6.8  0.5 kg) than those on the HEAR oil diet (5.0  0.4 kg), but no diet-related gross or histological
abnormalities were observed among the piglets.
Friend et al. (1975) fed growing and fattening boars and gilts on diets supplemented with soybean
oil or three rapeseed oils with varying levels (1.6%, 4.3% and 22.3%) of erucic acid. The oils were
included at either 5% or 10% of the diet. See Appendix G, Table G.2 for further details. Although
there was a small reduction in weight gain (p < 0.05) at the highest level of inclusion of the HEAR oil
at the end of the ﬁrst 4 weeks of the study, there were no effects on feed intake or live weight gain
after 16 weeks. There were slightly higher feed intakes and live weight gains (non-signiﬁcant) for the
LEAR oil diets, such that the live weight gain and feed intakes resulted in a signiﬁcantly (p < 0.05)
improved feed conversion efﬁciency for the pigs on the LEAR oil diets. In a second study these authors
fed boars diets supplemented with 20% soybean or HEAR oil (22.3% erucic acid). The pigs were on
experiment for 16 weeks. Feed intake, average daily live weight gain and feed efﬁciency were
signiﬁcantly lower (p < 0.01) in pigs on the rapeseed oil-supplemented diet.
In a subsequent series of experiments, Friend et al. (1976) fed boars diets without supplementation
(control) or supplemented with 25% of corn oil, LEAR or HEAR oils for 24 weeks. Erucic acid doses
were 0, 0.1 and 1.6 g/kg bw per day (see Appendix G, Table G.2 for further details). There were no
treatment effects on average daily gain; however, feed intakes on the oil-supplemented diets were
signiﬁcantly lower (p < 0.05) than those on the control diet. Feed intakes and weight gain of boars on
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the rapeseed oil-supplemented diets were not signiﬁcantly different to pigs on the corn oil, suggesting
that the production effects observed were due to the total oil content of the diet rather than the
presence of erucic acid.
B€öhme et al. (2005) used crambe press cake and solvent-extracted crambe seed meal to examine
the effect of erucic acid on feed intake and live weight gain of 100 crossbred pigs during their growing
(26–60 kg bw) and fattening (60–120 kg bw) periods. Pigs on the control treatment (erucic acid
content 0.2 g/kg DM) achieved daily live weight gains of 782 g/day. The inclusion of 5% and 10%
crambe press cake gave diets containing 3.1 and 7.1 g erucic acid/kg DM in the growing period and
4.3 and 7.8 g erucic acid/kg DM. in the ﬁnishing period. The equivalent ﬁgures for crambe seed meal
were 0.4 and 0.7 (5% and 10% inclusion, respectively) in the growing period and 0.3 and 0.7 g erucic
acid/kg DM in the ﬁnishing period. Total intake of erucic acid ranged from 47 (control) to 1,912 g
(crambe press cake, 20% inclusion). The pigs were fed a restricted intake for an average live weight
gain of 750 g/day, and therefore, there were no differences between treatments in feed intake. Only
the highest level of erucic acid (crambe seed meal 20%, 7.8 g erucic acid/kg DM) resulted in a 10%
reduction in growth rate, to 742 g per day (p < 0.05). The inclusion of crambe press cake at 5% and
10% produced diets, containing 0.3 and 0.7 g erucic acid/kg f.w. resulted in small (1% and 3%,
respectively) but not signiﬁcant reductions in weight gain. There were also differences in the fatty acid
composition of the body fat, but these did not result in signiﬁcant changes in meat quality parameters
such as juiciness, tenderness or taste. However, the CONTAM Panel have not used this study for the
risk assessment of erucic acid due to the presence of glucosinolates in crambe press cake and solvent-
extracted crambe seed meal to which pigs are particularly sensitive (Tripathi and Mishra, 2007; EFSA,
2008).
Aherne et al. (1975) compared HEAR (20.6%), LEAR (4.0%) and soybean oil in the diet for
fattening pigs (25–90 kg bw) when included at a level of 15%. There were no differences in feed
intake, live weight gain or feed conversion efﬁciency between pigs receiving HEAR (0.9 g/kg bw, see
Appendix G, Table G.2 for further details) and those receiving LEAR (0.2 g/kg bw) or the soybean
oil-supplemented diet.
In a subsequent study, Aherne et al. (1976) fed diets supplemented with HEAR oil (34.2% erucic
acid in the fatty acid) or rapeseed oil from three low erucic acid cultivars (range 0.3–4.9% erucic acid
in the fatty acid) to pigs from 19 to 130 kg bw. There were no signiﬁcant differences between
treatments in feed intake, average daily live weight gain or feed: live weight gain ratio. Exposure to
erucic acid ranged from 0.02 to 2.6 g/kg bw per day (see Appendix G, Table G.2).
In summary, the effects of erucic acid on production-related parameters in pigs have mainly
involved the use of oils from LEAR or HEAR cultivars, and in most studies the use of HEAR oil – which
is not now used as a feed material - did not have an adverse effect on feed intake or growth rate.
Although feed intakes by boars were signiﬁcantly lower when fed diets containing rapeseed oil (no
signiﬁcant difference between diets supplemented with LEAR and HEAR oils, with erucic acid content 1
and 24 mol% of total fatty acids, respectively) compared to the control, but the authors (Friend et al.,
1976) speculated that this was due to a higher consumption of the lower energy control diet to satisfy
a common energy requirement. An earlier study by the same authors reported that exposure to 2.2 g
erucic acid/kg bw per day resulted in a signiﬁcant reduction in feed intake, average daily gain and feed
efﬁciency (Friend et al., 1975). However, this contrasts with reports that exposures to 2.5 g erucic
acid/kg bw per day had no adverse effect on feed intake or live weight gain (Aherne et al., 1976).
Since none of the studies used erucic acid per se, the effects of other dietary constituents or
characteristics, where production-related differences have been reported, cannot be ruled out.
3.3.5.3. Poultry
Toxic effects in poultry
Rations containing 25% of either HEAR oil (36% erucic acid), LEAR oil (1.9% erucic acid), soybean
oil or a mixture of lard and corn oil were fed to chickens, ducks and turkeys for 52 days. Levels of
erucic acid in the HEAR- and LEAR-supplemented diets were 90 and 4.75 g/kg, respectively. In the
absence of default values for body weight and feed intake of young poultry species, the doses of
erucic acid were not estimated. A signiﬁcant decrease in body weight was observed in all species
exposed to HEAR and the effect was most severe in ducks. HEAR oil exposure caused also anaemia.
Relative liver weight was increased in all species fed HEAR oil. No ducks fed HEAR oil survived 28 days
of age. Severe fatty change in the heart (myocardium), skeletal muscles, liver, spleen and kidney was
found at an early age in all birds fed HEAR oil. Pale hearts and pale muscles were noted in all species
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fed HEAR oil. Hydropericardium was observed in all chickens and ducks fed HEAR oil. A thickening of
the epicardium and increased ﬁbrous tissue in myocardium was noted in heart of ducks fed HEAR oil
which died during the experiment. Some turkeys, fed HEAR oil had degenerative foci with inﬁltrations
of histiocytic and giant cells in the myocardium (Ratanasethkul et al., 1976).
The effects of erucic acid on the reproductive performance of laying hens was studied by including
5% or 15% of high (B. rapa, 26.2% erucic acid) or low (B. rapa45 cv. Span, 4.1% erucic acid) erucic
acid rapeseed oils or soybean oil (0% erucic acid). These levels correspond to doses of 0, 0.1, 0.4, 0.8
and 2.4 g/kg bw per day using the default values of 2 kg body weight and a mean feed intake of
120 g/day (EFSA FEEDAP Panel, 2012). During a 28-day pre-treatment period all hens received a low-
fat control diet. The treatment period lasting 56 days was divided into two periods of 28 days. Body
weights of the laying hens in the different groups were not signiﬁcantly different within the pre-
treatment or within the treatment period. Feed consumption decreased signiﬁcantly when the hens
received diets containing 15% oil in the second treatment period. HEAR and LEAR oil-fed hens had the
lowest and soybean oil-fed hens the highest daily feed intake when diets contained 5% oil. Per cent
egg production was inﬂuenced signiﬁcantly by the kind of oil in the diet. Signiﬁcantly lower egg
production was noted when hens were fed a diet containing 15% HEAR oil compared to hens receiving
15% soybean oil; the production being intermediate with LEAR oil (Vogtmann et al., 1974).
Single Comb White Leghorn cockerels (Hyline strain) were fed either an isocaloric basal (control)
diet or a diet supplemented with 20% by weights of soybean oil or oil extracted from different
rapeseed cultivars; one LEAR oil from Brassica napus cv. Tower (0.15% 22:1 n-9) and one LEAR oil
from B. rapa46 cv. Candle (1.3% 22:1 n-9), one HEAR oil extracted from a seed mixture of B. rapa cv.
Echo47 85% and cv. Arlo 15% (30.66% 22:1 n-9) and one HEAR oil from B. rapa cv. R-50048 (51.55%
22:1 n-9), a cultivar developed to produce oil for industrial purposes. Levels of erucic acid in the feed
were: < 0.002%, < 0.002%, 0.03%, 0.3%, 6.1% and 10.3%, respectively. These levels correspond to
doses of < 0.001, < 0.001, 0.02, 0.16, 3.7 and 6.2 g/kg bw per day using the default values of 2 kg
body weight and a mean feed intake of 120 g/day (EFSA FEEDAP Panel, 2012). Three birds from each
group were killed at 4, 8, 12 and 16 weeks. The mean body weight of birds fed control diet was
signiﬁcantly higher at week 8 and 12 than for birds fed the other diets. This difference was not evident
at week 4 and had largely disappeared by week 16. Feeding 3.7 g/kg bw per day had no consistent
effect on body weights, heart weights or heart-to-body weight ratio. Cardiac lipid levels consistently
increased in the group receiving 6.2 g/kg bw per day. Signiﬁcant post-mortem changes were reported
in 12 birds from the group receiving 6.2 g/kg bw per day dying or been killed during the study. Two
cockerels receiving 3.7 g/kg bw per day had similar gross lesions. Gross lesions were: a marked ascites
resulting in distension of the abdominal wall, shrunken ﬁrm liver with uneven surfaces and thickened
capsule, hydropericardium, dilation of the heart, thickened pericardium, oedema of the lung and
marked muscle wasting, especially of the pectoral muscles. In addition, mineralisation of myocardium
was noted in one bird and haemorrhage was found in the liver of two birds from the group receiving
3.7 g/kg bw per day. Histopathological changes were found in the brain, heart, liver and skeletal
muscle. Healed encephalomalacia was observed in all groups. Heart lesions (vacuolation of myocytes
indicating lipidosis, foci of degenerative and necrotic myocardium, ﬁbrosis and in some birds
mineralisation of the necrotic debris and formation of granulomas, scarring, mononuclear cell
inﬁltration, signs of degenerate mitochondria) were observed in the two highest dose groups, the
highest dose group being the most severely affected. Liver lesions (mild to moderate fatty
metamorphosis, focal sinusoidal distension, periacinar necrosis, marked thickening of the capsule,
increased ﬁbrous connective tissue) were observed in all groups with an increase in the two highest
dose groups. Mild bile duct hyperplasia was seen in some of these livers. Muscle lesions were also
observed in all groups except controls with an increase in the two highest dose groups (hyaline
degeneration of ﬁbres of the superﬁcial pectoral and semitendinosus, and cachetic muscular atrophy).
Testes were examined for the presence of spermatids at 84 days but none were found. At 112 days,
spermatids were found in a small number of birds in each treatment group. From this study, the
CONTAM Panel identiﬁed a NOAEL of about 0.16 g/kg bw per day for heart lesions and a LOAEL of
0.02 g/kg bw per day for liver toxicity (increase incidence of sinusoidal distension) (Hulan et al., 1982;
Corner et al., 1985).
45 Reported by the authors as B. campestris cv. Span.
46 Reported by the authors as B. campestris cv. Candle
47 Reported by the authors as B. campestris cv. Echo
48 Reported by the auhrors as B. campestris cv. R-500.
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Male White Leghorn chicks (5/group) were fed basal diet or diets supplemented with soybean oil or
four different rapeseed oils at 20% by weight of the diet from day 1 of age to 3 days, 1, 2 and
4 weeks. The four rapeseed oils contained 0.9%, 1.6%, 4.3% and 22.3% erucic acid.49 Chicks fed diet
containing rapeseed oils grew at a slower rate than chicks fed basal diet or diet containing soybean oil.
Retardation in body weight was most pronounced in the HEAR group. After the ﬁrst week, there was
no signiﬁcant difference in heart weights of the chicks in the different groups. The total cardiac lipid
was consistently higher in chicks from the HEAR group throughout the feeding trial. Chicks from the
other rapeseed oil groups also showed elevated levels of cardiac fat within the ﬁrst week compared to
chicks fed the basal diet, but these differences had disappeared by week 2 (Kramer and Hulan,
1977b).
Abdellatif and Vles (1970c) reported a series of experiments in Pekin ducklings. Firstly, 1 or 7-day-
old Pekin ducklings were fed a diet containing various levels (10%, 20% and 30% by weight) of
rapeseed oil with an erucic acid content of 40% for 20 days.50 In addition to cardiac lipidosis, the
animals showed severe hydropericardium and liver cirrhosis in the two highest dose groups. A
mortality of 80% was noted in the highest dose group. In a dose–response study, ducklings were fed
isocaloric diets containing 5%, 10%, 12.5%, 15%, 17.5% and 20% by weight of rapeseed oil (50%
erucic acid; dose of erucic acid not reported) for 3 weeks. Mortality occurred only in the highest dose
group, which also showed signiﬁcant growth retardation in comparison with the other groups.
Reticulocyte count and haematocrit increased with increasing level of rapeseed oil in the diet. There
was a dose-related increase in heart weights (absolute and relative). Absolute mean liver weights
increased with rapeseed oil levels up to 15% but decreased at higher doses. The following
histopathological changes were observed at rapeseed oil levels ≥ 15%: hydropericardium, vacuolation,
cell inﬁltration and oedema of myocardium and skeletal muscles, cirrhotic changes, centrolobular
necrosis, engorgement of the liver and atrophy of the red pulp and increased erythropoiesis and lipid-
laden cells in the spleen. In a third experiment, seven-day-old ducklings were fed an isocaloric diet
containing 8.8% erucic acid (supplied by rapeseed oil (18.5% by weight) or glycerol trierucate (10%
by weight) for 3 weeks. A control group received 20% hardened palm oil. The results indicate that the
animals fed glycerol trierucate grow as poorly and develop the same lesions (hydropericardium,
vacuolation of the myocardium and skeletal muscles and cirrhotic changes of the liver) as the animals
fed rapeseed oil. However, the lesions were slightly severer in the rapeseed oil group which showed
also mortality (3/10 ducklings) than those in the glycerol trierucate group which showed no mortality.
Abdellatif and Vles (1971a) investigated the effects of supplementing HEAR with olive oil, safﬂower
oil or tallow in diets for 1-week-old Peking duck for 3 weeks. The diets contained (1) 30% by weight
olive oil, (2) 30% by weight rapeseed oil (27.8% erucic acid in the diet), (3) 20% by weight rapeseed
oil (18.5% erucic acid in the diet), (4) 20% by weight rapeseed oil plus 10% by weight tallow (18.6%
erucic acid in the diet), (5) 20% by weight rapeseed oil plus 10% by weight safﬂower (18.5% erucic
acid in the diet) or (6) 20% by weight rapeseed oil plus 10% by weight olive oil (18.5% erucic acid in
the diet). The highest mortality (7/10) and growth retardation were observed in the group receiving
the highest dose of erucic acid (2). The characteristic pathological effects of HEAR (hydropericardium,
myocardial vacuolation, vacuolation of skeletal muscles, degenerative changes of the liver and lipidosis
in the spleen) were observed in the groups fed rapeseed oil, being more severe in group (2). The
incidence of liver and skeletal muscle changes was not appreciably different among the different
groups. No lesion was observed in the group receiving olive oil (1).
In a second experiment, the effects of supplementing diets isocaloric in fats and in erucic acid for
3 weeks with increasing levels of hardened palm oil or glycerol trilaurate were investigated in
ducklings. Erucic acid was supplied either as rapeseed oil or as glycerol trierucate. A group fed 20% by
weight hardened palm oil was used as control. Mortality was highest in the groups fed rapeseed oil
alone or rapeseed oil with glycerol trilaurate and was absent or very low in the other groups. Growth
was signiﬁcantly lower in the groups given erucic acid (groups fed rapeseed oil, glycerol trierucate or
rapeseed oil with glycerol trilaurate compared to the control group and groups given erucic acid with
palm oil supplement. No lesion was observed in the control group. Increasing levels of palm oil
decreased the incidence and severity of liver cirrhosis, hydropericardium and splenic lipidosis. Vacuolar
changes of the skeletal muscles were not improved, but those of the heart became more severe.
49 In the absence of default values for body weight and feed intake of chicks, the doses of erucic acid for chicks were not
estimated.
50 In the absence of default values for body weight and feed intake of ducklings, the doses of erucic acid for ducklings were not
estimated.
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Supplementing the rapeseed oil diet with glycerol trilaurate increased the severity of the lesions. The
authors concluded that the nutritional and pathological properties of rapeseed oil in ducklings are
determined by the excess of erucic acid and the deﬁcit of palmitic acid in the diet (Abdellatif and Vles,
1971a).
When diets containing 25% by weight rapeseed oil with 25% or 4.3% erucic acid were fed to
ducklings, severe toxicity as described in the earlier study and high mortality was observed in the high
erucic acid group after 2 weeks. The surviving animals developed cardiac ﬁbrosis after 3 months. The
ducks of the low erucic acid group showed no mortality and hydropericardium, but some of them
developed vacuolar changes of the heart and skeletal muscles. These lesions had largely disappeared
after 3 months (Abdellatif and Vles, 1973b).
Summary on toxic effects in poultry
Cardiac lipid levels increased in cockerels or chickens receiving diets containing erucic acid. This
increase disappears at low doses after 2 weeks, but persists in animals fed higher doses. Cardiac
lesions occurred in cockerels at doses of 3.7 g/kg bw per day and above with vacuolation and
degeneration of myocardial cells, necrosis, ﬁbrosis and mineralisation, formation of granulomas,
thickening of the epicardium, scarring, mononuclear cell inﬁltration, signs of degenerate mitochondria
and dilation. Hydropericardium was also observed in chickens fed HEAR oil. In the liver, fatty
metamorphosis, focal sinusoidal distension, necrosis, ﬁbrosis and marked thickening of the capsule
were observed. In skeletal muscles, hyaline degeneration of ﬁbres and muscular atrophy were noted.
These effects were also reported in animals fed control or soybean oil, but the incidence and severity
of lesions were signiﬁcantly higher in cockerels fed rapeseed oil and especially in those fed high doses
of erucic acid. The CONTAM Panel identiﬁed a LOAEL of 0.02 g/kg bw per day based on liver toxicity.
Growth retardation was reported in chickens fed diets containing rapeseed oil compared to chickens
fed soybean oil, especially at high dose of erucic acid.
In turkeys fed HEAR oil signiﬁcant decrease in body weight, increase in relative liver weight, severe
fatty change (at an early age) in the heart, skeletal muscles, liver, spleen and kidney were observed.
In addition, degenerative foci with hystiocytic inﬁltration and giant cells occurred in the myocardium.
Several studies in ducklings conﬁrm the observations in other species: growth retardation, cardiac
lipidosis, hydropericardium, myocardial vacuolation, vacuolation of skeletal muscles, liver cirrhosis
resulting in mortality in highest dose erucic acid fed animals.
Production-related effects in poultry
In addition to the pathological effects described above, many studies have been undertaken to
examine production-related effects of feeding full-fat rape seed, rapeseed meal and rapeseed oil on
poultry. Many of the early studies showed that supplementation of diets with high erucic acid (HEAR)
oils resulted in increased mortality and reductions in feed intake, live weight gain, egg production and
egg weight (Abdellatif and Vles, 1971a, 1973b; Vogtmann et al., 1973; Clement and Renner, 1977).
Abdellatif and Vles (1973b) attributed the increased mortality in ducks fed HEAR oil (50% erucic acid)
to refusals by the birds to consume the feed, resulting in starvation.
Following the development of LEAR varieties, research has conﬁrmed that full-fat rape seed,
rapeseed meals and rapeseed oils can be used as feed for poultry. Early LEAR varieties included Tower
and Candle, and Clandinin et al. (1978) found that both varieties could be included at 20% in diets for
broilers without adverse effects, while increasing to 30% resulted in a small decrease in growth rate
but no effect on feed conversion efﬁciency or mortality was observed. These authors also reported
that Tower rapeseed meal could be included in diets of layers without adverse effects on feed intake,
egg production or egg weight. Similar results were reported for Candle rapeseed meal (Slinger et al.,
1978). For turkeys, Salmon (1979) reported that both Candle and Tower rapeseed meals could be
successfully included at up to 30% in turkey diets. Based on an extensive review, Fenwick and Curtis
(1980) concluded that rations for broilers and turkeys could be supplemented with up to 30%
rapeseed meal, or 20% full-fat rape seed, without adverse effects on feed intake or growth rate. At
that time, recommended levels for laying hens were lower because of the risk of producing eggs with
a ﬁsh-ﬂavour taint (Appendix D.2.2).
Sim et al. (1985) fed broiler chicks diets containing canbra oil (5.1% erucic acid) or sunﬂower oil
which contained no erucic acid, with or without the addition of the free form of erucic acid, such that
erucic acid contents of the diets were 0%, 40.5% and 42.0% of fatty acids. The feed intake and live
weight of chicks at 28 days fed the canbra oil diet were signiﬁcantly smaller than those fed the
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sunﬂower oil diet, while the addition of erucic acid to the sunﬂower oil resulted in reduced feed intake
and ﬁnal live weight relative to the controls (p < 0.05) on the sunﬂower oil-containing diet.
In summary, early studies in which poultry were fed diets supplemented with oils and meals derived
from HEAR cultivars clearly demonstrated adverse effects on production-related factors. However, as
for other livestock, the possible effects of other dietary constituents or characteristics on feed intake,
growth rate and egg production cannot be excluded. At least one study attributed the high oil content
of the diet to the reluctance by the birds to consume the feed, resulting in starvation (Abdellatif and
Vles, 1973b). Similarly, feed intakes were signiﬁcantly reduced when diets were supplemented with
15% oil irrespective of the levels of erucic acid in the diet (Vogtmann et al., 1974). Consequently, the
CONTAM Panel has been unable to derive any LOAEL or NOAEL for production-related characteristics
for poultry.
3.3.5.4. Rabbits
One study on the toxic effects caused by erucic acid in rabbits was identiﬁed and is described in
Appendix G, Table G.4. No NOAEL for rabbits could be identiﬁed.
3.3.5.5. Fish
The CONTAM Panel has been unable to identify studies that have speciﬁcally examined the adverse
effects of erucic acid in ﬁsh. Numerous studies have examined the effect of including rapeseed meal
and other rapeseed products on feed intake, growth rate, physiological and biochemical parameters of
aquatic animals, but in most cases the levels of erucic acid in the diets used have not been given (e.g.
Yurkowski et al., 1978; Higgs et al., 1982; Lanari and D’Agaro, 2005). In addition, the identiﬁed
studies used ﬁsh oil or meal as a control. Since in these experimental settings, erucic acid is not the
only source of variation in fatty acid composition between ﬁsh oil/meal and rapeseed oil/meal, these
studies were not considered relevant for the risk assessment and the CONTAM Panel could not
conclude on a NOAEL. Assuming that the erucic acid contents in the rapeseed products used in the
studies do not exceed maximum permitted levels, then the inclusion of rapeseed meal at up to 30% of
the diet is unlikely to result in adverse effects on growth or ﬁsh health (Lim et al., 1998; Burel et al.,
2001; Enami, 2011). Similarly, rapeseed oil may replace ﬁsh oil without any adverse effects on growth
rate or feed conversion efﬁciency.
3.3.5.6. Horses
Harris et al. (1999) fed eight thoroughbred horses diets that provided 1 g erucic acid/day
(equivalent to approximately 0.002 g/kg bw per day) in vegetable oil for 10 months. No signiﬁcant
effects on glucose tolerance test, or on haematological parameters, monitored monthly, were
observed. Total protein and gamma glutamyl transferase remained within the normal range
throughout.
3.3.5.7. Companion animals
No studies on adverse effects in companion animals were identiﬁed.
3.3.6. Consideration of critical effects, dose response assessment and derivation
of a health-based guidance value
3.3.6.1. Considerations of critical effects
The epidemiological studies were considered insufﬁcient as a basis for risk assessment. The
CONTAM Panel noted, however, that cardiac lipidosis shown in the animal studies, is relevant also for
human health. The ﬁnding of an association between congestive heart failure and 22:1 fatty acids
(Imamura et al., 2013), is consistent with animal studies, since associations between myocardial
lipidosis (also termed steatosis in clinical studies) and heart failure (diastolic dysfunction) has been
shown in humans (Lindsey and Marso, 2008; Rijzewijk et al., 2008; Wei et al., 2016). The therapeutic
use of Lorenzo’s oil (containing erucic acid) in ALD patients results in haematological effects, most
notably thrombocytopenia and morphological alterations of thrombocytes, at erucic acid doses of
about 0.1 g/kg bw per day.
A large body of evidence has been published, starting from the 1960s, showing that HEAR oils have
toxic effects on the heart in experimental animals. Administration of dietary HEAR oils to rats, pigs and
monkeys results in myocardial lipidosis i.e. an accumulation of triacylglycerols in myocardium that
appear as neutral lipid droplets. The basis for this large accumulation of neutral lipid is likely to be the
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poor b-oxidation of erucic acid by mitochondria. The lipid droplets are adjacent to, and in close contact
with, the mitochondria. Mitochondrial damage has been reported only after exposure to HEAR oil for
several months (e.g. degeneration of mitochondria in pigs). Prolonged administration of high erucic
acid oils is associated with the development of multiple microscopic foci of myocardial necrosis, leading
to myocyte loss and ﬁbrosis, particularly common in the rat. Repeated exposure to HEAR oils has been
associated with signs of cardiac distress (e.g. systolic and diastolic dysfunction in rats, degeneration of
mitochondria in pigs) even if the levels of free fatty acids do not reach the levels required to
signiﬁcantly impact on the heart function.
However, the acute increases in neutral lipids within the myocardial cells are reversible, questioning
whether the accumulation of these lipids might be a direct mediator of irreversible injury. Accordingly,
administration of erucic acid during a few days produces a marked relative increase in neutral lipid
content but there is no evidence that this may result in functional myocardium alteration or necrosis.
Factors other than, or in addition to, erucic acid may be responsible for the increased incidence of
these lesions.
Based on these considerations, the CONTAM Panel decided:
1) not to establish an acute reference dose because of the lack of endpoints indicative of acute
toxicity on target organs;
2) to select myocardial lipidosis as critical effect for establishing a tolerable daily intake (TDI)
for erucic acid.
The CONTAM Panel considered that the approach followed for the establishment of the TDI is
conservative. Indeed, the effect selected, myocardial lipidosis, is transient and reversible: erucic acid
induced lipidosis regresses after prolonged exposure and was reversible after return of the animals to
a low-fat diet without erucic acid.
Upon repeated feeding with erucic acid-containing diets, non-cardiac effects such as changes in the
liver, kidneys, skeletal muscle, adrenals and testis weight have also been reported in rats and
haematological effects as well as liver morphological alterations in newborn piglets. In all cases, these
effects are observed at somewhat higher doses (LOAELs of 4–13 g/kg bw per day) than those leading
to cardiac lipidosis in the same species.
3.3.6.2. Dose–response assessment and derivation of a health based guidance value
Since there are no adequate data from human studies for dose–response assessment, the CONTAM
Panel considered the data from studies on experimental animals to identify reference points.
Regarding myocardial lipidosis, six studies were identiﬁed in rats and one in pigs that were
conducted in a wide dose-range and where erucic acid was reported as the main source of variation in
fatty acid composition of the diet (see Section 3.3.2.2). No studies with these characteristics were
identiﬁed in monkeys. Lipidosis is a complex endpoint characterised by several factors (i.e. incidence
and severity) that should be taken into account for the identiﬁcation of a reference point. Considering
that incidence was generally high in control animals, that appropriate controls were not always available
and that severity was not always reported quantitatively, the CONTAM Panel selected the NOAEL
approach to identify the reference point. In rats, the NOAELs for myocardial lipidosis ranged from 0.7 to
2.6 g/kg bw per day and the LOAELs ranged from 1.0 to 7.1 g/kg bw per day (Table 11). In newborn
piglets the NOAEL was 0.7 g/kg bw per day and the LOAEL was 1.1 g/kg bw per day (Table 12).
The CONTAM Panel selected the overall NOAEL for lipidosis of 0.7 g/kg bw per day, observed in a
7-day feeding study in young rats and in a 2-week feeding study in newborn piglets, as reference
point for the risk assessment. Based on this NOAEL, the CONTAM Panel established a TDI of 7 mg/kg
bw for erucic acid using the default uncertainty factor of 100 to account for intra- and interspecies
differences. No additional uncertainty factor was applied to extrapolate from the short-term to long-
term duration of the exposure because lipidosis is transient and reversible. The CONTAM Panel noted
that this TDI is well below the erucic acid dose of 100 mg/kg bw causing haematological effects in
ALD patients treated with Lorenzo’s oil.
3.4. Risk characterisation
3.4.1. Human health risk characterisation
The CONTAM Panel established a TDI of 7 mg/kg bw for erucic acid based on a NOAEL for
myocardial lipidosis in rats and pigs.
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Data on human dietary exposure levels of erucic acid across dietary surveys and age groups are
presented in Table 6 and show mean exposure values that range from 0.3 (minimum LB) to 4.4 mg/kg
bw per day (maximum UB), across dietary surveys and age groups. Mean dietary exposures for adults
ranged from 0.3 to 1.9 mg/kg bw per day across European surveys and was highest for toddlers and
infants, ranging from 0.5 to 4.4 mg/kg bw per day. These exposures are below the TDI of 7 mg/kg bw
per day.
The 95th percentile dietary exposure levels range from 0.7 (minimum LB) to 7.4 mg/kg bw per day
(maximum UB) across dietary surveys and age groups, with a range for adults from 0.9 to 4.3 mg/kg
bw per day. The 95th percentile dietary exposure was highest in infants and other children, ranging
from 1.3 to 7.4 mg/kg bw per day; the upper range being at the level of the TDI. This may indicate a
risk for young individuals with high erucic acid exposure.
3.4.2. Animal health risk characterisation
Dietary exposure to erucic acid from rapeseed meal and oil was calculated for different livestock
species (Tables 8 and 9). In the absence of any feed industry data on levels of rapeseed meal and oil
in livestock feeds in the EU, the CONTAM Panel has used maximum recommended inclusion levels from
industry guidelines (Ewing, 1997; Canola Council of Canada, 2015). Therefore, levels of exposure
calculated in this opinion represent worst-case scenarios. It should be mentioned that insufﬁcient data
on levels of erucic acid in rapeseed meal or cake were available to allow P95 estimates of exposure to
be made. The CONTAM Panel identiﬁed a NOAEL of 700 mg/kg bw per day for myocardial lipidosis in
newborn piglets. Production-related effects were only observed at doses higher than the NOAEL for
lipidosis. The dietary exposure of pigs ranges from 3.9 (minimum LB) to 8.6 mg/kg bw per day
(maximum UB), which is well below the NOAEL for lipidosis in pigs.
For poultry, a LOAEL of 20 mg/kg bw per day was identiﬁed for liver toxicity, which is about double
the upper exposure range (4.4 (minimum LB) to 12 mg/kg bw per day (maximum UB)). The small
margin between the LOAEL and the estimated exposure may indicate a health risk for poultry where
maximum inclusion rates are applied.
The available database on adverse effects in ruminants was too limited to identify an overall
NOAEL. However, no effect on milk yield was observed in the study by B€öhme et al. (2005) at a dose
of 170 mg/kg bw per day. The dietary exposure of dairy cattle ranges from 1.8 (LB) to 2.6 mg/kg bw
per day (UB), which is well below the dose at which no effect is observed on the milk yield. However,
the risk of other adverse effects or for other ruminants could not be assessed.
No NOAEL/LOAEL could be identiﬁed for horses, ﬁsh and rabbits, and therefore, the risk of erucic
acid exposure could not be assessed for these species. However, the CONTAM Panel noted that the
exposure of horses (0.95/1.5 mg/kg bw per day (LB/UB)) and rabbits (6.4/13 mg/kg bw per day
(LB/UB)) is well below the NOAEL of 700 mg/kg bw per day for pigs.
Since rapeseed meal and rapeseed oil are not commonly used in the diets of cats and dogs, the
dietary exposure to erucic acid is considered to be negligible and no risk characterisation has been
undertaken.
3.5. Uncertainty analysis
3.5.1. Assessment objectives
The objectives of the assessment were clearly speciﬁed in the terms of reference.
3.5.2. Exposure scenario/exposure model
A ﬁnal dataset of 12,444 food samples was available to estimate chronic dietary exposure to erucic
acid. Apart from the samples of rapeseed oil that were mainly reported as collected in the European
Union without further details, most of the other food samples (~ 75%) were collected in one Member
State. Therefore, there is uncertainty on whether possible country-based differences in the levels of
erucic acid in diverse food commodities are well represented; this may affect for instance food
commodities such as ‘Fine bakery wares’ particularly important in the dietary exposure to erucic acid.
Likewise, the lack of information on the analytical method used to analyse some food samples
(~ 30%) adds some uncertainty to the levels of erucic acid reported for some food commodities. There
is also uncertainty in the occurrence values of few food samples for which the fat content was
imputed, as this information was originally not provided.
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In relation to exposure assessment, uncertainties and limitations related to the use of the EFSA
Comprehensive Food Consumption Database have already been described in EFSA (EFSA, 2011a) and
are not further detailed. Among those with a particular implication for the dietary exposure to erucic
acid, the uncertainty associated to the eating occasions reported for ‘Composite food’ should be
mentioned as no information is available on whether they referred to homemade dishes or ready-to-
eat foods. This is particularly important in the estimation of dietary exposure to erucic acid, and,
together with the different level of disaggregation reported in the consumption data and the low
number of occurrence data reported, made it necessary to carry out speciﬁc exposure scenarios for
these food commodities. The speciﬁc exposure scenarios for ‘Custard’ and ‘Chutneys and pickles’ are
surrounded by uncertainty due the low number of samples reported. In particular, the exposure
scenario for the latter group is surrounded by further uncertainty as the low number of samples raises
doubts about the representativity of a rather heterogeneous food group, and the fact that the number
of eating occasions in the Comprehensive database for ‘Chutneys and pickles’ is very low.
There is also uncertainty associated to the contribution of ‘Fish and other seafood’ since in both the
Comprehensive and the occurrence database for certain reported data there is no clear information on
whether they refer to oil canned samples (and the type of oil used) or not. In addition,
misidentiﬁcation between erucic acid (22:1 n-9) and cetoleic acid (22:1 n-11) in ﬁsh and seafood is
relatively common during fatty acid analysis. Consequently there is uncertainty regarding the reported
levels of erucic acid in ﬁsh and other seafood in the occurrence data reported to EFSA as well as in
food nutrients databases and scientiﬁc literature. Misidentiﬁcation between erucic acid and other 22:1
fatty acids may also occur in other foods as for example due to the presence of trans and positional
isomers after partial oil hydrogenation. Therefore, there is some uncertainty associated to the
occurrence data and subsequently to the exposure estimations.
Further uncertainty is identiﬁed when excluding different types of vegetable oils (olive oil, sunﬂower
oil, among others) that do not naturally contain erucic acid but for which levels of this fatty acid were
reported. The presence of such adulterated oils in the market would imply an increase in the dietary
exposure to erucic acid. This increase would be rather small in most of the dietary surveys under the
LB scenario, and would imply a maximum of 1.9-fold/1.6-fold increase under the UB scenario
(mean/95th percentile dietary exposure). Since the presence of erucic acid was reported for very few
samples of these vegetable oils, exposure estimations under the UB would be surrounded by large
uncertainty. In any case, the inﬂuence of these samples is negligible for the maximum estimates of the
mean and 95th percentile dietary exposure across the different dietary surveys.
Dietary exposure to erucic acid may be underestimated to a certain extent due to the lack of
occurrence data in animal-derived foods and the evidence that erucic acid in the feed is transferred to
products of animal origin.
The animal risk assessment is hampered by limited representative feed consumption data for
livestock and ﬁsh across Europe. Furthermore, insufﬁcient data on levels of erucic acid in rapeseed
meal or cake were available to allow P95 estimates of exposure to be made. As a result, there is
considerable uncertainty regarding the total dietary exposure to erucic acid in the animal risk
assessments. Due to the limited data on the amount of rapeseed meal/oil used in animal diets, the
CONTAM Panel has used published maximum recommended inclusion rates for each of the livestock
categories which is likely to have overestimated exposure in most cases, although the extent of this is
uncertain.
Rapeseed meal is a major feed ingredient and likely to be the single most important source of
erucic acid for all livestock. While in excess of 6 million tonnes of rapeseed meal are used as feed for
livestock in the EU, data for only 28 samples were reported. Furthermore, these were classiﬁed as
rapeseed expeller, while the meal – which would be expected to have a lower erucic acid content - is
the more commonly used feed material. The calculation of exposure was therefore based on a very
limited number of quantiﬁed results, which has added to the uncertainties of exposure estimates.
3.5.3. Model input (parameters)
Performance criteria for the analytical methods used for the ofﬁcial control of levels of erucic acid in
foodstuffs are laid down in Commission Regulation (EC) No 2015/705 and no speciﬁc methods are
prescribed at EU level.
The analytical results used for the exposure assessment were performed by different laboratories at
largely varying LOQ/LODs. This fact together with the large proportion of samples with left-censored
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data (72%) introduces uncertainty to the overall dietary exposure estimates. While the LB values tend
to underestimate the chronic dietary exposure to erucic acid, UB values tend to overestimate it.
3.5.4. Other uncertainties
Present knowledge on the absorption, distribution and excretion of erucic acid in animal models
and humans is based on old studies using high doses of rapeseed oil with high levels of erucic acid
and employing imprecise methods. These data do not necessarily reﬂect the toxicokinetic situation
when low levels of glycerol erucates are present in the diet.
Although the metabolic fate of erucic acid in the mammalian organism is well known in qualitative
terms, there is only preliminary information about quantitative metabolic differences between humans
and various animal species used for toxicity testing. The metabolic degradation of erucic acid in cardiac
and hepatic mitochondria and peroxisomes appears to play a major role in the mode of action and
may explain observed species differences in the toxicity of erucic acid, but data on the activity and
inducibility of these organelles are scant. Another uncertainty relates to the implication of physiological
differences (rate and strength of contraction, and energy demand) of the heart between species for
the toxicological sequelae of erucic acid.
Many toxicological studies are decades old, do not meet current standards and were not designed
to determine a reference point. No pure erucic acid was administered to the experimental animals, but
they were fed diets containing oils with various levels of erucic acid, mainly rapeseed oil but also other
vegetable oils. These vegetables oils contain besides erucic acid, other fatty acids and other nutrients,
which may have harmful or protective effects. Thus the dietary background may have a large inﬂuence
on the outcome of the studies. In most toxicological studies, oil enriched feed was used which is
particularly energy dense. Since most studies did not report the used doses, the CONTAM Panel used
default values to convert levels in the diet into doses. However, due to the high calorie content of oil
enriched feed, experimental animals do not eat such feed as much as they would eat standard feed
and the actual doses may be lower than the calculated doses. This may result in an overestimation of
the NOAEL. In addition, the use of oil enriched feed may lead to compromised levels of some
micronutrients. According to a study in which the feed was enriched with 20% of ﬁsh oil, the rats in
the control groups had approximately 30% lower feed intake compared to rats fed standard laboratory
rodent feed (Vaskonen et al., 1996). Some studies did not report the weight % of erucic acid in the oil
but the calorie %. In this case, the CONTAM Panel assumed that the weight % equals half of the
calorie %, an assumption that is used in many studies. Several studies reported only the level of 22:1
or 22:1 n-9 (without speciﬁcation of cis or trans conﬁguration) in the oil. Since erucic acid is by far the
most important 22:1 fatty acid in rapeseed oil, the CONTAM Panel assumed that all 22:1 present in
rapeseed oil is erucic acid. Overall the use of studies with rapeseed oil and the assumptions for dose
calculations adds to the uncertainty.
The critical effect selected for the derivation of the health-based guidance value (HBGV) is
myocardial lipidosis in experimental animals. This is regarded as a short-term, reversible effect, and
therefore, it is not a direct mediator of irreversible injury. However, when myocardial lipidosis is
observed following feeding with HEAR oils, myocardial distress is also described. Moreover, myocardial
lipidosis has never been reported in humans exposed to erucic acid and an extrapolation from effects
on the rat or pig heart to the human heart is complicated by differences in physiology.
Other antinutritive factors present in rapeseed meal may also have contributed to any adverse
effects reported in livestock. Regarding production-related adverse effects in livestock, relatively few
studies have reported all the information necessary to estimate exposure (feed intake and live weights
of the species, erucic acid contents of the feed), thus adding further uncertainty to the levels of
exposure at which adverse effects may be observed. In addition, many studies were done 40 years or
more ago, and therefore, their applicability for the current genotypes is uncertain.
3.5.5. Summary of uncertainties
In Table 13, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the respective source of uncertainty might have led
to an over- or underestimation of the exposure or the resulting risk.
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The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of
human and animal exposure to erucic acid through consumption of food and feed is considerable.
Based on the lipidosis selected as the critical effect to derive the TDI, the CONTAM Panel concluded
that the risk assessment of human exposure to erucic acid presented in the opinion is more likely to
overestimate than to underestimate the risk. For the same reason, the CONTAM Panel concluded that
the risk assessment for pigs is more likely to overestimate than to underestimate the risk. The use of
maximum inclusion rates resulted in an overestimation of the exposure for poultry. However,
considering the uncertainties related to the use of a LOAEL as toxicological reference point for poultry,
it is not possible to conclude whether the risk for this species is overestimated.
4. Conclusions
Erucic acid is the trivial name of the fatty acid Z-13-docosenoic acid, abbreviated as 22:1D13c,
although it is more frequently found in the literature as 22:1 n-9. Erucic acid is mainly present in the
seeds of species of the Brassicaceae, which includes important seed crops such as rapeseed and
mustards, and also important vegetable crops such as the diverse group of kales, cabbages and
turnips. Cultivars of Brassicaceae with very low erucic acid content have been developed for seed oil
production for food and feed use in most countries, including the EU. Mustard seed production is
based on cultivars with high erucic acid content. Erucic acid is also present at low concentrations in
other food sources such as ﬁsh. Erucic acid is present in Lorenzo’s oil, a drug used for therapy for ALD
patients. Erucic acid doses range from 0.09 to 0.51 g/kg bw per day.
4.1. Occurrence/exposure
• The dietary exposure was estimated using a ﬁnal dataset of 12,444 food samples representing
most of the food commodities with potential presence of erucic acid.
• Samples were collected between 2000 and 2015 (half of them in 2014) in 15 different
European countries, but most of them from one Member State.
Table 13: Summary of qualitative evaluation of the impact of uncertainties on the risk assessment
of erucic acid in food and feed
Sources of uncertainty Direction
Use of LB and UB occurrence data in the exposure estimations +/(a)
Exclusion of composite foods from the general scenario 
Lack of occurrence data on foods of animal origin 
Misidentiﬁcation of erucic acid during the analytical measurements +/
Exclusion of different types of vegetable oils for human dietary exposure 
Imputation of fat content in certain foods +/
Extrapolation of occurrence data to the whole of Europe +/
Use of maximum inclusion levels of rapeseed meal and oil in livestock diet +
Few occurrence data in feed +/
Insufﬁcient data on levels of erucic acid in rapeseed meal or cake to allow P95 estimates of
livestock dietary exposure

Lack of quantitative studies on the absorption, distribution and excretion of erucic acid from
dietary glycerol erucates
+/
Lack of comparative studies on the activity of mitochondria and peroxisomes of humans, pigs, rats,
and other animal species for the metabolism of erucic acid
+/
Implication of physiological differences of the heart between species +/
Dose calculation of erucic acid in experimental animals 
Inﬂuence of other fatty acids and other minor components in the oil, and of high-fat diet on the
induction of lipidosis/necrosis in experimental animals
+/
Limited studies on current genotypes of livestock +/
Dose calculation of erucic acid in livestock +/
Use of lipidosis as critical effect for establishing the HBGV +
(a): + = uncertainty with potential to cause overestimation of exposure/risk;  = uncertainty with potential to cause
underestimation of exposure/risk.
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• The percentage of left-censored data reported (results below limit of detection and/or limit of
quantiﬁcation) was high (72%). The highest number of reported samples corresponded to the
food group ‘Animal and vegetable fats and oils’ (~ 60%) and in particular to ‘Rapeseed oil’
(n = 5,832). Other food groups that were well represented were ‘Starchy roots and tubers’
(n = 1,223), ‘Grains and grain-based products’ (n = 982) and ‘Food for infants and small
children’ (n = 810).
• Mean values reported in rapeseed oil were 630/1,900 mg/kg (LB/UB) with more than 90%
being left-censored data.
• The presence of erucic acid in ‘Fine bakery wares’ indicates the use of high erucic acid oil in
their preparation. For ‘Pastries and cakes’, erucic acid was quantiﬁed in half of the samples
(mean 240/290 mg/kg (LB/UB)), and for ‘Biscuits’, in 25% of the samples (mean 300/400 mg/kg
(LB/UB)).
• The highest mean values were reported for ‘Infant formulae, powder’ (220/286 mg/kg (LB/UB)
and the lowest for ‘Ready-to-eat meal for infants and young children’ (77/86 mg/kg, (LB/UB)).
• Only 275 feed samples were available to estimate animal dietary exposure to erucic acid, most
of the samples were collected in the European Union between 2003 and 2015.
• Most of the feed samples referred to ‘Rapeseed oil’ (n = 193). The erucic acid content of only
28 samples of rapeseed expeller was provided, and no data for rapeseed meal, which is the
more commonly used feed. The highest average levels of erucic acid were reported for
‘Rapeseed oil’ (1,300/4,200 mg/kg (LB/UB)).
• The highest human chronic dietary exposure was estimated in the youngest population. For
the mean dietary exposure, the highest estimate at the LB corresponded to the age classes
‘Infants’ and ‘Toddlers’ with a maximum value of 2.8 mg/kg bw per day, while at the UB the
maximum estimate was observed in the age class ‘Toddlers’ (4.4 mg/kg bw per day). In
the highly exposed population (95th percentile), the highest estimates were in ‘Infants’
(5.8/7.4 mg/kg bw per day (LB/UB)).
• Overall, the food group ‘Fine bakery wares’, more precisely ‘Pastries and cakes’ and ‘Biscuits
(cookies)’ was the main contributor of dietary exposure to erucic acid. At the middle bound
(MB), the contribution of ‘Fine bakery wares’ in ‘Toddlers’ represented up to 39% of the total
exposure (median = 21%) and in ‘Other children’ contributed up to 48% to the total exposure
(median = 28%).
• Since the levels of erucic acid in ‘Fine bakery wares’ were not that high (~ 200/400 mg/kg
(LB/UB)), its relevant contribution is mainly driven by the high consumption of this
heterogeneous food category (e.g. croissants, doughnuts, cakes, mufﬁns, wafﬂes, biscuits,
cookies, etc.).
• In the age class ‘Infants’, ‘Food for infants and small children’ (FoodEx level 1) was the main
contributor to the exposure. The contribution of the food group ‘Ready-to-eat meal for infants
and young children’ reached 54% at the MB scenario (range 20–54%) among the dietary
surveys for ‘Infants’.
• Speciﬁc exposure scenarios (consumers only) were used to estimate the potential exposure via
the consumption of ‘Composite foods’ and ‘Custard’. Both maximum mean exposure (UB) and
maximum 95th percentile dietary exposure (UB) via the consumption of prepared pasta alone
were around sixfold higher than the maximum exposure estimates in ‘Toddlers’ and ‘Adults’
considering the whole diet.
• Exposures to erucic acid by farmed livestock were estimated using typical feed intakes and
body weights, and feed industry guidelines for the maximum inclusion rates of rapeseed meal
and oil in livestock diets. Therefore, mean levels of exposure calculated in this opinion
represent worst-case scenarios. However, insufﬁcient data on levels of erucic acid in rapeseed
meal or cake were available to allow P95 estimates of exposure to be made. In the category
‘Ruminants and horses’, the highest exposure was for lactating goats (5.0/7.5 mg/kg bw per
day (LB/UB)).
• For pigs and poultry, the highest exposure was for fattening chickens (9.4/12 mg/kg bw per
day (LB/UB)).
• Since rapeseed oil or meals are not commonly included in diets for cats and dogs, no
estimates of exposure have been made for these animals.
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4.2. Hazard identiﬁcation and characterisation
4.2.1. Toxicokinetics
• Erucic acid is well absorbed from the gastrointestinal tract to an extent varying between 60%
and 100%, depending on the species.
• Erucic acid is distributed to all organs; however, there is little distribution into the brain.
• Mitochondrial b-oxidation of erucic acid is poor in rats and pigs. Human heart mitochondria
appear to also have low activity for erucic acid.
• Little is known regarding the excretion of erucic acid.
• There is evidence that erucic acid in the feed is transferred to products of animal origin and a
dose-related increase in erucic acid in food of animal origin has been shown.
• In ruminants, erucic acid is also partially hydrogenated or isomerised in the rumen.
4.2.2. Toxicity in experimental animals
• The heart is the principal target organ for toxic effects following short-term or long-term
exposure of rats, pigs, monkeys, rabbits and gerbils to diets with oils containing erucic acid.
• The most common and sensitive effect observed in all species is myocardial lipidosis. This
effect is reversible and transient during prolonged exposure. Myocardial lipidosis has been
reported to reduce the contractile force of the heart muscle. The manifestation of cardiac
lipidosis varies among species.
• The overall NOAEL for lipidosis was 0.7 g/kg bw per day in a 7-day feeding study in young rats
and in a 2-week feeding study in newborn piglets.
• Feeding rats with high erucic acid doses for 4 or more weeks is associated with the occurrence
of myocardial necrosis and ﬁbrosis. Factors other than, or in addition to, erucic acid are likely
to be responsible for the increased incidence of these lesions, e.g. fatty acid imbalance.
Therefore, necrosis was not considered a suitable endpoint for the risk assessment. A causal
link between myocardial lipidosis and myocardial lesions has not been established.
• Because of the lack of adequate studies, no conclusions can be drawn on the genotoxicity and
carcinogenicity of erucic acid.
• No major adverse reproductive and developmental effects were associated with feeding female
rats, mice and hamsters with erucic acid-containing diets prior to mating and during
pregnancy.
4.2.3. Observations in humans
• A higher level of 22:1 in plasma phospholipids has been associated with higher incidence of
congestive heart failure in two independent cohorts whereas higher circulating levels of erucic
acid in erythrocytes have been associated with lower incidence of coronary heart disease.
• Two studies on the possible association between cancer and erucic acid exposure were
identiﬁed but no conclusion can be drawn due to the intrinsic limitations or lack of speciﬁcity of
the outcome.
• The therapeutic use of erucic acid results in haematological effects, most notably
thrombocytopenia and morphological alterations of thrombocytes, at doses of about 0.1 g/kg
bw per day.
• Erucic acid induced lipidosis has not been described in humans.
4.2.4. Mode of action
• A high intake of erucic acid leads to lipidosis in pigs and rats, particularly in the heart, due to
the poor b-oxidation of erucic acid in mitochondria.
• Cardiac lipidosis is transient (reversible), even after prolonged intake of erucic acid because of
the induction of peroxisomal degradation of erucic acid.
4.2.5. Adverse effect in livestock
• A reduction in feed intake and milk yield by dairy cows was reported at an intake of 0.4 g
erucic acid/kg bw per day from rapeseed meal. However, the possible role of glucosinolates or
other antinutritional factors in the meal could not be ruled out.
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• For pigs, the CONTAM Panel identiﬁed a NOAEL of 700 mg/kg bw per day for myocardial
lipidosis.
• Feeding poultry with diets containing HEAR oil resulted in growth retardation and cardiac
lipidosis. High doses of erucic acid also increased the incidence and severity of cardiac lesions
(similar to those observed in the rat). In addition, hydropericardium, effects on the liver and
skeletal muscles were induced in several species fed diets containing high doses of erucic acid.
The CONTAM Panel identiﬁed a LOAEL of 0.02 g/kg bw per day for liver toxicity in poultry.
• Studies in which poultry were fed diets supplemented with oils and meals derived from HEAR
cultivars clearly demonstrated adverse effects on production-related factors. However, as for
other livestock, the possible effects of other dietary constituents or characteristics on feed
intake, growth rate and egg production cannot be excluded.
• No conclusion regarding the adverse effects in ﬁsh, rabbits and horses could be drawn due to
the limited studies available.
• No studies on adverse effects in companion animals were identiﬁed.
4.2.6. Considerations of critical effects, dose–response modelling and possibilities
for derivation of a health-based guidance value
• An acute reference dose was not established because of the lack of endpoints indicative of
acute toxicity on target organs.
• Myocardial lipidosis, as reported in rats and pigs following feeding with HEAR oils, was selected
as critical effect for establishing a tolerable daily intake (TDI) for erucic acid.
• Non-cardiac effects, such as changes in the liver, kidneys, skeletal muscle, adrenals and testis
weight, have also been reported in rats and haematological and liver alterations in newborn
piglets. In all cases, these effects are observed at somewhat higher doses than those leading
to cardiac lipidosis in the same species.
• Since there are no adequate data from human studies for dose–response assessment, the
CONTAM Panel considered the data from studies on experimental animals to identify reference
points.
• The CONTAM Panel selected the overall NOAEL for lipidosis of 0.7 g/kg bw per day, observed
in a 7-day feeding study in young rats and in a 2-week feeding study in newborn piglets, as
reference point for the risk assessment.
• Based on this NOAEL, the CONTAM Panel established a TDI of 7 mg/kg bw for erucic acid
using the default uncertainty factor of 100 to account for intra- and interspecies differences.
• The CONTAM Panel noted that this TDI is well below the erucic acid dose of 100 mg/kg bw per
day causing haematological effects in ALD patients treated with Lorenzo’s oil.
4.3. Risk characterisation
4.3.1. Human health risk characterisation
• Mean human dietary exposure to erucic acid across dietary surveys and age groups ranges
from 0.3 (minimum LB) to 4.4 mg/kg bw per day (maximum UB) across dietary surveys and
age groups, which is below the TDI of 7 mg/kg bw per day.
• The 95th percentile dietary exposure range from 0.7 (minimum LB) to 7.4 mg/kg bw per day
(maximum UB) across dietary surveys and age groups, with the highest exposure in infants
and other children. The upper range being at the level of the TDI. This may indicate a risk for
young individuals with high erucic acid exposure.
4.3.2. Animal health risk characterisation
• For ruminants, no NOAEL could be identiﬁed. The dietary exposure of dairy cattle is well below
the dose at which no effect is observed on milk yield. However, the risk of other adverse
effects or for other ruminants could not be assessed.
• The dietary exposure of pigs is well below the NOAEL for myocardial lipidosis of 700 mg/kg bw
per day.
• For poultry, a LOAEL of 20 mg/kg bw per day was identiﬁed for liver toxicity, which is about
double the upper exposure range (12 mg/kg bw per day). The small margin between the
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LOAEL and the estimated exposure may indicate a health risk for poultry where maximum
inclusion rates are applied.
• No NOAEL/LOAEL could be identiﬁed for horses, ﬁsh and rabbits, and therefore, the risk of
erucic acid exposure could not be assessed for these species. However, the CONTAM
Panel noted that the exposure of horses (0.95/1.5 mg/kg bw per day (LB/UB)) and rabbits
(6.4/13 mg/kg bw per day (LB/UB)) is well below the NOAEL of 700 mg/kg bw per day for
pigs.
• The dietary exposure of cats and dogs to erucic acid is considered to be negligible and no risk
characterisation has been undertaken.
5. Recommendations
• To generate more analytical data on the occurrence of erucic acid in relevant food and feed
commodities using sensitive and speciﬁc methods. Special attention should be paid to
processed foods such as ‘Fine bakery wares’, ‘Food for infants and small children’ and
‘Composite foods’.
• There should be more information on the levels in animal-derived products (meat, milk and
eggs) resulting from the transfer of erucic acid from animal feed.
• There is a need for a repeated-dose toxicity study in newborn rats or pigs with pure erucic
acid in order to clarify the potential confounding effects of other fatty acids present in the oil
and to provide information regarding the dose–response relationship.
• Studies should be conducted on species differences in the cardiac and hepatic metabolism of
erucic acid.
• Further studies are required to determine reference points for target livestock animals and ﬁsh.
Documentation provided to EFSA
1) Henkel KGaA 1981a. Unpublished data, Archive-No. Dr. Kastner 945.
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112-86-7. 94 p.
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Abbreviations
alb albumin
ALD adrenoleukodystrophy
AOAC Association of Ofﬁcial Analytical Chemists
AOCS American Oil Chemists’ Society
AP alkaline phosphatase
ARIC Atherosclerosis Risk in Communities Study
ATP adenosine triphosphate
ATR-FTIR Attenuated total reﬂection-Fourier transform infrared
BIPEA International Bureau for Analytical Studies
bw body weight
CAD coronary artery disease
Car carnitine
CAS Chemical Abstracts Service
CHD coronary heart disease
CHF congestive heart failure
CHS Cardiovascular Health Study
Chylo chylomicron
CoA coenzyme A
CONTAM EFSA Panel on Contaminants in the Food Chain
DATA EFSA Evidence Management Unit
DHA docosahexaenoic acid
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DM dry matter
EA erucic acid
ECG electrocardiogram
ELOV1 elongation of very long-chain fatty acid
EPA eicosapentaenoic acid
exp experiment
f.w. fresh weight
FADH2 ﬂavin adenine dinucleotide
FAME fatty acid methyl esters
FEDIAF European Pet Food Industry Federation
FEDIOL European Vegetable Oil and Proteinmeal Industry
FEFAC European Feed Manufacturers’ Federation
FERA Food and Environment Research Agency
FID ﬂame ionisation detectors
FSA Food Standards Agency
FSANZ Food Standards Australia and New Zealand
FT-NIR Fourier-transform near-infrared
GC gas chromatography
GLA c-linolenic acid
GTE glycerol trierucate
H2O2 hydrogen peroxide
Hb haemoglobin
HBGV health-based guidance value
HDL High density lipoprotein
HEAR high erucic acid rapeseed
HPLC high-performance liquid chromatography
i.p. intraperitoneal
IPCS International Programme on Chemical Safety
IUPAC International Union of Pure and Applied Chemistry
LB lower bound
LC left-censored
LD50 lethal dose, median
LCMUFA long-chain monounsaturated fatty acids
LCO lard and corn oil
LEAR low erucic acid rapeseed
LOAEL lowest observed adverse effect level
LOD limit of detection
LOQ limit of quantiﬁcation
LPL lipoprotein lipase
Max maximum
MB middle bound
MDA malonaldehyde
Min minimum
ML maximum level
MS mass spectrometry
MUFA monounsaturated fatty acids
N Number
n.r. Not reported
NADH nicotinamide adenine dinucleotide
NHANES National Health and Nutrition Examination Survey
NIR near-infrared
NIST National Institute of Standards and Technology
NMR nuclear magnetic resonance
NOAEL no observed adverse effect level
NOEL no observed effect level
OECD Organization for Economic Co-operation and Development
P/O phosphate oxygen ratio
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PCV packed cell volume
PHFO partially hydrogenated ﬁsh oil
PHHO partially hydrogenated herring oil
PL phospholipid
PPAR proliferator-activated receptor
pTDI provisional tolerable daily intake
PUFA polyunsaturated fatty acids
RASFF Rapid Alert System for Food and Feed
RBC red blood cell
RES reticuloendothelial system
RFO reﬁned ﬁsh oil
RSO rapeseed oil
SBO soybean oil
SCF Scientiﬁc Committee on Food
SGOT serum glutamic oxaloacetic transaminase
SNE Specialised Nutrition Europe
SOP standard operational procedure
SUN sunﬂower seed oil
TDI tolerable daily intake
TG triacylglycerol
UB upper bound
VLCFA very long-chain fatty acid
VLDL very low-density lipoproteins
WG Working group
WHO World Health Organization
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Appendix A – Erucic acid content in rapeseed cultivars
Table A.1: Erucic acid content (% total fatty acids) in rapeseed cultivars marketed in France, from
plants grown in multilocation experiments conducted in three different geographical
areas of the country from 2005 to 2015 (Terres Inovia/Terres Univia, 2015, E-mail
Communication, 17 August 2015)
Year Location
Number of
cultivars
Average erucic acid
concentration (%)
2005 Atlantic Border 13 0.10
Centre 15 0.10
East 14 < 0.10
2006 Atlantic Border 11 < 0.10
Centre 16 0.30
East 11 0.10
2007 Atlantic Border 14 0.10
Centre 14 0.10
East 14 0.10
2008 Atlantic Border 33 < 0.10
Centre 30 < 0.10
East 16 < 0.10
2009 Atlantic Border 37 0.11
Centre 35 0.10
East 39 0.23
2010 Atlantic Border 39 0.10
Centre 40 –
East 40 0.10
2011 Atlantic Border 32 < 0.10
Centre 32 0.49
East 33 0.11
2012 Atlantic Border 18 < 0.10
Centre 21 < 0.10
East 18 < 0.10
2013 Atlantic Border 17 0.20
Centre 17 0.10
East 16 0.10
2014 Atlantic Border 15 < 0.10
Centre 15 < 0.10
East 15 0.25
2015 Atlantic Border 24 0.10
Centre 27 0.10
East 24 0.10
Erucic acid in feed and food
www.efsa.europa.eu/efsajournal 93 EFSA Journal 2016;14(11):4593
Appendix B – Internationally recognised protocols for fatty acid analysis
based on GC of FAMEs
There is no optimal protocol for analysis of fatty acids in biological and food products. Several
associations and institutions have proposed protocols that can be used for analysis of the fatty acid
composition of the oil in biological samples and food products. A list of relevant methods is given below:
• Association Francaise de Normalisation (AFNOR): NF EN ISO 12966. Corps gras d’origines
animale et vegetale - Chromatographie en phase gazeuse des esters methyliques d’acides gras
• American Oil chemists’ Society (AOCS): AOCS Ofﬁcial Method Ce 1h-05(09). Determination of
cis-, trans-, Saturated, Monounsaturated and Polyunsaturated Fatty Acids in Vegetable or
Non-Ruminant Animal Oils and Fats by Capillary GLC
• American Oil chemists’ Society (AOCS): AOCS Ofﬁcial Method Ce 1i-07(09). Determination of
Saturated, cis-Monounsaturated, and cis-Polyunsaturated Fatty Acids in Marine and Other Oils
Containing Long Chain Polyunsaturated Fatty Acids (PUFAs) by Capillary GLC
• American Oil chemists’ Society (AOCS): AOCS Ofﬁcial Method Ce 1j-07(15). Determination of
cis-, trans-, Saturated, Monounsaturated, and Polyunsaturated Fatty Acids in Extracted Fats by
Capillary GLC
• American Oil chemists’ Society (AOCS): AOCS Ofﬁcial Method Ce 1b-89(09). Fatty Acid
Composition of Marine Oils by GLC
• AOAC International: Method 991.39. Fatty acids in encapsulated ﬁsh oils and ﬁsh oil methyl
and ethyl esters
• AOAC International: Method AOAC (2012) 996.06. Fat (total, saturated, and unsaturated) in
foods
• International Organization for Standardization (ISO): ISO 12966-1:2014. Animal and vegetable
fats and oils – Gas chromatography of fatty acid methyl esters - Part 1: Guidelines on modern
gas chromatography of fatty acid methyl esters
• International Organization for Standardization (ISO): ISO 12966-2:2011. Animal and vegetable
fats and oils – Gas chromatography of fatty acid methyl esters - Part 2: Preparation of methyl
esters of fatty acids
• International Organization for Standardization (ISO): ISO 12966-3:2009. Animal and vegetable
fats and oils – Gas chromatography of fatty acid methyl esters – Part 3: Preparation of methyl
esters using trimethylsulfonium hydroxide (TMSH)
• International Organization for Standardization (ISO): ISO 12966-4:2015. Animal and vegetable
fats and oils – Gas chromatography of fatty acid methyl esters – Part 4: Determination by
capillary gas chromatography
• International Organization for Standardization (ISO): ISO 6800:1997. Animal and vegetable
fats and oils – Determination of the composition of fatty acids in the 2-position of the
triglyceride molecules
• International Organization for Standardization (ISO): ISO/TS 17764-1:2002. Animal feeding
stuffs – Determination of the content of fatty acids – Part 1: Preparation of methyl esters
• International Organization for Standardization (ISO): ISO/TS 17764-2:2002. Animal feeding
stuffs – Determination of the content of fatty acids – Part 2: Gas chromatographic method
• National Standard of the People’s Republic of China: GB/T 17376-2008. Animal and vegetable
fats and oils - Preparation of methyl esters of fatty acids
• National Standard of the People’s Republic of China: GB/T 17377-2008. Animal and vegetable
fats and oils - Analysis by gas chromatography of methyl esters of fatty acids
• National Standard of the People’s Republic of China: GB/T 24894-2010. Animal and vegetable
fats and oils - Determination of the Composition of fatty acids in the 2-position of the
triglyceride molecules
• National Standard of the People’s Republic of China: GB 5413.27-2010. Determination of fatty
acids in foods for infants and young children, milk and milk products
• National Standard of the People’s Republic of China: GB/T 21514-2008. Determination of the
content of fatty acids in feeds
• Deutsche Gesellschaft f€ur Fettwissenschaft e.V. (DGF): C-VI 10 (13). Gaschromatographie der
Fetts€auremethylester. Hinweise und Erl€auterungen zu den Methoden
• Deutsche Gesellschaft f€ur Fettwissenschaft e.V. (DGF): C-VI 10a (00). Gaschromatographie:
Analyse der Fetts€auren und Fetts€aureverteilung
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Table C.2: Food samples excluded from the ﬁnal dataset used to estimate dietary exposure and the
criteria used for exclusion
Number of
samples excluded
Criteria for exclusion
129 Samples identiﬁed as duplicates
423 Reported as suspect samples (not random sampling)
1,729 Samples of coconut oil, almond oil, corn oil, grape seed oil, linseed oil, olive oil, palm oil,
soybean oil, sunﬂower oil, safﬂower oil, walnut oil, wheat germ oil. Erucic acid does not
occur naturally in these oils
415 Samples of unspeciﬁed oil
998 Samples for which analytical results were reported on fat basis without information on the
fat content, and the imputation of fat values from similar samples was not possible
178 Samples eliminated due to the application of LOQ cut-offs on key food commodities (Food
for infants and Grain products)
63 Samples of composite food. They were excluded because the EFSA Comprehensive
database does not differentiate between composite foods prepared at home or bought in
retails/consumed outside, and this could have an important inﬂuence on the levels of
erucic acid present (based on the type of oil used). Additionally, the level of disaggregation
of the composite food varies from one dietary survey to another what could bias the
exposure estimations
They were excluded from the dataset used to estimate exposure but ad-hoc scenarios
were built for these food commodities to estimate the exposure to erucic acid from the
consumption of diverse types of composite food
6 Samples recodiﬁed as Feed
8 Samples of linseeds. Erucic acid does not occur naturally in linseed
1 Sample of unspeciﬁed ﬂour. No reason to ﬁnd erucic acid in this food commodity
1 Sample of boiled potatoes. No reason to ﬁnd erucic acid in this food commodity
1 Sample of plain yoghurt. No reason to ﬁnd erucic acid in this food commodity
1 Sample of mackerel with levels above 10% erucic acid (100 g/kg). The reported
concentration most probably refers to the concentration of erucic acid in the oil or
misidentiﬁcation with cetoleic acid. No answer received from the data provider
1 Sample of walnut. No reason to ﬁnd erucic acid in this food commodity
1 Sample of rice. No reason to ﬁnd erucic acid in this food commodity
2 Samples of custard as no food commodities containing erucic acid is usually used in the
elaboration of this dessert
EFSA: European Food Safety Authority; LOQ: limit of quantiﬁcation.
Erucic acid in feed and food
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Table C.4: Samples of composite food excluded from ﬁnal dataset
Food groups(a) Number of samples LB/UB
Mean concentration
(mg/kg)
Composite food (including frozen products),
unspeciﬁed
7 LB 703
UB 708
Cereal-based dishes, unspeciﬁed 2 LB 0
UB 94
Pasta, cooked 3 LB 2,667
UB 2,667
Rice-based meals 1 LB 67,300
UB 67,300
Meat-based meals 18 LB 429
UB 442
Fish and seafood based meals 1 LB 5,000
UB 5,000
Ready-to-eat soups 28 LB 24
UB 77
Prepared salads 3 LB 2,141
UB 2,141
LB: lower bound; UB: upper bound.
(a): The food groups in bold refer to FoodEx level 2 and the other food groups to FoodEx level 3.
Table C.5: Erucic acid occurrence values in different food commodities (mg/kg), grouped at
different FoodEx levels (FoodEx link) depending on their occurrence values before
estimating dietary exposure
Mean concentration
(mg/kg)
95th percentile
concentration
(mg/kg)FoodEx 1
level
FoodEx link(a) N % LC
LB MB UB LB MB UB
Grains and
grain-based
products-
Grain milling products,
unspeciﬁed
5 100 0 38 76 0 150 300
Bread and rolls 43 56 42 52 63 – – –
Pasta (Raw) 2 50 36 38 41 – – –
Breakfast cereals 30 50 73 79 84 – – –
Fine bakery wares,
unspeciﬁed
12 42 650 671 691 – – –
Pastries and cakes 733 50 237 263 290 1,100 1,100 1,100
Biscuits (cookies) 157 76 272 332 393 1,800 1,800 1,800
Vegetables
and vegetable
products
(including
fungi)
Brassica vegetables 1 100 0 166 331 – – –
Mustard seedling
(Sinapis alba)
1 0 179,000 179,000 179,000 – – –
Lamb’s lettuce
(Valerianella locusta)
1 100 0 0 1 – – –
Cocoa beans and cocoa
products
27 100 0 88 176 – – –
Vegetable products,
unspeciﬁed
1 100 0 7 14 – – –
Erucic acid in feed and food
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Mean concentration
(mg/kg)
95th percentile
concentration
(mg/kg)FoodEx 1
level
FoodEx link(a) N % LC
LB MB UB LB MB UB
Starchy roots
and tubers
Potatoes and potatoes
products, unspeciﬁed
34 53 320 331 342 – – –
French fries 1,178 38 283 292 300 859 859 859
Potato fried 4 25 170 174 178 – – –
Potato croquettes 5 60 92 122 151 – – –
Potato boiled 2 100 0 7 14 – – –
Legumes,
nuts and
oilseeds
Soybeans (Glycine max) 2 100 0 32 63 – – –
Peanut (Arachis
hypogea)
28 11 1,703 1,709 1,716 – – –
Tree nuts 108 100 0 57 113 0 100 200
Oilseeds, unspeciﬁed 68 100 0 56 113 – – –
Rape seed (Brassica
napus)
2 50 1,500 2,750 4,000 – – –
Poppy seed (Papaver
somniferum)
2 100 0 80 160 – – –
Sesame seed (Sesamum
indicum syn. S. orientale)
6 100 0 50 101 – – –
Sunﬂower seed
(Helianthus annuus)
8 100 0 50 99 – – –
Pumpkin seeds
(Cucurbita pepo var.
oleifera)
1 100 0 47 93 – – –
Fruit and fruit
products
Stone fruits 1 100 0 50 100 – – –
Miscellaneous fruits 2 100 0 14 29 – – –
Dried fruits 1 100 0 500 1,000 – – –
Meat and
meat products
(including
edible offal)
Livestock meat 2 100 0 500 1,000 – – –
Textured soy protein 11 0 934 934 934 – – –
Fish and other
seafood
(including
amphibians,
reptiles, snails
and insects)
Fish meat, unspeciﬁed 1 0 76 76 76 – – –
Herring (Clupea) 3 0 3,560 3,560 3,560 – – –
Anchovy (Engraulis) 1 100 0 30 60 – – –
Sardine and pilchard
(Sardina)
14 29 858 933 1,009 – – –
Salmon and trout (Salmo
spp.)
9 0 992 992 992 – – –
Mackeral (Scomber) 1 0 370 370 370 – – –
Tuna (Thunnus) 18 94 7 40 73 – – –
Other ﬁsh offal (not ﬁsh
roe)
1 0 6,768 6,768 6,768 – – –
Octopus 2 100 0 6 11 – – –
Erucic acid in feed and food
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Mean concentration
(mg/kg)
95th percentile
concentration
(mg/kg)FoodEx 1
level
FoodEx link(a) N % LC
LB MB UB LB MB UB
Milk and dairy
products
Milk and dairy products,
unspeciﬁed
17 53 125 149 173 – – –
Cow milk 26 100 0 113 225 – – –
Flavoured milk 1 100 0 1 2 – – –
Concentrated milk 21 100 0 136 271 – – –
Whey and whey products 2 100 0 113 225 – – –
Cream and cream
products
222 100 1 146 290 0 150 300
Fermented milk products,
unspeciﬁed
4 50 363 368 373 – – –
Cheese, unspeciﬁed 21 81 88 158 229 – – –
Quark 6 100 0 138 275 – – –
Cheese, processed,
sliceable
43 70 170 222 273 – – –
Cheese, processed
spreadable
14 86 115 243 371 – – –
Cheese, processed
cheese, plain
5 100 0 67 134 – – –
Cheese, Appenzeller 3 100 0 181 362 – – –
Cheese, Edam 9 100 0 142 283 – – –
Cheese, Blue Castello 1 100 0 150 300 – – –
Cheese, Camembert 2 100 0 150 300 – – –
Cheese, Cheddar 1 100 0 150 300 – – –
Cheese, Emmental 7 100 0 167 335 – – –
Cheese, Maasdam 3 100 0 150 300 – – –
Cheese, Mozzarella 4 100 0 150 300 – – –
Cheese, Ricotta 1 100 0 150 300 – – –
Cheese, Smoked Gouda 1 100 0 75 150 – – –
Cheese, Feta 35 66 212 276 339 – – –
Cheese, Gouda 14 79 141 252 363 – – –
Cheese, Trappist 23 96 57 193 330 – – –
Milk and milk product
imitates
18 72 114 209 304 – – –
Eggs and egg
products
Eggs and egg products,
unspeciﬁed
3 100 0 11 21 – – –
Eggs, fresh 44 100 0 34 68 – – –
Eggs, powder 12 100 0 150 300 – – –
Erucic acid in feed and food
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Mean concentration
(mg/kg)
95th percentile
concentration
(mg/kg)FoodEx 1
level
FoodEx link(a) N % LC
LB MB UB LB MB UB
Sugar and
confectionary
Sugar and confectionary,
unspeciﬁed
12 75 198 228 259 – – –
Chocolate (Cocoa)
products
39 100 0 101 201 – – –
Bitter chocolate 29 100 0 134 269 – – –
Chocolate coated
confectionery
17 100 0 133 267 – – –
Filled chocolate 13 100 0 150 300 – – –
White chocolate 9 100 0 201 401 – – –
Chocolate substitutes 8 100 0 131 263 – – –
Chocolate, cream 32 63 173 213 253 – – –
Milk chocolate 150 99 7 128 250 0 150 300
Pralines 52 98 2 101 201 – – –
Confectionery (non-
chocolate)
9 100 0 196 392 – – –
Animal and
vegetable fats
and oils
Animal and vegetable
fats and oils, unspeciﬁed
2 50 2,533 2,783 3,033 – – –
Animal fat, unspeciﬁed 8 100 0 448 896 – – –
Duck fat 1 100 0 500 1,000 – – –
Tallow 4 100 0 500 1,000 – – –
Butter 67 88 38 204 370 200 413 826
Butter oil 3 67 198 298 398 – – –
Pork lard (Schmaltz) 30 93 50 401 751 – – -
Fish oil, unspeciﬁed 3 0 7,000 7,000 7,000 – – –
Cod liver oil 1 0 14,000 14,000 14,000 – – –
Vegetable fat,
unspeciﬁed
36 56 492 600 708 – – –
Peanuts butter 10 70 203 536 869 – – –
Coconut fat 14 100 0 307 614 – – –
Palm fat 13 100 0 475 950 – – –
Cocoa butter 1 100 0 150 300 – – –
Vegetable oil unspeciﬁed 415 67 5,026 5,325 5,623 6,600 6,600 6,600
Oil, frying, blend 250 82 235 655 1,075 1,000 1,000 1,000
Peanut oil 96 29 1,884 2,014 2,144 5,500 5,500 5,500
Rapeseed oil 5,832 89 633 1,249 1,864 5,000 5,000 5,000
Fats of mixed origin 181 40 985 1,031 1,078 3,800 3,800 3,800
Margarine and similar
products, unspeciﬁed
343 40 663 742 820 1,979 1,979 1,979
Margarine, normal fat 29 31 877 922 968 – – –
Margarine, low fat 42 19 662 670 679 – – –
Margarine with other
ingredients
69 13 1,422 1,438 1,454 3,900 3,900 3,900
Fat emulsions 14 36 805 867 929 – – –
Alcoholic
beverages
Coffee liqueur 3 67 3 6 9 – – –
Egg liqueur 7 100 0 2 5 – – –
Cream liqueur 8 100 0 12 24 – – –
Erucic acid in feed and food
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Mean concentration
(mg/kg)
95th percentile
concentration
(mg/kg)FoodEx 1
level
FoodEx link(a) N % LC
LB MB UB LB MB UB
Drinking
water
Drinking water 4 100 0 500 1,000 – – –
Herbs, spices
and
condiments
Herbs, spices and
condiments, unspeciﬁed
5 20 627 636 645 – – –
Spices undeﬁned 2 100 0 53 107 – – –
Paprika powder 1 0 2,000 2,000 2,000 – – –
Chilli powder 1 100 0 67 133 – – –
Herb and spice mixtures 2 100 0 1,000 2,000 – – –
Mixed spices 3 67 62,000 62,177 62,355 – – –
Seasoning or extracts,
unspeciﬁed
1 100 0 47 94 – – –
Stock cubes (bouillon
cube)
2 100 0 89 177 – – –
Gravy instant granules 25 96 38 140 242 – – –
Vegetable extracts 2 100 0 7 13 – – –
Condiment unspeciﬁed 6 67 1,881 2,059 2,236 – – –
Mustard, sweet 8 0 10,433 10,433 10,433 – – –
Mustard, mild 9 11 14,081 14,082 14,083 – – –
Mustard, hot 51 0 19,712 19,712 19,712 – – –
Horseradish sauce 1 0 656 656 656 – – –
Curry sauce 1 100 0 29 58 – – –
Tartar sauce 2 50 1,300 1,500 1,700 – – –
Dressing 168 5 2,266 2,269 2,272 5,600 5,600 5,600
Savoury sauces,
unspeciﬁed
16 31 12 33 53 – – –
White sauce (Bechamel
sauce, Cheese sauce)
2 50 53 87 120 – – –
Emulsion sauce
(Hollandaise sauce)
13 77 243 332 421 – – –
Oil-based sauce (Pesto,
Aioli sauce)
16 94 4 74 145 – – –
Vegetable sauce 3 100 0 14 29 – – –
Flavourings or essences 1 100 0 150 300 – – –
Glaze 1 100 0 97 194 – – –
Food for
infants and
small children
Food for infants and
small children,
unspeciﬁed
79 51 168 262 356 790 790 1,000
Infant formulae, powder 218 32 220 253 286 552 552 553
Follow-on formulae,
powder
191 51 142 187 232 430 483 483
Cereal-based food for
infants and young
children
166 44 128 145 161 620 620 620
Ready-to-eat meal for
infants and young
children
156 31 77 81 86 281 281 281
Erucic acid in feed and food
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Mean concentration
(mg/kg)
95th percentile
concentration
(mg/kg)FoodEx 1
level
FoodEx link(a) N % LC
LB MB UB LB MB UB
Products for
special
nutritional
use
Products for special
nutritional use,
unspeciﬁed
2 100 0 500 1,000 – – –
Food for weight
reduction
23 65 63 79 95 – – –
Dietary supplements,
unspeciﬁed
22 32 12,150 12,286 12,423 – – –
Mineral supplements 1 100 0 17 35 – – –
Protein and amino acids
supplements
1 100 0 150 300 – – –
Supplements containing
special fatty acids (e.g.
omega-3, essential fatty
acids)
26 12 4,237 4,280 4,322 – – –
Plant extract formula 1 0 4 4 4 – – –
Algae formula (e.g.
Spirulina, Chlorella)
7 14 1,014 1,021 1,029 – – –
Pollen-based supplement 1 0 328 328 328 – – –
Dietetic food for
diabetics (labelled as
such)
47 91 51 114 176 – – –
Medical food 75 31 650 706 762 2,000 2,000 2,000
Snacks,
desserts, and
other foods
Snack food, unspeciﬁed 12 100 0 34 68 – – –
Potato crisps 67 90 27 80 133 100 100 200
Pretzels 1 100 0 18 35 – – –
Ice and desserts,
unspeciﬁed
19 89 101 121 141 – – –
Ice cream, milk-based 325 96 1 33 65 0 92 164
Ice cream, not milk-
based
110 97 0 26 51 0 54 108
Starchy pudding 18 78 398 450 502 – – –
Sorbet 1 10 0 150 300 – – –
Other foods (foods which
cannot be included in
any other group)
3 67 308 367 426 – – –
LB: lower bound; LC: left-censored; MB: middle bound; N: number; UB: upper bound.
(a): This column explains how the different food commodities were grouped at different FoodEx levels depending on the
reported occurrence values: FoodEx Level 2 (non-italics), FoodEx level 3 (italics).
Erucic acid in feed and food
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Appendix D – Feed Intake and composition of diets used in estimating
animal exposure to erucic acid
Estimates of exposure require information on both the amount of feed consumed and levels of
erucic acid in the feed. This Appendix gives feed intakes (on a per day basis) for different categories of
farmed livestock and ﬁsh that have been assumed in this Scientiﬁc Opinion to estimate exposure to
erucic acid.
Both the amount of feed consumed and the composition of the diets vary considerably, both
between and within animal categories, within the European Union (EU). In this Opinion, the
composition of diets for each of the major farm livestock species are based on published guidelines on
nutrition and feeding (e.g. Carabano and Piquer, 1998; NRC 2007a,b; Leeson and Summers, 2008;
McDonald et al., 2011; EFSA FEEDAP Panel, 2012; OECD, 2013) and data on the EU manufacture of
compound feeds.51 They are therefore estimates of the Panel on Contaminants in the Food Chain
(CONTAM Panel), but are in agreement with common practice.
In estimating exposure, it has been assumed that erucic acid is only present in rapeseed meal and
rapeseed oil. The amounts of these feeds included in the diets of farmed and companion animals also
vary. In the absence of any European data on levels of rapeseed meal fed, the CONTAM Panel have
adopted the maximum levels recommended by a number of sources (Ewing, 1997; Cottrill et al., 2007;
Canola Council of Canada, 2015) for the different animal categories. Similarly for rapeseed oil, industry
recommendations for the maximum inclusion rates have been adopted. In practice, the amounts fed
are likely to be lower than recommended maxima; rapeseed oil is often part of a mix of vegetable oils,
with inclusion rates determined by the prices of the different oils. However, by adopting this approach
likely worst-case exposures have been calculated.
The levels of erucic acid in rapeseed meal and oil are given in Table 5 (Section 3.1.2.2). Based on
these, and estimates of feed intake given below, the lower bound (LB) and upper bound (UB)
exposure estimates of erucic acid were calculated for the farm livestock species, and are given in this
Appendix.
Information provided to EFSA by the European Pet Food Industry Federation (FEDIAF) indicated
that meal, rapeseed oil and meals and oils from other Brassicaceae crops are not common constituents
of cat and dog foods (FEDIAF, Personal communication by email, May 2016). Therefore, no exposure
assessments have been undertaken for these animals.
D.1. Feed intakes
D.1.1. Ruminants and horses
The diets of cattle, sheep and goats consist predominantly of forages supplemented mainly with
cereal grains and vegetable proteins and other by-products of food production as necessary. In some
situations, forages may represent the total diet.
For this scientiﬁc opinion, exposure has been estimated for a 650-kg dairy cow, with a milk yield of
40 kg/day (considered as a high milk yield), and where non-forage feeds account for 40% of the total
diet. For many beef cattle, forage will comprise the total ration, but where higher growth rates or
physiological status require it, additional non-forage feeds will be provided. The amount of feed
consumed varies considerably between systems, and depends on the breed and live weight of the
animal, the amount and quality of the feeds available and the intended rate of live weight gain and
body condition. In this opinion, exposure estimates are given for fattening beef cattle with live weights
of 400 kg and a daily live weight gain of 1.0 kg.
The diets of sheep and goats reared for meat production consist predominantly of forage, with
additional non-forage feeds given when high levels of live weight gain are required. Total daily dry
matter (DM) intakes can range from 1.9% to 3.8% of their body weight (Devendra and Burns, 1983),
of which forages typically account for 75% or more of total intake. Goats reared for meat production
and with a body weight > 10 kg are often fed green fodder ad libitum (AFRC, 1993) supplemented
with cereal grains (barley, oats or maize), cereal by-products and vegetable proteins (McDonald et al.,
2011).
For milking sheep and goats, compound feeding usually commences in late pregnancy and
continues into lactation. Due to physiological and metabolic differences, goats are able to consume
51 www.fefac.eu
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diets with higher proportions of non-forage feeds without adversely affecting feed intake or production
(Avondo et al., 2008), but the actual amounts fed depend on the quality of the forage available.
Non-lactating animals usually receive only forage feeds.
The live weights, feed intakes, the proportion of the daily ration that is non-forage feed and growth
rates/productivity for cattle, sheep, goats and horses used in this Scientiﬁc Opinion are given in
Table D.1.
D.1.2. Pigs, poultry and farmed ﬁsh
Exposure estimates for this Opinion have been made for piglets (20 kg bw), fattening pigs (100 kg
bw) and lactating sows (200 kg bw) using feed intakes proposed by EFSA (2009).
The amount of feed voluntarily consumed by poultry is largely determined by the size and age of
the bird and the production system (rearing, fattening or laying). Under ad libitum feeding, daily intake
increases as the birds get older, although relative to body weight it declines with age. For meat
producing and egg-laying birds, ad libitum feeding is widely practiced, but for breeding stock feed
intake is frequently restricted to maintain a steady body weight (Leeson and Summers, 2008).
Commercially reared species of farmed ﬁsh include Atlantic salmon, rainbow trout, sea bass, sea
bream, cod, halibut, tuna, eel and turbot. Traditionally, the principal raw materials used for the
manufacture of ﬁsh feeds in Europe have been ﬁshmeal and ﬁsh oils, and although alternative sources
of oil and protein are increasingly being used ﬁsh-derived feeds still remain the major ingredients.
Data for feed intake and live weight of pigs, poultry and farmed ﬁsh are from EFSA FEEDAP
Panel (2012) and of ducks from Leeson and Summers (2008) are used in this Scientiﬁc Opinion
(Table D.2).
Table D.1: Live weights, growth rate/productivity, dry matter intake for cattle, sheep, goats and
horses, and the proportions of the diet as non-forage
Live weight
(kg)
Growth rate or
productivity
Dry matter intake
(kg/day)
% diet as non-
forage feed
Reference
Dairy cows,
lactating
650 40 kg milk/day 20.7 40 AFRC (1993)
Fattening cattle:
beef (a)
400 1 kg/day 9.6 15 AFRC (1993)
Sheep: lactating 80 Feeding twin lambs 2.8 50 AFRC (1993)
Goats: milking(b) 60 6 kg milk/day 3.4 65 NRC (2007a)
Goats: fattening 40 0.2 kg/day 1.5 40 NRC (2007a)
Horses 450 Moderate activity 9.0 50 NRC (2007b)
(a): Housed castrate cattle, medium maturing breed.
(b): Months 2–3 of lactation.
Table D.2: Live weights and feed intake for pigs, poultry and ﬁsh
Live weight (kg) Feed intake (kg dry matter/day)
Pigs: piglets 20 1.0
Pigs: fattening pigs 100 3.0
Pigs: lactating sows 200 6.0
Poultry: broilers(a) 2 0.12
Poultry: laying hens 2 0.12
Turkeys: fattening turkeys 12 0.40
Ducks: fattening ducks 3 0.14
Salmonids 2 0.04
(a): Chickens for fattening.
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D.1.3. Rabbits
Commercial rabbit production takes place in at least 14 EU Member States, with the largest
producers being Italy, France and Spain. Rabbits are usually fed a pelleted diet of dried forages,
cereals and vegetable proteins supplemented with minerals, vitamins and trace elements. A daily
intake of 75 g/kg bw for a 2-kg rabbit is used in this Scientiﬁc Opinion to estimate exposure (derived
from Carabano and Piquer, 1998).
D.1.4. Farmed mink
For estimating exposure, the CONTAM Panel has assumed a live weight of 2.07 kg for a male mink
at pelting, and with a feed intake of 227 g/day (75 g DM) (NRC, 1982).
D.2. Diet composition and estimates of erucic acid concentration in
diets of farmed livestock and ﬁsh
Many livestock in the EU are fed proprietary commercial compound feeds and for some, particularly
non-ruminant animals, they are often the sole feed. However, insufﬁcient data have been provided on
levels of erucic acid in species-speciﬁc compound feeds, and therefore, it has been necessary to
estimate exposure using inclusion rates of rapeseed meal and rapeseed oil in the daily rations. These
data are given below.
D.2.1. Ruminants and horses
As described above, forages are major constituents of ruminant diets, but erucic acid has not been
reported in these feeds and it has therefore been assumed that they make no contribution to
exposure. For all categories of ruminants, rapeseed cakes/meals are extremely important sources of
protein, and inclusion levels of 25% or more in the non-forage part of the ration are not uncommon.
Vegetable oils are also frequently added to ruminant rations, although inclusion rates are normally
restricted to < 5% because of the potential adverse effects of the oils on rumen fermentation. Since
this normally consists of a blend of vegetable oils, an inclusion rate of 2% in the non-forage part of
the ration has been assumed. In sheep and goat rations, rapeseed meal should not exceed 20% of
their total non-forage ration (Ewing, 1997).
There has been relatively little research on optimum levels of rapeseed meal in diets for horses.
Sutton (1988) reported that up to 15% canola meal, the highest level tested, in recreational horse
diets had no adverse effect on feed intake, and this value has been used to assess exposure to erucic
acid from rapeseed meal.
Table D.3 gives assumed levels of rapeseed meal and rapeseed oil in the non-forage part of
ruminant and horse diets, but it should be noted that estimated mean LB and UB concentrations of
erucic acid refer to the whole diet, i.e. they take account of the relative proportions of forage and
non-forage feeds in the diet (as given in Table D.1).
Table D.3: Assumed inclusion rates of rapeseed meal and rapeseed oil in the non-forage part of
diets for ruminants and horses, and calculated mean lower bound and upper bound
concentrations of erucic acid in the total diet
Feed materials
Lactating dairy
cows
Fattening
beef cattle
Lactating
sheep
Dairy
goats
Fattening
goats
Horses
Rapeseed meal (%) 25 25 20 20 20 15
Rapeseed oil (%) 2 2 2 2 2 2
Estimated mean erucic acid concentration
Lower bound (lg/kg) 56.2 21.1 58.9 88.3 47.1 47.5
Upper bound (lg/kg) 80.0 30.0 88.4 132 70.7 76.7
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D.2.2. Pigs and poultry
Rapeseed meal may be fed at up to 5–10% for young pigs and to 15–20% for older pigs
(McDonald et al., 2011).
Rapeseed meal may be included in diets for broilers and laying hens, at levels of about 30% and
20%, respectively (Canola Council of Canada, 2015), but is not recommended for young birds.
Rapeseed oil may also be included in diets depending on its price relative to soybean and other
vegetable oils. Some feed producers prefer rapeseed oil because of its lower linoleic acid content and
also its non-genetically modiﬁed status, and rape oil will also potentially ﬁnd its way into fat blends. In
addition, whole (full-fat) rape seeds are now used as a key ingredient in broiler diets, at inclusion
levels of up to 8%.
For some time, rapeseed meal was not recommended as a feed for laying hens, and particularly
brown-shelled layers, because eggs tended to have a ﬁshy ﬂavour. It was found that these birds
produced lower levels of trimethylamine oxidase than white leghorn type birds and since the
trimethylamine was not metabolised it passed into the yolk, giving this taint. However, recent research
has identiﬁed the gene responsible for this and breeding programmes have now removed the defect
from most birds (Daun et al., 2011).
The assumed inclusion rates of rapeseed meal and rapeseed oil in diets of pigs and poultry,
together with the calculated mean LB and UB concentrations of erucic acid, are given in Table D.4.
D.2.3. Farmed rabbits, ﬁsh (salmonids) and mink
Although soybean meal has been the protein supplement of choice for rabbit producers, rapeseed
(Canola) meal may be used as a complete replacement (McNitt et al., 2013). Inclusion rates of 10%
and 3% for rapeseed meal and rapeseed oil, respectively, have been used in estimating exposure to
erucic acid (Table D.5).
As discussed elsewhere in this Opinion (Sections 3.3.1.6 and 3.3.5.5), there has been considerable
research to identify optimum levels of rapeseed meal and/or oil in ﬁsh diets. In diets for aquatic
species, the Canola Council of Canada recommends maximum inclusion levels of between 15% (for
prawns) and 60% (Red Sea bream) (Canola Council of Canada, 2015). For salmon and trout, it
recommends a maximum inclusion level of 20%, and this has been used to estimate exposure for a
2 kg salmon with a feed intake of 0.04 kg/day (EFSA FEEDAP Panel, 2012) (Table D.5).
In common with other plant proteins, rapeseed meals have relatively high levels of which mink
cannot digest very well. As a result, commercially manufactured mink feed consists largely of ﬁsh and
land animal by-products, with lesser amounts of cereals and cereal by-products, and supplemented
with mineral/vitamin premixtures. The assumed inclusion rates of rapeseed meal and rapeseed oil in
diets of mink together with the calculated mean lower bound and upper bound concentrations of
erucic acid, are given in Table D.5.
Table D.4: Assumed inclusion rates of rapeseed meal and rapeseed oil in the diets of pigs and
poultry, and the calculated mean lower bound and upper bound concentrations of erucic
acid in the total diet
Feeds Piglets
Fattening
pigs
Lactating
sow
Broilers
Laying
hens
Fattening
turkeys
Fattening
ducks
Rapeseed meal (%) 10 20 20 30 20 20 15
Rapeseed oil (%) 3 3 3 1.5 1.5 3 3
Estimated mean erucic acid concentration
Lower bound (lg/kg) 85.4 131 131 157 111 131 108
Upper bound (lg/kg) 172 216 216 203 156 218 195
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Table D.5: Assumed inclusion rates of rapeseed meal and rapeseed oil in the diets of rabbits, ﬁsh
(salmonids) and mink, and calculated mean lower bound (LB) and upper bound (UB)
concentrations of erucic acid in the total diet
Feed materials Rabbits Farmed ﬁsh (Salmonids) Farmed mink
Rapeseed meal 10 20 15
Rapeseed oil 3 5 3
Estimated mean erucic acid concentration
Lower bound (lg/kg) 85.4 158 108
Upper bound (lg/kg) 172 302 195
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Appendix E – Identiﬁcation and selection of evidence relevant for the risk
assessment of erucic acid in food and feed
E.1. Search for scientiﬁc literature
Chemistry and methods of analysis
A search in web of science and PubMed was conducted to identify papers on chemistry and
methods of analysis by using the following search strings.
A. Web of science
Used search string: TOPIC: (“erucic acid” OR “cis-13-docosenoic acid” OR erucate) AND TOPIC:
(chemistry OR analysis OR determination OR detection OR spectroscopy OR chromatography OR TLC
OR GC OR GC-MS OR HPLC OR LC-MS OR ICP-MS) NOT TOPIC: (petroleum OR breeding OR biodiesel
OR genome OR “genetic changes”); Reﬁned by: RESEARCH AREAS: (AGRICULTURE OR FOOD SCIENCE
TECHNOLOGY OR CHEMISTRY OR TOXICOLOGY); Timespan=1995-2015; Search language=Auto
Result in web of science: 399
B. PubMed
Used search string: (((((“erucic acid” OR “cis-13-docosenoic acid” OR erucate)) AND (chemistry OR
analysis OR determination OR detection OR spectroscopy OR chromatography OR TLC OR GC OR GC-
MS OR HPLC OR LC-MS OR ICP-MS)) NOT (petroleum OR breeding OR biodiesel OR genome OR
“genetic changes”))) AND (“1995/1/1”[Date - Publication]: “3000”[Date - Publication])
Results in PubMed: 137
Occurrence, Exposure
A search in web of science and PubMed was conducted to identify papers on occurrence and
exposure by using the following search strings.
A. Web of science
Used search string: TOPIC: (“erucic acid” OR “cis-13-docosenoic acid” OR erucate) AND TOPIC:
(food OR “rapeseed oil” OR “mustard oil” OR “canola oil” OR brassica OR “ﬁsh oil” OR “vegetable oil”
OR “dietary exposure” OR feed OR intake) NOT TOPIC: (petroleum OR breeding OR biodiesel OR
genome OR “genetic changes”); Reﬁned by: RESEARCH AREAS: (AGRICULTURE OR FOOD SCIENCE
TECHNOLOGY OR CHEMISTRY OR FISHERIES OR VETERINARY SCIENCES); Timespan=1995-2015;
Search language=Auto
Result in web of science: 751
B. PubMed
Used search string: ((((“erucic acid” OR “cis-13-docosenoic acid” OR educate)) AND (food OR
“rapeseed oil” OR “mustard oil” OR “canola oil” OR brassica OR “ﬁsh oil” OR “vegetable oil” OR “dietary
exposure” OR feed OR intake)) NOT (petroleum OR breeding OR biodiesel OR genome OR “genetic
changes”)) AND (“2015/1/1”[PDAT]: “3000”[PDAT])
Results in pubmed: 109
Human milk
A search in web of science and PubMed was conducted to identify papers on human milk by using
the following search strings:
A. Web of science
TOPIC: (“human milk” OR “breast milk”) AND TOPIC: (“fatty acid”) AND TOPIC: (Europe);
Timespan=1995-2016; Search language=Auto
Results in web of science: 131
B. PubMed
Used search string: Search (((“human milk” OR “breast milk”)) AND TOPIC: (“fatty
acid”) AND TOPIC: (Europe) AND (“1995/01/01”[PDAT]: “3000”[PDAT])
Results in PubMed: 53
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Processing
A search in web of science and PubMed was conducted to identify papers on processing by using
the following search strings.
A. Web of science
Used search string: TOPIC: (“erucic acid” OR “cis-13-docosenoic acid” OR erucate) AND TOPIC:
(cooking OR roasting OR frying OR boiling OR baking OR sterilization) NOT TOPIC: (petroleum OR
breeding OR biodiesel OR genome OR “genetic changes”); Reﬁned by: RESEARCH AREAS: (FOOD
SCIENCE TECHNOLOGY OR AGRICULTURE OR CHEMISTRY); Timespan=All years; Search language=Auto
Result in web of science: 114
B. PubMed
Used search string: (((“erucic acid” OR “cis-13-docosenoic acid” OR erucate)) AND (cooking OR
roasting OR frying OR boiling OR baking OR sterilization)) NOT (petroleum OR breeding OR biodiesel
OR genome OR “genetic changes”)
Results in PubMed: 6
Toxicity
A search in web of science and PubMed was conducted to identify papers on toxicity by using the
following search strings.
A. Web of science
Used search string: TOPIC: (“erucic acid” OR “cis-13-docosenoic acid” OR erucate) AND TOPIC: (toxicity
OR toxi*ORmutagen*OR teratogen*OR carcinogen*OR carcino*OR genotox*OR reprotox*OR nephrotox*
OR neurotox* OR hepatotox* OR immunotox* OR haemotox* OR hematotox* OR cytotox* OR “develop*
toxicity” OR endocri* OR “adverse effect” OR cardio* OR cardia*) NOT TOPIC: (petroleum OR breeding OR
biodiesel); Reﬁned by: RESEARCH AREAS: (RESPIRATORY SYSTEM OR CARDIOVASCULAR SYSTEM
CARDIOLOGY OR HEMATOLOGY OR ENDOCRINOLOGY METABOLISM OR BIOCHEMISTRY MOLECULAR
BIOLOGY OR ONCOLOGY OR TOXICOLOGY OR RHEUMATOLOGY OR CELL BIOLOGY OR PHARMACOLOGY
PHARMACY OR GASTROENTEROLOGY HEPATOLOGY OR PHYSIOLOGY OR DEVELOPMENTAL BIOLOGY OR
VETERINARY SCIENCES OR DERMATOLOGY OR NEUROSCIENCES NEUROLOGY OR ANATOMY
MORPHOLOGY OR RESEARCH EXPERIMENTAL MEDICINE OR PATHOLOGY OR UROLOGY NEPHROLOGY OR
REPRODUCTIVE BIOLOGYOR IMMUNOLOGY); Timespan=All years; Search language=Auto
Results in web of science: 561
B. PubMed
Used search string: ((“erucic acid” OR “cis-13-docosenoic acid” OR erucate)) AND (toxicity OR toxi*
OR mutagen* OR teratogen* OR carcinogen* OR carcino* OR genotox* OR reprotox* OR nephrotox*
OR neurotox* OR hepatotox* OR immunotox* OR haemotox* OR hematotox* OR cytotox* OR
“develop* toxicity” OR endocri* OR “adverse effect” OR cardio* OR cardia*)
Results in PubMed: 115
Metabolism, kinetics
A search in web of science and PubMed was conducted to identify papers on metabolism and
kinetics by using the following search strings.
A. Web of science
Used search string: TOPIC: (“erucic acid” OR “cis-13-docosenoic acid” OR erucate) AND TOPIC: (metabol*
OR distribut* OR excret* OR absorp* OR biotransformation OR toxicokinetics) NOT TOPIC: (petroleum OR
breeding OR biodiesel OR genome OR “genetic changes”); Reﬁned by: RESEARCH AREAS: (BIOCHEMISTRY
MOLECULAR BIOLOGY OR PHARMACOLOGY PHARMACY OR LIFE SCIENCES BIOMEDICINE OTHER TOPICS
OR VETERINARY SCIENCES OR ENDOCRINOLOGY METABOLISM OR CARDIOVASCULAR SYSTEM
CARDIOLOGY OR RESPIRATORY SYSTEM OR CELL BIOLOGY OR GASTROENTEROLOGY HEPATOLOGY OR
PHYSIOLOGY OR TOXICOLOGY OR PUBLIC ENVIRONMENTAL OCCUPATIONAL HEALTH OR REPRODUCTIVE
BIOLOGY OR RESEARCH EXPERIMENTAL MEDICINE OR UROLOGY NEPHROLOGY OR HEMATOLOGY);
Timespan=All years; Search language=Auto; Timespan: all years
Result in web of science: 2,330
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B. PubMed
Used search string: (((“erucic acid” OR “cis-13-docosenoic acid” OR erucate)) AND (metabol* OR
distribut* OR excret* OR absorp* OR biotransformation OR toxicokinetics)) NOT (petroleum OR
breeding OR biodiesel OR genome OR “genetic changes”)
Results in PubMed: 339
Human studies
A search in web of science and PubMed was conducted to identify papers on human data by using
the following search strings.
A. Web of science
Used search string: TOPIC: (“erucic acid” OR “cis-13-docosenoic acid” OR erucate) AND TOPIC:
(epidemiology OR biomarker OR cohort OR case control OR case stud* OR “incidental poisoning” OR
“clinical stud*”) NOT TOPIC: (petroleum OR breeding OR biodiesel); Reﬁned by: RESEARCH
AREAS: (BIOCHEMISTRY MOLECULAR BIOLOGY OR REPRODUCTIVE BIOLOGY OR CARDIOVASCULAR
SYSTEM CARDIOLOGY OR NEUROSCIENCES NEUROLOGY OR HEMATOLOGY OR ENDOCRINOLOGY
METABOLISM OR DEVELOPMENTAL BIOLOGY OR TOXICOLOGY OR RESPIRATORY SYSTEM OR
PEDIATRICS OR ONCOLOGY OR RHEUMATOLOGY OR PHYSIOLOGY OR GASTROENTEROLOGY
HEPATOLOGY OR GERIATRICS GERONTOLOGY OR OBSTETRICS GYNECOLOGY OR PHARMACOLOGY
PHARMACY OR ANATOMY MORPHOLOGY OR CELL BIOLOGY OR UROLOGY NEPHROLOGY OR
IMMUNOLOGY OR PATHOLOGY OR PUBLIC ENVIRONMENTAL OCCUPATIONAL HEALTH); Timespan=All
years; Search language=Auto
Result in web of science: 70
B. Pubmed
Used search string: (((“erucic acid” OR “cis-13-docosenoic acid” OR erucate)) AND (epidemiology
OR biomarker OR cohort OR case control OR case stud* OR “incidental poisoning” OR “clinical stud*”))
NOT (petroleum OR breeding OR biodiesel)
Results in PubMed: 36
E.2. Exclusion criteria for abstracts
The references resulting from the literature search were imported and saved using a software
package (EndNote52), which allows effective management of references and citations. After deletion of
the duplicate reference, a list of about 1,900 references was obtained. The titles and abstracts of
these references were screened to identify the relevant papers. Papers on the following subjects were
excluded:
• Papers focused on nutritional aspects without studying toxic effects
• Papers related to plant science
• Papers on non-edible oil
• Papers related to antimicrobial/insecticide activity
• Papers related to quality of oil (e.g. oxidative stability, oil composition)
• Papers on environmental science
• Papers related to economic aspects
• Papers on compounds in oil other than erucic acid
E.3. EFSA guidance documents applied for the risk assessment
• EFSA (European Food Safety Authority), 2005. Opinion of the Scientiﬁc Committee on a
request from EFSA related to a harmonised approach for risk assessment of substances which
are both genotoxic and carcinogenic. EFSA Journal 2005;3(10):282, 31 pp. doi:10.2903/
j.efsa.2005.282
• EFSA (European Food Safety Authority), 2006. Guidance of the Scientiﬁc Committee on a
request from EFSA related to uncertainties in Dietary Exposure Assessment. EFSA Journal
2007;4(1):438, 54 pp. doi:10.2903/j.efsa.2007.438
52 EndNote X5, Thomson Reuters. Available at: http://endnote.com/
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• EFSA (European Food Safety Authority), 2009a. Guidance of the Scientiﬁc Committee on use of
the benchmark dose approach in risk assessment. EFSA Journal 2009;6(6):1150, 72 pp.
doi:10.2903/j.efsa.2009.1150
• EFSA (European Food Safety Authority), 2009b. Guidance of the Scientiﬁc Committee on
transparency in the scientiﬁc aspects of risk assessments carried out by EFSA. Part 2: General
principles. EFSA Journal 2009;6(5):1051, 22 pp. doi:10.2903/j.efsa.2009.1051
• EFSA (European Food Safety Authority), 2010a. Standard sample description for food and
feed. EFSA Journal 2010;8(1):1457, 54 pp. doi:10.2903/j.efsa.2010.1457
• EFSA (European Food Safety Authority), 2010b. Management of left-censored data in dietary
exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp.
doi:10.2903/j.efsa.2010.1557
• EFSA (European Food Safety Authority), 2011a. Guidance of EFSA on the use of the EFSA
Comprehensive European Food Consumption Database in Intakes Assessment. EFSA Journal
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Appendix F – Previous occurrence data
Table F.1: Erucic acid(a) concentration (mg/kg) in grains and grain-based products(b)
Product N Mean Median Range Reference
Biscuits 17 29 0 0–200 Public Health England (2015)
Biscuits 8 0 0 0–0 US Department of Agriculture (2015)
Biscuits 12 2,792 0 0–14,600 National Food Institute of Denmark (2015)
Biscuits 27 237 0 0–3,660 Max Rubner Institut (2010)
Bread 74 2 0 0–40 US Department of Agriculture (2015)
Bread 33 6 0 0–200 Public Health England (2015)
Bread 12 0 0 0–0 NFI (2015)
Bread 258 160 20 0–1,500 Max Rubner Institut (2010)
Bu~nuelos 1 – – 50 US Department of Agriculture (2015)
Cakes 32 2 0 0–30 US Department of Agriculture (2015)
Cakes 14 243 200 0–700 Public Health England (2015)
Cakes 6 10,412 11,450 320–14,700 NFI (2015)
Cakes 355 204 50 0–3,540 Max Rubner Institut (2010)
Cereal bars 2 50 50 0–100 Public Health England (2015)
Cereals ready-to-eat 145 1 0 0–50 US Department of Agriculture (2015)
Cereals ready-to-eat 27 48 0 0–500 Public Health England (2015)
Cereals ready-to-eat 1 – – 0 NFI (2015)
Cereals ready-to-eat 70 1 0 0–10 Max Rubner Institut (2010)
Cookies 77 3 0 0–80 US Department of Agriculture (2015)
Cookies 2 410 410 0–820 NFI (2015)
Crackers 50 11 0 0–50 US Department of Agriculture (2015)
Crackers 1 – – 0 Public Health England (2015)
Crackers 1 – – 0 NFI (2015)
Crackers 3 937 820 820–1,170 Max Rubner Institut (2010)
Cream of wheat 11 1 0 0–10 US Department of Agriculture (2015)
Crispbreads 148 158 30 0–470 Max Rubner Institut (2010)
Croissants 6 5 0 0–30 US Department of Agriculture (2015)
Croissants 1 – – 100 Public Health England (2015)
Croissants 1 – – 530 NFI (2015)
Currant buns 1 – – 100 Public Health England (2015)
Dough 8 33 30 0–100 Max Rubner Institut (2010)
Doughnuts 8 1 0 0–10 US Department of Agriculture (2015)
Doughnuts 2 50 50 0–100 Public Health England (2015)
Doughnuts 4 1,173 520 460–3,190 Max Rubner Institut (2010)
Dumplings 45 101 40 0–610 Max Rubner Institut (2010)
Flapjacks 1 – – 200 Public Health England (2015)
Garlic bread 2 10 – 0–20 US Department of Agriculture (2015)
Muesli 1 – – 100 Public Health England (2015)
Mufﬁns 28 2 0 0–40 US Department of Agriculture (2015)
Mufﬁns 3 567 800 0–900 Public Health England (2015)
Mufﬁns 8 720 670 0–1,040 Max Rubner Institut (2010)
Oatcakes 1 – – 100 Public Health England (2015)
Pancakes 40 147 30 0–1,960 Max Rubner Institut (2010)
Pasta 100 0 0 0–10 Max Rubner Institut (2010)
Pastries 13 0 0 0–0 US Department of Agriculture (2015)
Pastries 11 209 200 100–600 Public Health England (2015)
Pastries 13 0 0 0–0 NFI (2015)
Pastries 230 674 50 0–24,660 Max Rubner Institut (2010)
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Product N Mean Median Range Reference
Pie 36 0 0 0–0 US Department of Agriculture (2015)
Pie 6 133 100 0–300 Public Health England (2015)
Quinoa 3 1,008 1,004 954–1,066 Wood et al. (1993)
Quinoa 2 55 55 30–80 Max Rubner Institut (2010)
Rolls and buns 175 92 0 0–330 Max Rubner Institut (2010)
Scones 7 29 0 0–100 Public Health England (2015)
Semolina 2 0 0 0–0 US Department of Agriculture (2015)
Semolina 1 – – 0 NFI (2015)
Semolina 5 36 5 0–160 Max Rubner Institut (2010)
Strudel 1 – – 300 Public Health England (2015)
Tarts 3 200 200 100–300 Public Health England (2015)
Wafers 2 15 15 0–30 US Department of Agriculture (2015)
Wafers 1 – – 100 Public Health England (2015)
Wafﬂes 8 3 0 0–20 US Department of Agriculture (2015)
Wafﬂes 20 944 115 0–3,960 Max Rubner Institut (2010)
Wheat rusk 2 585 585 510–660 NFI (2015)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark andMax Rubner Institut for which no erucic acid has been reported. The cumulative number
of samples included in both databases is given in brackets: Amaranth (1); bagels (12); bannocks (2); barley (25); biscuits (4);
breakfast bars (2); buckwheat (16); bulgur (3); cereals and cereals ﬂour (16); cheesecake (5); coffeecake (6); corn (15); cous
cous (3), cream of rice (3); croutons (2); crumble (9); farina (5); ﬂan (11); glutenmeat (4); malted drink mix (8); millet (16); oats
(17); polenta (4); popcorn (3); rice (101); rye (31); sorghum ﬂour (1); Spelt ﬂour (12); Swiss rolls (1); turnovers (2); wheat (74).
Table F.2: Erucic acid(a) concentration (mg/kg) in vegetables and vegetable products(b)
Product N Mean Median Range Reference
Broccoli sprouts 1 – – 3,200 West et al. (2002)
Brassica oleracea sprouts 8 28,277 27,438 13,563–48,048 Vale et al. (2015)
Canola sprouts(c) 4 34,607 25,024 1,101–87,280 Bhardwaj and Hamama (2009)
Instant oatmeal 12 17 20 0–50 US Department of Agriculture (2015)
Kale leaves 1 – – 2 Ayaz et al. (2006)
Pickled vegetables with
mustard
2 550 550 460–640 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: arrowhead (2); alfalfa sprouts (6); amaranth leaves (2);
artichoke (23); asparagus (28); aubergine (30); bamboo shoots (16); balsam pear (2); beetroot (31); beet greens (6); betel
leaves (1); borage (5); broccoli (42); Brussels sprouts (25); bush beans (8); cabbage (86); capers (1); cardoon (7); carrots
(42); cauliﬂower (24); celeriac (24); celery (16); chard (14); chayote (11); chicory (10); chicory greens (2); Chinese cabbage
(13); cocoa powder (17); coconut (1); collards (5); coriander leaves (1); courgettes (8); cress (8); cucumber (20); dandelion
greens (10); drumstick, leaves and pods (4); endive (9); escarole (1); fennel (17); fungi (100); garlic (27); gherkins, raw and
pickled (2); gourd (7); grape leaves (4); horseradish (10); instant breakfast powder (13); instant chocolate (21); instant coffee
(16); kale (23); kohlrabi (23); leek (21); lettuce (27); marrow (3); morel (11); mushrooms (57); nopal (2); okra (20); onions
(80); orache (8); pak choi (2); palm heart (7); parsley (7); parsnip (16); peppermint (2); peppers (140); pickled vegetables
(18); popcorn (5); pumpkin (44); purslane (11); radicchio (6); radish (33); radish leaves (1); rape leaves (1); rhubarb (18);
Romanesco (2); root parley (13); rutabaga (3); salad rocket (2); salsify (16); sauerkraut (20); seaweeds (26); shallots (8);
sorrel (6); spinach (41); squash (32); stinging nettle (8); swede (2); sweet corn (25); tomatoes (74); tea (11); trufﬂe (10);
turnip (34); turnip greens (12); vegetables mix (118); watercress (9); water chestnut (5); Welsh onion (10); zucchini (25).
(c): The authors reported the use of four canola cultivars although two of them should be considered as rapeseed instead of
canola according to the deﬁnition provided in Section 1.3.1 of this opinion.
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Table F.3: Erucic acid(a) concentration (mg/kg) in starchy roots and tubers(b)
Product N Mean Median Range Reference
French fries 8 21 20 0–40 US Department of Agriculture (2015)
French fries 1 – – 110 NFI (2015)
French fries 7 1,169 0 0–4,290 Max Rubner Institut (2010)
Sweet potato 11 4 0 0–40 US Department of Agriculture (2015)
Sweet potato 1 – – 0 NFI (2015)
Sweet potato 5 0 0 0–0 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: arrowroot (8); burdock root (2); cassava (10); ginger
(3); Jerusalem artichoke (7); lotus root (2); potato (82); tapioca (2); taro (13); yucca chips (1); yam (14); yam bean (6).
Table F.4: Erucic acid(a) concentration (mg/kg) in legumes, nuts and oilseeds(b)
Product(d),(e) N Mean Median Range Reference
Black mustard 5 143,352 137,120 122,653–192,921 Tahoun et al. (1999)
Borage 6 12,794 7,236 3,060–42,744 de Haro et al. (2002)
Camelina 8 12,646 12,530 11,360–13,870 Budin et al. (1995)
Canola 3(c) 44 44 43–45 Barthet (2014)
Cowpea 4 29 0 0–117 Antova et al. (2014)
Crambe 1 – – 191,310 Lalas et al. (2012)
Ethiopian mustard 5 148,111 144,146 79,072–198,852 Tahoun et al. (1999)
Hazelnut 3 0 0 0–0 US Department of Agriculture (2015)
Hazelnut 1 – – 0 Public Health England (2015)
Hazelnut 10 55 0 0–280 Max Rubner Institut (2010)
Hazelnut 1 – – 0 NFI (2015)
Kola nut 3 203 300 0–310 Max Rubner Institut (2010)
Lupines 2 1,928 1,928 1,699–2,157 Bhardwaj et al. (2004)
Lupines 6 1,839 1,841 1,206–2,457 Oliveira and Ferreira (1988)
Lupines 18 2,221 2,062 815–4,942 Boschin et al. (2008)
Macadamia 4 1,185 1,185 0–2,370 Max Rubner Institut (2010)
Mustard seeds 2 115,630 115,630 115,630–115,630 Max Rubner Institut (2010)
Nuts 8 143 130 0–270 US Department of Agriculture (2015)
Nuts 3 307 460 0–460 Max Rubner Institut (2010)
Oriental mustard 5 115,605 106,240 69,758–178,144 Tahoun et al. (1999)
Peanuts 8 135 0 0–540 US Department of Agriculture (2015)
Peanuts 9 247 320 0–480 Max Rubner Institut (2010)
Rape seed 4 103,646 103,809 51,935–155,030 Tahoun et al. (1999)
Sesame 3 0 0 0–0 US Department of Agriculture (2015)
Sesame 1 – – 0 Public Health England (2015)
Sesame 1 – – 0 NFI (2015)
Sesame 6 92 0 0–280 Max Rubner Institut (2010)
Sunﬂower 7 0 0 0–0 US Department of Agriculture (2015)
Sunﬂower 2 0 0 0–0 Public Health England (2015)
Sunﬂower 8 72 0 0–280 Max Rubner Institut (2010)
Turnip rape 5 136,426 140,624 70,686–177,390 Tahoun et al. (1999)
Walnuts 3 0 0 0–0 US Department of Agriculture (2015)
Walnuts 1 – – 0 Public Health England (2015)
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Product(d),(e) N Mean Median Range Reference
Walnuts 1 – – 0 NFI (2015)
Walnuts 17 32 0 0–280 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: almond (30); beans (167); bean sprouts (14); beech nut
(4); betel nut (1); black gram (6); Brazil nut (10); breadnut (1); broad beans (2); butternut (1); carob ﬂour (1); cashew
(19); chestnuts (21); chevra (1); chickpea (25); chickpea sprouts (1); coconut (10); cottonseed (2)d; fenugreek (2); ginkgo
nut (1); hickorynut (6); lablab (4); lentil (37); lentil sprouts (2); lima bean (11); linseed (11); mungbean (21); mungbean
sprouts (2); peas (86); pea sprouts (2); pecans (12); pigeon pea (10); pine nuts (6); pistachio (8); poppy seed (4); pumpkin
seed (14); safﬂower seeds (0)e; soy ﬂour (6); soybeans (31)
(c): Refers to number of years (2010, 2011, 2012) of harvest surveys in Western Canada, including 2,108, 1,749 and 1,641
samples/year, respectively.
(d): Five samples of cottonseed seeds and meal with 22:1 content between 30 and 370 mg/kg (Max Rubner Institut, 2010) are
not included because there is scientiﬁc evidence that cotton seeds lack 22:1 fatty acids (Dowd et al., 2010).
(e): Two samples of safﬂower seeds with 22:1 content of 370 mg/kg each (Max Rubner Institut, 2010) are not included because
there is scientiﬁc evidence that safﬂower seeds lack 22:1 fatty acids (Matthaus et al., 2015).
Table F.5: Erucic acid(a) concentration (mg/kg) in fruit and fruit products(b)
Product N Mean Median Range Reference
Plantains 4 3 0 0–10 US Department of Agriculture (2015)
Plantains 6 0 0 0–0 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: acerola (10); ackee (9); amla (1); apple (55); apple
butter (2); apricot (33); avocado (15); babaco (1); banana (23); bilberry(3); blackberry (20); blackcurrant (3); blueberry
(10); boysenberry (9); breadfruit (9); Cape gooseberry (7); carambola (1); Carissa (7); cashew apple (9); chayote (3);
cherimoya (24); cherries (60); coconut (3); cranberry (20); currants (34); damsons (6); dates (15); durian (9); elderberry
(8); feijoa (5); ﬁg (21); fruit compote (57); fruit mix (22); fruit paste (2); fruit salad (8); gooseberry (15); grapefruit (55);
greengages (6); grenadilla (7); gr€une Gr€utze (3); guava (20); hackelberry (2); jabuticaba (6); jackfruit (9); jam (121);
jujube (8); kaki (10); kiwi (14); kumquat (9); lemon (12); lime (9); litchi (13); loganberry (12); longan (10); loquats (2);
lychees (4); mamey (9); mandarine (39); mango (13); mangosteen (7); medlar (12); melon (44); mulberry (10); naranjilla
(9); nectarine (13); olive (16); orange (16), orange peel (1); papaya (15); passion fruit (12); peach (35); pear (37);
persimmon (1); physalis (1); pineapple (39); plum (91); pokeberry (1); pomelo (2); pomegranate (10); prickly pear (7);
prunes (9); quince (14); raisin (8); rambutan (2); raspberry (25); redcurrant (3); rose-apple (7); rosehip (9); r€ote Gr€utze
(9); rowan (7); sapote (9); sapotilla (9); seabuckhorn (9); sloe (3); strawberry (26); Surinam cherry (7); tamarillo (8);
tamarind (4); tangerines (5); tree gooseberry (9); watermelon (4); white currant (3); wild gooseberry (6); wild fruits (2).
Table F.6: Erucic acid(a) concentration (mg/kg) in meat and meat products(b)
Product N Mean Median Range Reference
Bacon 12 17 0 0–60 US Department of Agriculture (2015)
Bacon 6 0 0 0–0 Public Health England (2015)
Bacon 3 0 0 0–0 NFI (2015)
Bacon 21 0 0 0–0 Max Rubner Institut (2010)
Beef, raw 339 0 0 0–0 US Department of Agriculture (2015)
Beef, raw 8 0 0 0–0 NFI (2015)
Beef, raw 273 0 0 0–0 Max Rubner Institut (2010)
Beef, preserve 6 0 0 0–0 Max Rubner Institut (2010)
Beef 14 14 0 0–200 Public Health England (2015)
Bologna 10 176 0 0–890 US Department of Agriculture (2015)
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Product N Mean Median Range Reference
Chicken, raw 56 3 0 0–50 US Department of Agriculture (2015)
Chicken, raw 10 0 0 0–0 NFI (2015)
Chicken, raw 23 3 0 0–60 Max Rubner Institut (2010)
Chicken 16 100 0 0–500 Public Health England (2015)
Corn dogs 1 – – 280 US Department of Agriculture (2015)
Faggots 1 – – 100 Public Health England (2015)
Frankfurter 13 136 0 0–1,180 US Department of Agriculture (2015)
Frankfurter 1 – – 0 Public Health England (2015)
Lamb, raw 55 7 0 0–340 US Department of Agriculture (2015)
Lamb, raw 5 0 0 0–0 NFI (2015)
Lamb, raw 151 0 0 0–0 Max Rubner Institut (2010)
Lamb 14 0 0 0–0 Public Health England (2015)
Mince pie 2 100 100 0–200 Public Health England (2015)
Offal 130 30 0 0–450 Max Rubner Institut (2010)
Pa^te 5 0 0 0–0 US Department of Agriculture (2015)
Pa^te 17 55 20 0–290 Max Rubner Institut (2010)
Pa^te 2 0 0 0–0 Public Health England (2015)
Pepperoni 1 – – 40 US Department of Agriculture (2015)
Pigeon 12 66 70 50–80 Max Rubner Institut (2010)
Pork, raw 73 0 0 0–10 US Department of Agriculture (2015)
Pork, raw 6 0 0 0–0 NFI (2015)
Pork, raw 359 0 0 0–0 Max Rubner Institut (2010)
Pork, preserve 8 0 0 0–0 Max Rubner Institut (2010)
Pork 22 23 0 0–200 Public Health England (2015)
Salami 6 38 0 0–230 US Department of Agriculture (2015)
Salami 2 0 0 0–0 Public Health England (2015)
Sausages 46 60 0 0–930 US Department of Agriculture (2015)
Sausages 17 6 0 0–100 Public Health England (2015)
Sausages 10 0 0 0–0 NFI (2015)
Sausages 293 35 0 0–630 Max Rubner Institut (2010)
Soy sausages 3 3,527 4,020 2,540–4,020 Max Rubner Institut (2010)
Terrine 2 5 5 0–10 Max Rubner Institut (2010)
Turkey, raw 43 10 10 0–50 US Department of Agriculture (2015)
Turkey, raw 24 68 105 10–120 Max Rubner Institut (2010)
Turkey 4 150 100 100–300 Public Health England (2015)
Turkey 1 – – 0 NFI (2015)
Veal, raw 16 0 0 0–0 US Department of Agriculture (2015)
Veal, raw 269 0 0 0–10 Max Rubner Institut (2010)
Veal, preserve 5 10 10 0–20 Max Rubner Institut (2010)
Veal 2 0 0 0–0 Public Health England (2015)
Veal 1 – – 0 NFI (2015)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: animal fat (8); bison (2); caribou (1); chital (1); cured
meat (7); deer (32); duck (65); emu (5); game (21); goat (8); goose (41); Guinea fowl (2); grouse (2); ham (116); hare
(2); horse (9); kassler (28); luncheon (6); meat mix (35); mincemeat (2); mortadella (1); mutton (2); ostrich (2); ox (12);
partridge (4); pheasant (13); poularde (4); quail (8); rabbit (39); reindeer (8); squab (4); textured soy protein (10); venison
(3); wild boar (10).
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Table F.7: Erucic acid(a) concentration (mg/kg) in ﬁsh and other seafood(b)
Product N Mean Median Range Reference
Black Sea horse mackerel 21 54 – Not reported Stancheva et al. (2012)
Catﬁsh 2 295 295 0–590 NFI (2015)
Cod 7 157 0 0–500 Public Health England (2015)
Cod 6 0 0 0–0 NFI (2015)
Crab 2 100 100 0–200 Public Health England (2015)
Crab 3 840 570 570–1,380 NFI (2015)
Finﬁsh 37 170 30 0–1,680 Ackman (2008)
Fish 1 – – 300 Public Health England (2015)
Fish, fried 3 100 100 0–200 NFI (2015)
Fish pa^tes 7 2,200 1,900 400–4,300 Aquerreta et al. (2002)
Halibut 5 1,660 0 0–4,300 NFI (2015)
Herring 1 – – 0 Public Health England (2015)
Herring 4 1,393 1,425 240–2,480 NFI (2015)
Lemon sole 3 0 0 0–0 Public Health England (2015)
Lemon sole 1 – – 120 NFI (2015)
Lobster 4 470 465 440–510 NFI (2015)
Mackerel 1 – – 2,100 Public Health England (2015)
Mackerel 4 1,505 1,440 950–2,190 NFI (2015)
Mussels 2 0 0 0–0 Public Health England (2015)
Mussels 4 718 480 0–1,910 NFI (2015)
Oyster 2 0 0 0–0 Public Health England (2015)
Oyster 1 – – 340 NFI (2015)
Plaice 2 150 150 0–300 Public Health England (2015)
Pollock 2 50 50 0–100 Public Health England (2015)
Redﬁsh 1 – – 640 NFI (2015)
Roe 2 200 200 100–300 Public Health England (2015)
Round goby 12 320 – Not reported Stancheva et al. (2012)
Salmon 13 833 600 200–1,800 Public Health England (2015)
Salmon 7 1,139 800 0–3,990 NFI (2015)
Sardines 3 300 300 300–300 Public Health England (2015)
Sardines 3 0 0 0–0 NFI (2015)
Sea bass 2 250 250 200–300 Public Health England (2015)
Scampi 1 – – 600 Public Health England (2015)
Shad 6 4,077 – Not reported Stancheva et al. (2012)
Sole 1 – – 120 NFI (2015)
Sprat 1 – – 600 Public Health England (2015)
Sprat 33 1,003 – Not reported Stancheva et al. (2012)
Sprat 1 – – 2,390 NFI (2015)
Torsk 1 – – 30 NFI (2015)
Trout 2 100 100 100–100 Public Health England (2015)
Trout 1 – – 520 NFI (2015)
Tuna 5 20 0 0–100 Public Health England (2015)
Tuna 2 0 0 0–0 NFI (2015)
Erucic acid in feed and food
www.efsa.europa.eu/efsajournal 126 EFSA Journal 2016;14(11):4593
Product N Mean Median Range Reference
Wolﬁsh 1 – – 320 NFI (2015)
Whelks 1 – – 200 Public Health England (2015)
(a): The database of Public Health England reports separately 22:1 n-9 c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is
included in the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of Public Health England and National Food Institute of
Denmark for which no erucic acid has been reported. The number of samples included in the database is given in brackets:
anchovy (1); bucklingpate (1); calamari (1); carp (1); caviar (2); cod liver oil (1); coley (6); crayﬁsh (1); cuttleﬁsh (1);
dogﬁsh (9); eel (4); ﬁsh ﬁngers (1); ﬂounder (4); ﬂying ﬁsh (1); garﬁsh (1); haddock (26); hake (3); halibut (5); hare (1);
hoki (2); jackﬁsh (1); langoustine (1); lemon sole (5); monkﬁsh (3); mullet (6); octopus (1); parrot ﬁsh (1); plaice (2);
prawns (12); red snapper (5); sea bream (1); seaweed (4); shark (1); shrimps (8); skate (3); snail (1); squid (2); stockﬁsh
(1); swordﬁsh (3); turbot (4); whiting (9).
Table F.8: Erucic acid concentration (mg/kg) in milk and dairy products(a),(b)
Product N Mean Median Range Reference
Cheese 95 3 0 0–80 US Department of Agriculture (2015)
Cheese 19 32 0 0–400 Public Health England (2015)
Cheese 3 0 0 0–0 NFI (2015)
Cheese 390 1 0 0–40 Max Rubner Institut (2010)
Cream 8 6 0 0–30 US Department of Agriculture (2015)
Cream 3 0 0 0–0 Public Health England (2015)
Cream 3 0 0 0–0 NFI (2015)
Cream 44 11 0 0–230 Max Rubner Institut (2010)
Milk 32 0 0 0–0 US Department of Agriculture (2015)
Milk 13 15 0 0–100 Public Health England (2015)
Milk 5 0 0 0–0 NFI (2015)
Milk 50 3 0 0–10 Max Rubner Institut (2010)
Milk-based beverages 6 0 0 0–0 US Department of Agriculture (2015)
Milk-based beverages 81 4 0 0–10 Max Rubner Institut (2010)
Yogurt 16 0 0 0–0 US Department of Agriculture (2015)
Yogurt 8 0 0 0–0 Public Health England (2015)
Yogurt 187 0 0 0–10 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: buttermilk (15); cheese imitation (11); evaporated/
condensed milk (14); creme caramel (2); creme fra^ıche (2); cream substitute (1); keﬁr (23); milk powder (8); quark (19);
sour cream imitation (1); soy yogurt (2); soy drink (9); tofu (26); whey (17); ymer (1).
Table F.9: Erucic acid content (mg/kg) in sugar and confectionary(a),(b)
Product N Mean Median Range Reference
Chocolate 6 0 0 0–0 US Department of Agriculture (2015)
Chocolate 11 82 0 0–900 Public Health England (2015)
Chocolate 4 0 0 0–0 NFI (2015)
Chocolate 156 1 0 0–100 Max Rubner Institut (2010)
Chocolate bar 1 – – 300 Public Health England (2015)
Chocolate bar 19 92 0 0–910 Max Rubner Institut (2010)
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Product N Mean Median Range Reference
Dragees 9 41 0 0–370 Max Rubner Institut (2010)
Fondant 11 4 0 0–20 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: brandy snaps (1); brownies (1); candies (93); chewing
gum (2); chocolate syrup (3); chocolate buns (1); dessert toping powder (4); frostings (9); fructose (1); fruit gums (1);
gateau (2); glucose (1); honey (8); invert sugar (1); jelly (13); lactose (1); maltose (1); marshmallow (1); marzipan (9);
nougat (4); sugar (14); sugared fruits (22); sweets (1); sweetener (19); syrup (25); toppings (5).
Table F.10: Erucic acid(a) concentration (mg/kg) in animal and vegetable fats and oils(b)
Product N Mean Median Range Reference
Butter 7 7 0 0–50 US Department of Agriculture (2015)
Butter 4 500 400 0–1,200 Public Health England (2015)
Butter 1 – – 0 NFI (2015)
Butter 27 1,080 420 0–9,560 Max Rubner Institut (2010)
Cooking fat 1 – – 56,960 Max Rubner Institut (2010)
Cooking oil 1 – – 1,410 US Department of Agriculture (2015)
Corn oil 1 – – 0 US Department of Agriculture (2015)
Corn oil 1 – – 0 NFI (2015)
Corn oil 1 – – 1,910 Max Rubner Institut (2010)
Cottonseed oil 2 0 0 0–0 US Department of Agriculture (2015)
Cottonseed oil 1 – – 0 Public Health England (2015)
Cottonseed oil 1 – – 0 NFI (2015)
Cottonseed oil 1 – – 1,910 Max Rubner Institut (2010)
Fat spreads 9 1,267 1,200 0–2,600 Public Health England (2015)
Flaxseed oil 2 175 175 170–180 US Department of Agriculture (2015)
Margarine 39 39 0 0–330 US Department of Agriculture (2015)
Margarine 1 – – 2,200 Public Health England (2015)
Margarine 10 0 0 0–0 NFI (2015)
Margarine 23 21,071 17,210 2,680–45,890 Max Rubner Institut (2010)
Margarine 12 6,087 2,492 0–21,978 Kohiyama et al. (1990)
Mustard oil 5 113,540 47,600 9,100–341,200 Chowdhury et al. (2007)
Mustard oil 2 308,950 308,950 239,000–378,900 Abul-Fadl et al. (2011)
Mustard oil 3 385,030 418,000 217,300–519,800 Sarwar et al. (2014)
Mustard oil 9 248,330 215,000 3,000–508,000 Wendlinger et al. (2014)
Palm oil 2 0 0 0–0 US Department of Agriculture (2015)
Palm oil 1 – – 0 Public Health England (2015)
Palm oil 1 – – 0 NFI (2015)
Palm oil 2 1,910 1,910 1,910–1,910 Max Rubner Institut (2010)
Palm kernel oil 6 0 0 0–0 US Department of Agriculture (2015)
Palm kernel oil 1 – – 0 NFI (2015)
Palm kernel oil 1 – – 940 Max Rubner Institut (2010)
Peanut butter 10 197 0 0–1,090 US Department of Agriculture (2015)
Peanut butter 1 0 – 0 Public Health England (2015)
Peanut butter 5 274 440 0–470 Max Rubner Institut (2010)
Peanut oil 1 – – 0 US Department of Agriculture (2015)
Peanut oil 1 – – 1,000 Public Health England (2015)
Peanut oil 1 – – 0 NFI (2015)
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Product N Mean Median Range Reference
Peanut oil 1 – – 960 Max Rubner Institut (2010)
Rapeseed oil 1 – – 2,000 Public Health England (2015)
Rapeseed oil 1 – – 5,080 NFI (2015)
Rapeseed oil 1 – – 2,990 Max Rubner Institut (2010)
Rapeseed oil from
China
2 244,500 244,500 92,000–397,000 Wallingford et al. (2004)
Safﬂower oil 2 0 0 0–0 US Department of Agriculture (2015)
Safﬂower oil 1 – – 0 Public Health England (2015)
Safﬂower oil 1 – – 0 NFI (2015)
Safﬂower oil 1 – – 960 Max Rubner Institut (2010)
Sesame oil 1 – – 0 US Department of Agriculture (2015)
Sesame oil 1 – – 0 Public Health England (2015)
Sesame oil 1 – – 0 NFI (2015)
Sesame oil 1 – – 0 Max Rubner Institut (2010)
Sesame oil from China 2 91,500 91,500 4,000–179,000 Wallingford et al. (2004)
Shortenings 16 0 0 0–0 US Department of Agriculture (2015)
Shortenings 3 57,897 58,740 56,210–58,740 Max Rubner Institut (2010)
Spread 1 – – 190 NFI (2015)
Sunﬂower oil 1 – – 1,000 Public Health England (2015)
Sunﬂower oil 1 – – 0 NFI (2015)
Sunﬂower oil 2 475 475 0–950 Max Rubner Institut (2010)
Sunﬂower seed butter 2 30 30 30–30 US Department of Agriculture (2015)
Sunﬂower seed butter 1 – – 460 Max Rubner Institut (2010)
Vegetable oil 1 – – 2,000 Public Health England (2015)
Vegetable oil 3 0 0 0–0 Max Rubner Institut (2010)
Vegetable oil, pickles 71 22,110 3,000 0–270,000 Food Standards Agency (2004)
Vegetarian fat 3 15,320 16,440 13,080–16,440 Max Rubner Institut (2010)
Wheat germ oil 1 – – 0 US Department of Agriculture (2015)
Wheat germ oil 1 – – 0 Public Health England (2015)
Wheat germ oil 1 – – 0 NFI (2015)
Wheat germ oil 1 – – 1,900 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: almond butter (1); almond oil (2); animal fat (1); apricot
kernel oil (1); babassu oil (1); beef tallow (2); breadnut tree seed oil (1); chicken fat (1); cocoa butter (3); coconut oil (8);
cupuassu oil (1); duck fat (1); evening primrose oil (1); frying oil (1); goose fat (2); grapeseed oil (4); hazelnut butter (3);
hazelnut oil (3); kolanut butter (1); lard (3); linseed oil (2); mutton fat (1); nut butter (1); nutmeg butter (1); olive oil (4);
poppy seed oil (2); pumpkin seed oil (1); rice bran oil (1); sesame butter (3); sesame oil (3); sheanut butter (2);
shortenings (16); soybean oil (17); tea seed oil (1); tomato seed oil (1); ucuhuba butter (1); tallow (1); vegetable oil (3);
walnut oil (4).
Erucic acid in feed and food
www.efsa.europa.eu/efsajournal 129 EFSA Journal 2016;14(11):4593
Table F.11: Erucic acid(a) content (mg/kg) in fruit and vegetable juices(b)
Product N Mean Median Range Reference
Horchata 1 – – 20 US Department of Agriculture (2015)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: acai berry drink (1); acerola juice (1); almond milk (3);
Aloe vera juice (1); apple juice (9); apple sauce (2); apricot juice (1); barley water (4); blackberry juice (1); blackcurrant
juice (2); carrot juice (1); cereal grain beverage (3); citrus fruit juice (2); cocoa butter (1); coconut milk (7); cranberry juice
(6); fruit juice (217); fruit juice drink (35); grapefruit juice (14); lemon juice (6); lemonade (11); lime juice (5); orange juice
(16); passion fruit juice (3); pear nectar (1); pineapple juice (6); pomelo juice (1); pomegranate juice (3); prune juice (2);
rice milk (1); tangerine juice (2); tomato juice (5); tomato sauce (3); vegetable juice (8).
Table F.12: Erucic acid(a) content (mg/kg) in non-alcoholic beverages (excepting milk-based
beverages)(b)
Product N Mean Median Range Reference
Cocoa drink 2 1,915 1,915 380–3,450 Max Rubner Institut (2010)
Coffee 8 0 0 0–0 US Department of Agriculture (2015)
Coffee 1 – – 0 Public Health England (2015)
Coffee 39 1 0 0–10 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative number
of samples included in both databases is given in brackets: Soft drink (72); other non-alcoholic beverages (14); tea (57).
Table F.13: Erucic acid(a) concentration (mg/kg) in herbs, spices and condiments(b)
Product N Mean Median Range Reference
Chutney 3 23 20 20–30 Max Rubner Institut (2010)
Cloves 1 – – 180 US Department of Agriculture (2015)
Cloves 1 – – 0 Max Rubner Institut (2010)
Coleslaw 7 66 70 10–110 US Department of Agriculture (2015)
Coleslaw 2 800 800 600–1,000 Public Health England (2015)
Ginger 2 10 10 0–20 US Department of Agriculture (2015)
Herbs sauce 2 20 20 0–40 Max Rubner Institut (2010)
Mayonnaise 4 0 0 0–0 US Department of Agriculture (2015)
Mayonnaise 1 – – 3,100 Public Health England (2015)
Mayonnaise 3 1,707 1,280 850–2,990 NFI (2015)
Mayonnaise 15 163 10 0–740 Max Rubner Institut (2010)
Mustard 1 – – 10,560 US Department of Agriculture (2015)
Mustard 11 5,150 4,030 2,540–10,450 Lyczko et al. (2014)
Mustard 8 16,311 16,060 16,060–18,070 Max Rubner Institut (2010)
Mustard 15 17,410 18,200 4,340–20,790 Wendlinger et al. (2014)
Remoulade 2 1,775 1,775 1,410–2,140 NFI (2015)
Remoulade 6 235 190 0–450 Max Rubner Institut (2010)
Salad dressing 44 30 0 0–360 US Department of Agriculture (2015)
Salad dressing 3 0 0 0–0 Public Health England (2015)
Salad dressing 6 277 0 0–1,480 NFI (2015)
Salad dressing 61 155 0 0–1,190 Max Rubner Institut (2010)
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Product N Mean Median Range Reference
Sauces 43 60 0 0–1,210 US Department of Agriculture (2015)
Sauces 13 23 0 0–200 Public Health England (2015)
Sauces 288 80 20 0–1,180 Max Rubner Institut (2010)
Wasabi 1 – – 40 US Department of Agriculture (2015)
Yeast extract 10 434 155 50–1,870 Max Rubner Institut (2010)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: agar (3); allspice (1); anise (3); asafoetida (1); baking
powder (2); basil (6); bay leaf (4); bread sauce (3); burnet (2); capers (7); caraway seed (2); cardamom (2); cayenne (1);
celery (13); chervil (7); chilli (4); chives (11); cinnamon (5); common rue (1); coriander (7); cumin (4); curry (1); dill (10);
fennel (5); fenugreek (1); ﬂavourings and essences (19); garlic powder (1); gelatine (1); ginger (4); glaze (2); glutamate
(3); gravy (3); guacamole (1); gum (3); herbs mix (4); horseradish sauce (2); juniper (3); ketchup (4); leavening agent (1);
lemon balm (5); liquorice (1); lovage (2); mace (2); marjoram (5); meat extract (6); mint sauce (4); mugwort (2); nut meg
(3); onion powder (1); onion sauce (3); oregano (6); paprika (6); parsley (4); pectins (1); pepper (4); pickles mix (1);
poppy seeds (2); rosemary (6); saffron (3); sage (4); salt (17); sauerkraut (1); savoty (2); soy sauce (5); spice mix (8);
stock cubes (7); tamarind (4); tarragon (4); thyme (6); tomato ketchup (2); turmeric (3); tzatziki (3); vanilla (3); vegetable
extracts (2); vinegar (10); yeast (13).
Table F.14: Erucic acid concentration (mg/kg)(a) in food products for infants and small children
Product N Mean Median Range Reference
Baby food 207 0 0 0–20 US Department of Agriculture (2015)
Infant formula 94 0 0 0–0 US Department of Agriculture (2015)
Infant formula 3 46(b) 36(b) 17–86(b) Rzehak et al. (2011)
Infant formula 2 26(b) 26(b) 0–51(b) Billeaud et al. (1997)
Powdered infant milk 32 0 0 0–0 Zunin et al. (2015)
(a): The database of the US Department of Agriculture database reports the total 22:1c content, without differentiation of n-9
and n-11 isomers.
(b): mg/L.
Table F.15: Erucic acid concentration (mg/kg) in food for special nutritional use(a),(b)
Product N Mean Median Range Reference
Rolls, gluten free 2 20 20 0–40 US Department of Agriculture (2015)
Sandwich, gluten free 3 50 40 40–70 US Department of Agriculture (2015)
Wafﬂes, gluten free 1 – – 20 US Department of Agriculture (2015)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: bread, gluten free (1); bakery products, diabetics (1);
candies, diabetics (3); chocolate, diabetics (2); diet shake mix (3); energy drink (18); ice cream, diabetics (1); isotonic drink
(2); jam, diabetics (2); nutritional supplement (5); pancakes, gluten free; pastries, diabetics (1); soyburger (1); soymilk (8);
vitamin supplements (2).
Table F.16: Erucic acid concentration (mg/kg) in composite dishes(a),(b)
Product N Mean Median Range Reference
Beans-based meal 9 6 0 0–50 US Department of Agriculture (2015)
Beef, cooked 475 0 0 0–30 US Department of Agriculture (2015)
Beef, cooked 166 0 0 0–0 Max Rubner Institut (2010)
Beef, fried 11 3 0 0–30 US Department of Agriculture (2015)
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Product N Mean Median Range Reference
Biscuit 9 9 0 0–40 US Department of Agriculture (2015)
Burritos 12 8 0 0–40 US Department of Agriculture (2015)
Cereal-based dishes 38 89 0 0–3,080 Max Rubner Institut (2010)
Cheese-based dishes 24 111 20 0–960 Max Rubner Institut (2010)
Chicken, cooked 150 7 0 0–130 US Department of Agriculture (2015)
Chicken, cooked 2 0 0 0–0 NFI (2015)
Chicken, cooked 51 0 0 0–0 Max Rubner Institut (2010)
Chicken, fried 77 19 0 0–240 US Department of Agriculture (2015)
Chicken, fried 3 0 0 0–0 NFI (2015)
Chicken skin, roasted 1 – – 20,000 Public Health England (2015)
Cornish pasty 1 – – 100 Public Health England (2015)
Egg-based dishes 74 150 20 0–2,500 Max Rubner Institut (2010)
Empanadas 1 – – 10 US Department of Agriculture (2015)
Enchilada 3 3 0 0–10 US Department of Agriculture (2015)
Chickpea dish 1 – – 100 Public Health England (2015)
Fruit-based dishes 148 119 0 0–3,970 Max Rubner Institut (2010)
Hamburger 14 64 25 0–260 US Department of Agriculture (2015)
Hamburger 3 167 0 0–500 Public Health England (2015)
Hamburger 7 151 0 0–1,060 NFI (2015)
Hamburger 4 45 10 10–150 Max Rubner Institut (2010)
Herring, processed 3 1,650 2,000 850–2,100 NFI (2015)
Hot dog 5 250 0 0–1,250 NFI (2015)
Hash brown 8 39 39 20–120 US Department of Agriculture (2015)
Lamb, cooked 66 0 0 0–0 US Department of Agriculture (2015)
Lamb, cooked 64 0 0 0–0 Max Rubner Institut (2010)
Lamb, fried 12 20 0 0–220 US Department of Agriculture (2015)
Lasagne 8 1 0 0–10 US Department of Agriculture (2015)
Lasagne 1 0 0 0–0 Public Health England (2015)
Legume-based dishes 8 61 0 0–170 Max Rubner Institut (2010)
Macaroni 17 5 0 0–20 US Department of Agriculture (2015)
Meatballs 2 15 15 0–30 US Department of Agriculture (2015)
Meat-based dishes 787 272 0 0–5,040 Max Rubner Institut (2010)
Milk-based dishes 45 20 10 0–240 Max Rubner Institut (2010)
Moussaka 1 – – 100 Public Health England (2015)
Nachos 4 75 75 40–110 US Department of Agriculture (2015)
Onion rings 7 33 30 0–60 US Department of Agriculture (2015)
Pancakes 13 2 0 0–20 US Department of Agriculture (2015)
Pancakes 1 – – 200 Public Health England (2015)
Pasta 23 3 0 0–20 US Department of Agriculture (2015)
Pasta 17 6 0 0–100 Public Health England (2015)
Pasta 144 33 0 0–770 Max Rubner Institut (2010)
Pizza 50 53 20 0–300 US Department of Agriculture (2015)
Pizza 3 100 100 100–100 Public Health England (2015)
Pizza 6 0 0 0–0 NFI (2015)
Pizza 22 21 5 0–200 Max Rubner Institut (2010)
Pork, cooked 131 1 0 0–40 US Department of Agriculture (2015)
Pork, cooked 176 0 0 0–0 Max Rubner Institut (2010)
Pork, fried 10 11 0 0–0 US Department of Agriculture (2015)
Potato puffs 2 5 5 0–10 US Department of Agriculture (2015)
Potato salad 1 – – 140 US Department of Agriculture (2015)
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Product N Mean Median Range Reference
Potato-based dishes 156 193 10 0–3,740 Max Rubner Institut (2010)
Prepared salads 271 16 0 0–490 Max Rubner Institut (2010)
Pupusas 3 17 20 10–20 US Department of Agriculture (2015)
Quesadillas 2 15 15 10–20 US Department of Agriculture (2015)
Quiche 1 – – 200 Public Health England (2015)
Ravioli 6 3 0 0–10 US Department of Agriculture (2015)
Rice-based dishes 79 61 0 0–3,360 Max Rubner Institut (2010)
Rice-based dishes 16 1 0 0–10 US Department of Agriculture (2015)
Rice-based dishes 4 25 0 0–100 Public Health England (2015)
Rolls 22 2 0 0–40 US Department of Agriculture (2015)
Rolls 34 233 65 10–2,300 Max Rubner Institut (2010)
Salmon, grilled 1 – – 11,000 Public Health England (2015)
Samosas 2 500 500 0–1,000 Public Health England (2015)
Sandwiches 43 28 10 0–130 US Department of Agriculture (2015)
Sandwiches 16 102 50 0–430 NFI (2015)
Sandwiches 273 195 60 0–2,330 Max Rubner Institut (2010)
Soups 128 0 0 0–10 US Department of Agriculture (2015)
Soups 6 17 0 0–100 Public Health England (2015)
Soups 376 32 0 0–1,150 Max Rubner Institut (2010)
Spaghetti 11 5 0 0–20 US Department of Agriculture (2015)
Spaghetti 1 – – 0 Public Health England (2015)
Spring roll 1 – – 110 NFI (2015)
Soy-based meals 12 121 0 0–400 Max Rubner Institut (2010)
Tacos 14 11 10 0–20 US Department of Agriculture (2015)
Tamales 4 8 10 0–10 US Department of Agriculture (2015)
Turkey, cooked 51 11 0 0–50 US Department of Agriculture (2015)
Turkey, cooked 27 26 20 10–110 Max Rubner Institut (2010)
Turkey, fried 1 – – 0 US Department of Agriculture (2015)
Veal, cooked 25 0 0 0–0 US Department of Agriculture (2015)
Veal, cooked 59 0 0 0–0 Max Rubner Institut (2010)
Veal, fried 6 0 0 0–0 US Department of Agriculture (2015)
Vegetables with curry 1 – – 200 Public Health England (2015)
Vegetable-based dishes 472 79 10 0–5,680 Max Rubner Institut (2010)
Wraps 2 30 30 30–30 US Department of Agriculture (2015)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: arepas (1); bean burger (4); bhaji (41); bouillon 81);
buble and squeak (2); cannelloni (2); casserole (9); corn fritters (1); doner kebab (4); egg rolls (3); fajita strips (1); feijoa
(1); goulash (1); hummus (1); noodles (14); pakora (10); pilau (7); porridge (5); potato soup (1); risotto (4); rissoles (8);
salads (14); sapotriﬂe (3); vegetables in oil (13); vine leaves stuffed with rice (1).
Table F.17: Erucic acid concentration (mg/kg) in snacks, desserts, and other foods(a),(b)
Product N Mean Median Range Reference
Corn snack 1 – – 2,100 Public Health England (2015)
Custard 3 0 0 0–0 US Department of Agriculture (2015)
Custard 1 – – 0 Public Health England (2015)
Custard 16 5 5 0–10 Max Rubner Institut (2010)
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Product N Mean Median Range Reference
Ice cream 26 0 0 0–0 US Department of Agriculture (2015)
Ice cream 5 0 0 0–0 Public Health England (2015)
Ice cream 4 0 0 0–0 NFI (2015)
Ice cream 131 10 10 0–50 Max Rubner Institut (2010)
Milk-based desserts 94 46 0 0–3,190 Max Rubner Institut (2010)
Pretzels 2 0 0 0–0 US Department of Agriculture (2015)
Pretzels 5 366 50 0–880 Max Rubner Institut (2010)
Pudding 35 0 0 0–0 US Department of Agriculture (2015)
Pudding 1 – – 0 Public Health England (2015)
Pudding 75 29 10 0–360 Max Rubner Institut (2010)
Snack bars 7 13 0 0–70 US Department of Agriculture (2015)
Snacks 83 5 0 0–100 US Department of Agriculture (2015)
Snacks 10 60 0 0–300 Public Health England (2015)
Snacks 4 93 25 0–320 Max Rubner Institut (2010)
Tortilla chips 8 4 0 0–30 US Department of Agriculture (2015)
Tortilla chips 2 100 100 0–200 Public Health England (2015)
(a): The database of the Max Rubner Institut reports 22:1, without differentiation of n-9 and n-11 isomers or cis and trans. US
Department of Agriculture database reports the total 22:1c content, without differentiation of n-9 and n-11 isomers. The
database of Public Health England reports separately 22:1 n-9c+t and 22:1 n-11 c+t. Only data of 22:1 n-9c+t is included in
the table. The database of the National Food Institute of Denmark reports data on 22:1 n-9c.
(b): The following are products included in the nutrient databases of the US Department of Agriculture, Public Health England,
National Food Institute of Denmark and Max Rubner Institut for which no erucic acid has been reported. The cumulative
number of samples included in both databases is given in brackets: frozen novelties (19); popcorn (2); potato chips (2).
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